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CHAPTER I 
 
INTRODUCTION 
 
1.1 Abstract  
 
This chapter presents the background knowledge of this thesis research. First, 
pancreas anatomy and physiology are presented, with the function and regulation of 
endocrine hormones highlighted. Then, pancreas development is discussed. A few key 
transcription factors and their roles in pancreas morphogenesis and lineage allocation 
are covered in detail. Next, epidemiology and pathogenesis of diabetes mellitus, as well 
as its management, are briefly talked about. As gene and cell therapy is a promising 
route to the replenishment of lost β cells and restoration of euglycemia in diabetic 
patients, a subsequent section is devoted to β-cell regeneration and reprogramming, 
summarizing the most recent discoveries on this topic. This thesis research will 
contribute to our understanding of the molecular pathway of endocrine differentiation and 
shed light on new therapy development in the future, albeit far from clinical application at 
the moment. Lastly, because a large volume of this thesis research centers on lineage 
tracing and the Cre/loxP methodology, I also wrote a section to introduce cell lineage 
tracing, the Cre/loxP system, its variants and development in the last decade. 
 
1.2 Overview of Pancreas Physiology  
 
The human pancreas is a compound organ with both endocrine and exocrine 
functions. Anatomically, the pancreas resides in the abdominal cavity, behind the 
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stomach and underneath the liver (Fig 1.1 a). The exocrine pancreas is composed of 
acinar cells and duct cells. Acinar cells produce and secrete various digestive enzymes, 
such as lipase, protease, amylase and nuclease, etc. Duct cells form a highly branched 
transportation network, which ultimately merges into the main pancreatic duct. The main 
pancreatic duct in turn merges with the common bile duct from the gallbladder, and then 
enters the duodenum via the ampulla of Vater. Digestion enzymes and bicarbonate ions 
are thus delivered into the duodenum to aid food digestion (Shih et al., 2013; Slack, 
1995).  
The endocrine pancreas plays a more important role in maintaining metabolic 
homeostasis and is the main focus of my thesis. The endocrine pancreas is composed 
of endocrine cells, including α, β, δ, PP, and ε cells (Fig 1.1 c). These cells secrete 
glucagon, insulin, somatostatin, pancreatic polypeptide (PP) and ghrelin, respectively. 
The endocrine cells aggregate and form islets of Langerhans, which are the functional 
units of endocrine pancreas. Islets of Langerhans are scattered in the exocrine tissue 
and account for only 1-2% of total pancreas mass. The mouse islets have a well-defined 
spatial distribution of endocrine cells, with β cells in the center and other endocrine cells 
in the periphery. However, such a spatial architecture is not so obvious in human islets. 
In human islets, endocrine cells are mixed together with no obvious central vs marginal 
distinction (Bosco et al., 2010; Dai et al., 2012). In the adult mouse pancreas, β cells 
make up 60-80% of total endocrine cells; α cells represent 15-20%; δ cells take 5-10% 
and the rest of the endocrine cells take ~2% (Edlund, 2002). It should be noted that 
endocrine-cell percentages change over development and under different physiological 
conditions, as well as vary from species to species (Steiner et al., 2010). Islets are 
infiltrated by blood vessels and nerves. Secreted pancreatic endocrine hormones enter 
the circulation system through the capillary vessels and are transported to various target 
organs or tissues. On the other hand, the secretion activity of endocrine cells is subject  
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Fig 1.1 Anatomy of the mouse pancreas. (a) The pancreas resides right next to the 
duodenum. Main pancreatic duct and bile duct from the gallbladder merge and enter the 
duodenum. The pancreas comprises roughly two parts by their proximity to the 
duodenum, the head and the tail. (b) Exocrine pancreas, including duct cells and acinar 
cells. (c) An islet, showing α, β, δ, PP, and ε cells. Figure is adapted from Edlund, 2002.  
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to the regulation by circulating hormones from the bloodstream, as well as the nervous 
system (Chandra and Liddle, 2009).  
The insulin-secreting β cells receive the most attention from researchers. The 
main function of β cells is to maintain blood glucose homeostasis through the secretion 
of insulin. The insulin mRNA is translated as a preproinsulin peptide and its maturation 
into insulin requires C-peptide removal and disulfide-bond formation (Davidson, 2004; Fu 
et al., 2013). Groups of six insulin molecules then assemble into a stable hexamer and 
are stored in vesicles readily to be released upon secretogog stimulation (Dunn, 2005). 
The primary insulin secretagog is glucose. When blood glucose level rises, the glucose 
transporter 2 (Glut2) on β-cell membrane takes up glucose, which undergoes glycolysis 
and mitochondrial oxidation, leading to an increased ATP/ADP ratio. Increased 
ATP/ADP ratio shuts down ATP-sensitive KATP channels and results in plasma 
membrane depolarization, which in turn opens voltage-gated Ca2+ channels and causes 
Ca2+ influx. Elevated cytosolic Ca2+ concentration triggers the fusion of insulin vesicles 
with plasma membrane and eventually insulin release. This vesicle fusion and secretion 
is a SNARE (SNAP (soluble NSF attachment protein) REceptor)-dependent process and 
possibly regulated by Ca2+-sensing synaptotagmins (Ahren, 2009; Fu et al., 2013; 
Rorsman et al., 2000; Wang and Thurmond, 2009). In addition to this pathway, G 
protein-coupled receptors (GPCRs) transduce hormone (e.g., glucagon-like peptide 1, or 
GLP1) and metabolic signals (e.g., free fatty acids) into elevated second messengers, 
such as cyclic AMP (cAMP), diacylglycerol (DAG), and inositol-1,4,5-triphosphate (IP3), 
which eventually activate protein kinase A (PKA) and protein kinase C (PKC) signaling 
pathways as well as Ca2+ release from the endoplasmic reticulum (ER) reservoir to 
modulate insulin secretion (Ahren, 2009; Blad et al., 2012).  
Secreted insulin circulates to other body parts and exerts its anabolic function on 
target organs or tissues, including liver, skeletal muscle, and fat tissue (Saltiel and Kahn, 
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2001). The action of insulin involves many molecules and different signaling pathways. 
In brief, binding of insulin to insulin receptor, a tyrosine receptor kinase, leads to the 
receptor’s autophosphorylation and activation. Activated insulin receptor initiates a 
cascade of phosphorylation events, leading to the activation of insulin receptor 
substrates (IRS), MAP kinase, PI3K/Akt, mTOR, and PKC signaling pathways, etc. 
These pathways act concertedly to enhance anabolic metabolism (glucose uptake, 
glycogen synthesis, lipid synthesis, protein synthesis, etc.), inhibit catabolic metabolism 
(gluconeogenesis, glycogenolysis, etc.), as well as regulate cell growth and 
differentiation (Saltiel and Kahn, 2001; Taniguchi et al., 2006). 
Glucagon, on the other hand, antagonizes the function of insulin by promoting 
hepatic glucose production to prevent hypoglycemia. The coordination between 
glucagon and insulin maintains blood glucose level under tight control. In type II diabetic 
patients, the glucagon level is unexpectedly elevated and exacerbates the 
hyperglycemia resulting from insulin insufficiency and resistance (D'Alessio, 2011). It has 
become more evident in recent years that glucagon and α cells also play a role in 
diabetes pathology and they start to come into the center of research that has long been 
dominated by insulin and β bells (Burcelin et al., 2008; D'Alessio, 2011; Del Prato and 
Marchetti, 2004; Quesada et al., 2008). Besides its catabolic function as an endocrine 
hormone, glucagon also exerts a function directly on β cells to promote insulin secretion 
in a paracrine fashion, complementary to the regulation of insulin secretion by the blood 
glucose level, circulating hormones, and the nervous system. Concomitantly, insulin 
inhibits glucagon secretion, forming a feedback loop to keep blood glucose level under 
tight control (Elliott et al., 2015). Somatostatin, on the other hand, inhibits both glucagon 
and insulin secretion through binding to somatostatin receptors on α and β cells 
(Schwetz et al., 2013; Strowski and Blake, 2008). It is recently reported that β cell-
secreted urocortin3 augments somatostatin secretion from δ cells (van der Meulen et al., 
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2015). Such bidirectional regulation among endocrine cells establishes a fine-tuned 
feedback system, which enables islets to maintain metabolic homeostasis (Caicedo, 
2013). 
 
1.3 Overview of Pancreas Development  
 
The pancreas develops from a region in the foregut endoderm epithelium (Fig 1.2) 
(Collombat et al., 2006; Edlund, 2002; Pan and Wright, 2011; Rieck et al., 2012; Romer 
and Sussel, 2015). The first observable morphological structure is the two pancreatic 
bud evaginations, which appear at around E9.5 and are marked by the expression of a 
homeobox transcription factor Pdx1 (pancreatic and duodenal homeobox 1, also known 
as insulin-promoter-factor 1 or Ipf1) (Hale et al., 2005; Offield et al., 1996) (Fig 1.2 A, A’, 
A’’). These two Pdx1+ pancreatic buds further proliferate and invade into the surrounding 
mesenchyme, forming ventral pancreas and dorsal pancreas. The two buds rotate 
towards each other to form a single organ as pancreatic development progresses (Fig 
1.2 B’). In mouse, disruption of the Pdx1 gene causes pancreatic agenesis (Jonsson et 
al., 1994; Offield et al., 1996). Cell lineage tracing showed that Pdx1+ cells are the early 
multipotent progenitor cells (MPCs) that give birth to all pancreatic cell types, including 
duct cells, acinar cells, and endocrine cells (Gu et al., 2002). The expression of Sox9 
colocalizes with Pdx1 expression before E12.5 and it is thus considered as an early 
MPC maker, which is supported by lineage tracing results with Sox9Cre and Sox9CreER 
mouse models (Akiyama et al., 2005; Furuyama et al., 2011; Kopp et al., 2011). 
Consequently, deletion of Sox9 in the developing pancreas leads to the arrest of MPC 
expansion and pancreatic hypoplasia (Seymour et al., 2007).  Ptf1a, another 
transcription factor that labels the MPCs, is critical in committing the pancreatic fate from 
the gut endoderm. Lineage tracing demonstrates that Ptf1a is expressed in the early  
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Fig 1.2 Overview of pancreas development. The pancreas develops from a pre-
patterned region in the primitive gut endoderm epithelium. At E9.5, two observable 
pancreatic buds grow and invade into surrounding mesenchyme, forming ventral 
pancreas (vp) and dorsal pancreas (dp). Ventral pancreas and dorsal pancreas rotate 
towards each other and eventually form a single organ. As development progresses, 
Ngn3+ progenitors delaminate from the duct epithelium and differentiate into endocrine 
cells, which further aggregate into islets of Langerhans. (A-E): whole mount staining of 
beta-galactosidase from the Pdx1tTA/+; TgtetO-Pdx1-lacZ mouse embryos, showing the 
expression pattern of Pdx1. Figures are adapted from Hale et al. 2005. (A’-E’): 
schematic representation of pancreas development. Liver, gallbladder and spleen are 
omitted from E12.5 on for visual clarity. li: liver. vp: ventral pancreas. dp: dorsal 
pancreas. st: stomach. d: duodenum. Shaded area represents Pdx1+ area. (A’’-E’’): 
schematic drawing showing key cellular events. mes: mesenchyme. epi: epithelium. 
Figures are adapted from Pan and Wright, 2011. 
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pancreatic progenitor cells that eventually differentiate into duct, acinar and endocrine 
cells (Kawaguchi et al., 2002). Ptf1a-deficient mice manifest pancreas agenesis and the 
expansion of the duodenal epithelium domain, suggesting that Ptf1a regulates the 
adoption between pancreatic versus gut endoderm fate (Kawaguchi et al., 2002). Zhou 
et al. used a Cpa1CreER mouse model to show that carboxypeptidase A1 (Cpa1)-positive 
cells are multipotent before E14.5. They proposed a “tip-trunk” model in which the 
pancreatic MPC population is located at the tips of the branching pancreatic epithelium 
and is characterized by Pdx1+Ptf1a+Cpa1+ expression (Zhou et al., 2007) (Fig 1.2 C’’,D’’; 
Fig 1.3). Starting from E14.5, the expression of Ptf1a and Cpa1 becomes restricted to 
the tip compartment, which produces the eventual acinar cells, and the differentiation 
potential of the Ptf1a+ or Cpa1+ cells is progressively constrained to the acinar cell fate. 
The trunk compartment, on the other hand, harbors the Pdx1lowSox9hiPtf1a-Cpa1- 
bipotent cells that give birth to duct cells and endocrine cells (Schaffer et al., 2010) (Fig 
1.3). The downregulation of Ptf1a and Cpa1 expression is necessary for the acquisition 
of the bipotent progenitor cell fate (Pan et al., 2013). Hnf1β is another marker for the 
MPCs before E13.5. From E13.5 to E15.5, Hnf1β is highly expressed in the trunk 
domain and marks the bipotent progneitors, in contrast to Ptf1a and Cpa1 (Solar et al., 
2009). 
A portion of the bipotent progenitors turn on the expression of a basic helix-loop-
helix (bHLH) transcription factor Neurogenin 3 (Ngn3). These Ngn3+ cells mark the 
earliest endocrine progenitors. Ngn3+ progenitors delaminate from the duct epithelium 
and initiate a cascade of gene activation/inactivation events, leading to their 
differentiation into different endocrine cell lineages (Fig 1.3).  Much effort has been 
dedicated to the study of Ngn3 and demonstrated its central role in endocrine pancreas 
development. Ngn3-null mice produce almost no endocrine cells (Gradwohl et al., 2000). 
Conversely, ectopic expression of Ngn3 leads to the precocious differentiation of 
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pancreatic precursors into endocrine cells at the expense of exocrine lineages (Apelqvist 
et al., 1999; Schwitzgebel et al., 2000). Lineage tracing proves that Ngn3-expressing 
cells give rise to all endocrine cells (Gu et al., 2002; Schonhoff et al., 2004). It is notable, 
however, that Ngn3 expressing level is also crucial in determining endocrine versus 
exocrine cell fate. In the Ngn3-haploinsufficient or null conditions, the proportion of 
acinar and duct cells increases at the expense of endocrine cells (Wang et al., 2010). 
Immunostaining reveals two Ngn3+ populations, Ngn3low and Ngn3high progenitors, by us 
and other researchers (Seymour et al., 2008; Shih et al., 2012). A recent study of 
inducing human embryonic stem cells (hESCs) to differentiate into endocrine cells 
discovers that hESCs with Ngn3 being knocked-out by CRISPR/Cas9 (CRISPR: 
clustered regularly interspaced short palindromic repeats; Cas9: CRISPR-associated 
protein 9) fail to differentiate into endocrine cells but hESCs with shRNA-mediated Ngn3 
knockdown can form endocrine cells, though fewer than unmanipulated hESCs 
(McGrath et al., 2015). The different results from these two experiments can be 
explained by the fact that shRNA-mediated gene knockdown does not fully erase the 
expression of Ngn3 as compared to the CRISPR/Case9-mediated gene knockout 
method. Thus, the shRNA-mediated Ngn3 knockdown experiment phenocopies an 
Ngn3-haploinsufficient situation and produces an intermediate amount of endocrine cells 
(McGrath et al., 2015). Together, these studies suggest the importance of Ngn3 
expression level in endocrine specification in both mice and humans.   
Because of the importance of Ngn3 and its expression level in endocrine 
pancreas development, Ngn3 expression is subject to the regulation of many factors and 
signaling pathways. For instance, Sox9 (Lynn et al., 2007b), Pdx1 (Oliver-Krasinski et al., 
2009) and Hnf6 (Jacquemin et al., 2000) activate Ngn3 expression, while Notch 
signaling inhibits Ngn3 expression (Apelqvist et al., 1999; Lee et al., 2001). Notch 
inhibition limits the Ngn3+ progenitor pool size and thus keeps the endocrine and 
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exocrine lineages at balance, which is exemplified by many experiments perturbing 
Notch signaling (Apelqvist et al., 1999; Jensen et al., 2000). Ngn3 is expressed in the 
endocrine progenitors and diminishes in endocrine cells soon after birth, although it is 
also suggested that Ngn3 is expressed at a very low level in the adult islet cells and this 
sustained low level expression of Ngn3 is required for maintaining islet function (Wang et 
al., 2009a). An in vitro experiment demonstrates the self-inhibitory ability of Ngn3 (Smith 
et al., 2004). Once Ngn3 reaches a high expression level, it binds to its own promoter 
and prevents itself from further expression. This phenomenon is used to explain the 
reduced expression of Ngn3 after lineage commitment. Nonetheless, this result comes 
from an in vitro assay and may not represent the in vivo situation. We instead found that 
Ngn3 can augment its own expression, possibly by inducing the expression of certain 
miRNAs that can tune down Notch signaling components Hes1 and Psen1 and thus 
remove Notch inhibition on Ngn3 expression. The regulation of Ngn3 expression will be 
discussed in detail in Chapter V.   
Although Ngn3+ progenitors as a population produce all types of endocrine cells, 
it is unclear how an individual Ngn3+ progenitor makes its decision to become one 
endocrine cell type versus another. To this end, it is found that different endocrine cell 
types are not born randomly during pancreatic morphogenesis; rather, each endocrine 
cell type has its time window of production (Johansson et al., 2007). Using an Ngn3ERTM 
“add-back” mouse model, Johansson et al. was able to activate the exogenous Ngn3ERTM 
within defined time windows in the Ngn3-/- mouse pancreas and thus examine the 
differentiation potential of stage-specific Ngn3+ progenitors. They found that Ngn3+ 
progenitors give birth to α cells first, starting at as early as E9.5 and lasting to E14.5. A 
major wave of β-cell differentiation happens during the secondary transition, between 
E12.5-E16.5. δ and PP cells emerge in late gestational stages (Johansson et al., 2007). 
A competence window model based on this observation of successive but partially  
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Fig 1.3 Gene transcription cascade in pancreas organogenesis. Schematic 
representation of stepwise pancreatic lineage specification. Selected important 
transcription factors at each stage are indicated. The antagonizing Pax4 and Arx are 
emphasized with red lines. Modified from Pan and Wright, 2011. 
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overlapping differentiation of endocrine cells is proposed, stating that Ngn3+ endocrine 
progenitors pass through consecutive temporal windows during which their 
differentiation competence changes (Johansson et al., 2007). Johansson et al. also 
found that the competence of Ngn3+ progenitors is intrinsic to the epithelium but not 
influenced by signaling from the surrounding mesenchyme. When they recombined 
embryonic pancreatic epithelium and mesenchyme in a stage-matched or heterochronic 
manner for an in vitro culture assay, they discovered that the distribution of endocrine 
cells is similar between groups if the pancreatic epithelia used are of the same stage, 
regardless of the mesenchyme used (Johansson et al., 2007). This suggests that the 
competence shift is intrinsic to the pancreas epithelium rather than due to instructive 
signals from the surrounding mesenchyme. However, it should not be overlooked that 
Ffg10 signaling from the mesenchyme activates Notch signaling in the epithelium, which 
in turn inhibits the acquisition of the pro-endocrine marker Ngn3. Thus, Fgf10 signaling 
maintains the proliferation of Pdx1+ progenitors to ensure an ample source of 
progenitors in the very beginning of endocrine differentiation (Bhushan et al., 2001; 
Norgaard et al., 2003).  
The detailed mechanism of how the competence windows are established, 
maintained, and changed is largely unknown. It is well possible that upstream regulators, 
including Pdx1, Sox9, Hnf6, as well as Notch signaling and Fgf10 signaling from the 
mesenchyme concertedly modulate the expression of Ngn3 and subsequently its 
downstream targets, which form a transcription factor network that defines the status of 
the Ngn3+ progenitors and the differentiation pathways they can adopt (Jensen, 2004; 
Wilson et al., 2003). Many transcription factors have been validated as Ngn3 
downstream targets, including Arx (Collombat et al., 2003), Pax4 (Smith et al., 2003), 
NeuroD (Huang et al., 2000), Nkx2.2 (Watada et al., 2003), and Insm1 (Mellitzer et al., 
2006; Osipovich et al., 2014) etc. Among these, Arx and Pax4 have received most 
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investigation and they are found to specify α-cell and β/δ-cell lineages, respectively. Arx 
and Pax4 are co-expressed in the early endocrine progenitors but their expression 
becomes mutually exclusive and inhibits the expression of one other, committing the 
endocrine progenitors to different lineages (Collombat et al., 2005). Pax4 expression is 
gradually restricted to β and δ lineages and is switched off after birth; Arx expression, on 
the other hand, persists in mature α cells. The mutual repressive relationship between 
Arx and Pax4 has been interrogated with many loss-of-function and ectopic expression 
experiments (Collombat et al., 2005; Collombat et al., 2007; Collombat et al., 2003; 
Collombat et al., 2009; Courtney et al., 2013; Dhawan et al., 2011). For instance, Pax4 
knockout results in the loss of β and δ lineages (Sosa-Pineda, 2004). In contrast, loss of 
Arx leads to increased β and δ cells at the expense of α cells (Collombat et al., 2003). 
Not surprisingly, Pax4 ectopic expression in α cells converts them to β cells in vivo 
(Collombat et al., 2009) while misexpression of Arx in β cells leads to their conversion to 
glucagon+ and PP+ cells (Collombat et al., 2007). The homeodomain transcription factor 
Nkx2.2 is necessary for both β-cell specification and maintenance (Doyle and Sussel, 
2007; Sussel et al., 1998). NeuroD, a basic helix-loop-helix transcription factor and an 
Ngn3 downstream target (Huang et al., 2000), is required for endocrine differentiation. 
Loss of NeuroD results in the reduction of all endocrine cells and a reduced β-to-α and 
β-to-δ cell ratio, suggesting the significance of NeuroD in regulating endocrine 
differentiation, especially β-cell lineage specification (Naya et al., 1997). Nkx2.2-deficient 
mice display hyperglycemia due to the lack of insulin-secreting β cells and die at 
neonatal stages (Sussel et al., 1998). In β cells, Nkx2.2 can recruit a repressor complex 
composed of Groucho 3 (Grg3), DNA methyltransferase 3a (Dnmt3a) and histone 
deacetylase 1 (Hdac1) to enhance the methylation of the upstream regulatory elements 
of Arx gene and thus prohibit the acquisition of α-cell fate (Mastracci et al., 2011; 
Papizan et al., 2011). Like Nkx2.2, the homeodomain transcription factor family member 
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Nkx6.1 is also shown to directly repress the expression of Arx and thus responsible for 
β-cell specification (Schaffer et al., 2013). The zinc finger transcription factor Myt1 forms 
a feed-forward loop with Ngn3 as the two promote the expression of each other (Wang 
et al., 2008). Loss of Myt1 in the developing pancreas results in abnormal multi-hormone 
positive cells, suggesting that endocrine differentiation or maturation is disrupted (Wang 
et al., 2007). Insm1, another Ngn3 downstream gene (Mellitzer et al., 2006), is also 
important in regulating pancreatic endocrine differentiation through a gene network that 
involves cell adhesion, cell migration, extracellular matrix remodeling, cell proliferation, 
and mRNA alternative splicing etc. Loss of Insm1 decreases the delamination of pro-
endocrine progenitors, leads to the alternative splicing of Ngn3 mRNA, and decreases β-
cell production (Osipovich et al., 2014). Besides transcription factors, a gene that 
encodes a secreted protein, connective tissue growth factor (CTGF), also influences 
endocrine lineage allocation. Deletion of CTGF results in reduced β-to-α cell ratio and 
altered islet morphology in the adult mice (Crawford et al., 2009). The basic-leucine-
zipper MafA and MafB transcription factors, though not employed in lineage specification, 
are important to endocrine cell maturation. In the developing mouse pancreas, insulin+ 
cells switch from MafB+ to MafA+ with the concomitant high Pdx1 expression, marking 
the maturation of β cells (Artner et al., 2010; Nishimura et al., 2006). Reviews by Jensen 
(Jensen, 2004) and Pan (Pan and Wright, 2011) provide comprehensive summaries of 
transcription factors involved in pancreas development.  
Ngn3 not only dictates endocrine differentiation but also affects duct branching 
morphogenesis. Unlike other organs such as lung, kidney and mammary gland, 
pancreatic ductal network does not develop from the elongation and bifurcation of a 
single duct tube. Instead, a plexus comprising numerous small lumens first forms and 
gradually remodels and coalesces into a single-lumen ductal system (Iber and 
Menshykau, 2013; Villasenor et al., 2010) (Fig 1.2 B’’, C’’). Loss of Ngn3 leads to 
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reduced branching and dilated pancreatic plexus. In the opposite, Ngn3+ domain 
expansion by inhibiting Notch signaling results in thinning plexus (Magenheim et al., 
2011). It is speculated that endocrine differentiation and ductal morphogenesis are 
coupled events and perturbation of pancreatic branching morphogenesis could influence 
endocrine differentiation, which is an active research topic (Pan and Wright, 2011; Rieck 
et al., 2012).  
In summary, pancreas development initiates from two Pdx1+ pancreatic buds in 
the foregut endoderm. The multipotent Pdx1+Ptf1a+Cpa1+ progenitor cells bifurcate into 
the acinar cell lineage and a Pdx1lowSox9hiPtf1a-Cpa1-Hnf1β+ bipotent progenitor 
population. The bipotent progenitors further diverge into the duct cell lineage and the 
endocrine lineage mainly based on the activation of Ngn3, the endocrine master gene. 
Differentiation of Ngn3+ pro-endocrine progenitors into various endocrine lineages 
depends on the concerted interaction of various Ngn3 downstream genes, whose 
activation/inactivation determines which endocrine lineage Ngn3+ progenitors are able to 
commit. Nonetheless, the pancreatic endocrine differentiation process is far from well 
understood. When and how the Ngn3+ progenitors are specified to different endocrine 
cell lineages is one of the many mysteries, and this is the main focus of this thesis 
research.  
 
1.4 Diabetes and Significance of This Study 
 
Diabetes is a major health concern in the US and worldwide. According to the 
data of American Diabetes Association, the United States has witnessed a steady 
increase of diabetic cases during the last 50 years. By 2012, 29.1 million children and 
adults, roughly 9.3% of the total US population, had diabetes 
(http://www.diabetes.org/diabetes-basics/diabetes-statistics/). Worldwide, the prevalence 
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of diabetes was about 9% among adults above eighteen years old in 2014. WHO 
predicts that in 2030 diabetes will become the 7th leading cause of death worldwide and 
4th in high-income countries (http://www.who.int/mediacentre/factsheets/fs312/en/). 
There are two main types of diabetes: type I and type II (Zimmet et al., 2001). 
Type I diabetes is characterized by the loss of β cells and thus insulin insufficiency. It is 
generally believed that genetic susceptibility and environmental triggers induce β-cell 
auto-immune response, characterized by the presentation of autoantigens (insulin, 
glutamic acid decarboxylase (GAD65), tyrosine phosphatase islet antigen 2 (IA2 or 
ICA512)) and subsequent emergence of autoantibodies and autoreactive T cells capable 
of recognizing these autoantigens and destructing β cells (Atkinson, 2012; Knip et al., 
2005; Van Belle et al., 2011). Immunosuppressive drugs like cyclosporine delay type I 
diabetes progression but not prevent it (Van Belle et al., 2011). Type I diabetic patients 
eventually require insulin injection to compensate for the loss of β cells and maintain 
blood glucose within physiological range.  Recently, intestinal K cells are engineered to 
express insulin. By taking advantage of the K cells’ glucose-responsive machinery and 
their ability to escape autoimmune attack, researchers are able to protect non-obese 
diabetic (NOD) mice with an insulin transgene in the K cells from developing diabetes 
(Mojibian et al., 2014). The ethical controversy over human genome manipulation, 
however, precludes its clinical application in the short term. Type II diabetes is the 
dominant type of diabetes (~90% of diabetes cases) and is characterized by insulin 
resistance in insulin-responsive organs or tissues. The pathogenesis of type II diabetes 
is a result of many factors, including genetics, nutrition and lifestyle, etc. (Ashcroft and 
Rorsman, 2012). An overly simplified view holds that nutrient overload exposes tissues 
to deleterious metabolic intermediates, activates the endoplasmic reticulum (ER) stress 
and innate immune pathways, and eventually disrupts insulin signaling and causes 
insulin resistance, although the detail mechanisms are more sophisticated (Muoio and 
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Newgard, 2008; Samuel and Shulman, 2012). While calorie-rich diet style and lack of 
physical exercise are well-known risk factors of type II diabetes, recent research has 
also identified more than a dozen of single nucleotide polymorphisms (SNPs) associated 
with increased risk of type II diabetes by using genome-wide association study (GWAS) 
analysis (Ashcroft and Rorsman, 2012). These susceptible genes include Tcf7l2, 
Slc30a8, Kcnq1, etc., demonstrating the involvement of genetics in type II diabetes 
pathogenesis, though the mechanisms for these susceptible genes remain elusive. The 
current treatment for type II diabetes enhances insulin secretion from β cells to 
counteract insulin resistance, as well as targets periphery organs to inhibit 
gluconeogenesis. For instance, sulfonylurea targets KATP channels of β cells to increase 
glucose-stimulated insulin secretion; exendin-4 targets GLP1 receptor to enhance insulin 
secretion; metformin targets the liver to inhibit glucose production, etc. (Moller, 2001; 
Park et al., 2007; Viollet and Foretz, 2013). In late stage type II diabetes, impaired β-cell 
function such as glucose-stimulated insulin secretion (GSIS) and loss of β-cell mass 
arise as they become exhausted from excessive insulin secretion to counteract insulin 
resistance. This poses a new challenge and requires intervention with insulin injection 
(Ashcroft and Rorsman, 2012). 
Unfortunately, there is no cure for diabetes currently and diabetic patients have 
to take medicines and/or insulin injections regularly as well as adjusting their diet and 
lifestyle, which all have notorious patient compliance issues (Beckman et al., 2002; 
Grundy et al., 2005). Islet transplantation-based therapy is a promising direction and will 
cure insulin-dependent diabetes once and for all. In the next section, I will summarize 
recent progresses in the field of β-cell regeneration, reprogramming and the limitations 
of these studies at the moment.  
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1.5 Beta-cell Regeneration and Reprogramming as Diabetes Therapy  
 
In order to replenish β cells in diabetic patients, there are several strategies: 
increase the proliferation of existing β cells, induce the differentiation of endocrine 
progenitors in the adult pancreas, transplant cadaveric islets, produce transplantable β 
cells from in vitro differentiation of human embryonic stem cells (hESCs) or induced 
pluripotent stem cells (iPSCs), or convert other cell types into β cells (Bonner-Weir and 
Weir, 2005; Desgraz et al., 2011; Pagliuca and Melton, 2013; Ziv et al., 2013).  
One remedy for β-cell loss is accelerating β-cell replication. β cells are mostly 
generated during embryogenesis and the perinatal stage. In adult mice, β-cell 
proliferation is limited and decreases as the mice age (German, 2013; Pagliuca and 
Melton, 2013). Various factors have been found to enhance β-cell proliferation, including 
GLP1/exendin-4, betatrophin, CTGF, etc. (Riley et al., 2015; Stoffers et al., 2000; Xu et 
al., 1999; Yi et al., 2013), although controversies regarding their capacity of promoting β-
cell replication in humans still remain (Burcelin and Dejager, 2010; Espes et al., 2014; 
Jiao et al., 2014; Wang et al., 2013). Some small molecules are also found through high-
throughput screening to promote β-cell replication (Wang et al., 2015; Wang et al., 
2009b). These small molecules could be potentially used to treat diabetes but more 
rigorous studies should be carried out in in vivo mouse models and isolated human islets 
before they are introduced into clinical trials. Meanwhile, we should be wary of their 
potential tumorigenesis effects. 
Another way of replenishing β cells is through the differentiation of Ngn3+ 
progenitors. In adult mice, β-cell turnover rate is very low and its replenishment is 
completed by the proliferation of existing β cells but not differentiation from endocrine 
progenitors, as Ngn3 expression is low in adult islets (Dor et al., 2004). However, Xu et 
al. reported the reactivation of Ngn3 expression program and a two-fold increase of  
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Fig 1.4 Sources of β-cell regeneration. Several strategies of β-cell regeneration are 
proposed: (1) increase the proliferation of existing β cells; (2) induce the differentiation of 
endocrine progenitors, although the existence of dormant Ngn3+ progenitors in adults is 
controversial (see text); (3) convert other cell types into β cells either in vivo or in vitro; (4) 
in vitro differentiation of β cells from hESCs or iPSCs. Figure is adapted from Pagliuca 
and Melton, 2013. 
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insulin+ cell mass in a partial pancreatic duct ligation (PDL) mouse model (Xu et al., 
2008) . These Ngn3+ cells line the duct epithelium and are considered as latent 
endocrine progenitors in adult mice. It is also reported that Ngn3 is re-expressed in the 
duct epithelial cells upon α-to-β conversion mediated by Pax4 ectopic expression (Al-
Hasani et al., 2013). Nevertheless, whether PDL awakens endocrine progenitor 
differentiation program and increases actual β-cell number has been questioned. Some 
studies suggest that β cells are not regenerated in the PDL mouse model (Rankin et al., 
2013) or that no endocrine/β cells are differentiated from these resurging Ngn3+ cells 
(Kopp et al., 2011; Xiao et al., 2013).  
The third strategy of compensating β-cell loss is islet/β-cell transplantation. The 
Edmonton group led by Dr. Shapiro et al. published clinical trial results in which type I 
diabetic patients become insulin-independent after islet transplantation in conjugation 
with a glucocorticoid-free immunosuppressive regime. Some patients remain insulin-
independent for more than two years (Shapiro et al., 2000; Shapiro et al., 2006). 
Although this strategy is dampened by the difficulty of islet transplantation procedure, 
necessity of immunosuppression regimen to suppress host rejection, gradual loss of islet 
transplants, as well as scarcity of islet source (Merani and Shapiro, 2006; Rother and 
Harlan, 2004), this pioneer work represents the initial success that islet transplantation 
could be a promising cure for diabetes. Besides islet/β-cell transplantation, it is also 
notable that subcutaneous implantation of embryonic brown adipose tissue (BAT) can 
reverse hyperglycemia in type I diabetic mouse models without increasing β cells or 
insulin level (Gunawardana and Piston, 2012, 2015). The use of embryonic tissue is 
controversial and attempts to use BAT stem cells or BAT-secreted adipokines shall be 
made in the future. This topic will not be discussed in detail.  
To overcome the islet/β-cell scarcity obstacle, scientists have developed various 
protocols to generate β cells in vitro. In 2006, D’Amour and colleagues were able to 
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generate pancreatic endocrine cells from hESCs by using a stepwise induction protocol 
but the resulted β-like insulin-secreting cells respond poorly to glucose stimulation, 
indicative of functional immaturity (D'Amour et al., 2006). A few years later, the same 
group generated glucose-responsive insulin-secreting cells after transplanting hESCs-
derived pancreatic endoderm into immunocompromised mice. Most importantly, these 
cells protect mice from streptozotocin (STZ)-induced diabetes (Kroon et al., 2008). 
However, the transplanted pancreatic endoderm requires as long as three months of 
maturation time to become responsive to glucose and secret insulin (Kroon et al., 2008; 
Rezania et al., 2012). This maturation phase is ill-understood and it is doubtful whether 
this process could be replicated in humans. The Melton group reported a scalable 
method to differentiate β cells from hESCs (Pagliuca et al., 2014). These cells respond 
well to repeated glucose stimulation and reverse hyperglycemia in NRG-Akita mice 
within as fast as 18 days. Nonetheless, the authors also admitted that human insulin 
secreted in these mice is lower than that of mice transplanted with human cadaveric 
islets on a per cell basis, revealing the gaps of functionality between induced and 
authentic β cells. One possibility is that the presence of other endocrine cell types and 
proper vascularization is necessary to fine-tune the function of hESC-derived β cells 
(Brissova et al., 2014; Reinert et al., 2013; Rodriguez-Diaz et al., 2011). To this end, 
amid the current studies mostly focusing on in vitro generation of β cells, the 
differentiation of other endocrine cell type, three-dimensional tissue construction, and 
proper encapsulation and delivery strategies should be given equal attention in order to 
achieve therapeutic effectiveness. Meanwhile, the risk of teratoma formation 
accompanying hESC- or iPSC-based therapy should not be overlooked if the derived β 
cells are not fully differentiated and purified before transplantation.  
β cells can also be generated from terminally differentiated cells through 
transdifferentiation in vivo or in vitro. The source cells are full of choices but usually 
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etiologically related to β cells. For example, α cells could transdifferentiate into β cells in 
a diphtheria toxin-induced β-cell ablation model (Thorel et al., 2010) or in a forced Pdx1 
expression model (Yang et al., 2011). Another notable example involves the 
antagonizing Arx and Pax4, which determine α and β/δ cell fate, respectively. Pax4 
ectopic expression in α cells converts them into β cells in vivo (Collombat et al., 2009). 
On the contrary, misexpression of Arx in β cells leads to their conversion to glucagon+ 
and PP+ cells (Collombat et al., 2007). Moreover, remodeling epigenetic architecture 
with small molecules such as adenosine periodate oxidized (Adox) is also able to 
reprogram α cells to β cells (Bramswig et al., 2013). In addition to endocrine cells, 
exocrine cells also demonstrate the plasticity of being converted into other cell types. 
Duct cells contribute to endocrine cells when the latter is destroyed by diphtheria toxin or 
when Ngn3 is ectopically expressed in the duct cells (Criscimanna et al., 2011; 
Heremans et al., 2002; Lee et al., 2013). After partial pancreatic duct ligation, acinar 
cells can convert into duct cell and eventually endocrine/β cells (Pan et al., 2013). A 
cocktail of Ngn3, Pdx1, and MafA can reprogram adult mouse pancreatic exocrine cells 
to β cells in vivo (Zhou et al., 2008). Instead of genetic manipulation, a transient cytokine 
treatment can also reprogram acinar cells to β cells and restore euglycemia in diabetic 
mouse models (Baeyens et al., 2014). In addition to pancreatic cell types, human 
hepatocytes (Zalzman et al., 2005) and mouse fibroblasts (Li et al., 2014a) are also 
converted into β cells with in vitro protocols.  
The significance of β-cell reprogramming research is multi-fold. First and 
foremost, in vitro generated β cells provide an affluent source for clinical transplantation, 
bypassing the issue of limited cadaveric islet/β-cell donors.  Second, in vitro generated β 
cells cause less immune rejection if the source cells are the patient’s own hESCs, iPSCs 
or terminally differentiated cells as compared to cadaveric islets from orthogonal donors. 
This improves β cell engraftment and obviates the use of immunosuppressive reagents, 
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although autoimmune reaction in type I diabetic patients remains an issue to be resolved. 
Third, induced β cells not only can be used for transplantation but also serve as drug 
screening platforms, obviating the use of scarce human islets or mouse islet substitutes. 
Whether we are to regenerate β cells from the replication of existing β cells, direct 
differentiation of hESCs/iPSCs, or transdifferentiation, we need to first of all have a 
better understanding of pancreas development and β-cell generation during 
embryogenesis. This thesis work focuses on the transcription factors Ngn3 and Myt1 
and their roles in endocrine lineage allocation. I hope my research will contribute to our 
current knowledge of endocrine lineage specification and foster the informed design of 
β-cell regeneration protocols.  
 
1.6 Introduction to Lineage tracing and the Cre/loxP Technique 
 
For all multi-cellular organisms, how one cell proliferates and differentiates into a 
mature organism is always a fascinating topic. In order to understand the cell lineage 
relationships, researchers have developed various methods to track cell fate 
(Kretzschmar and Watt, 2012). Early cell lineage tracing methods include direct 
observation, label retaining, retroviral transduction, and tissue transplantation, etc. One 
of the most notable achievements in developmental biology is the mapping of C. elegans 
cell lineages by 1983 with time-lapse microscopy and differential interference contrast 
microscopy (Sulston et al., 1983). Useful as it is with C. elegans development research, 
direct observation with microscopes is not suitable for the study of higher organisms 
such as mouse whose number of cells increases by several orders of magnitude and 
embryonic development takes place in utero. Direct observation is also not feasible for 
studying hematopoietic stem cell differentiation, which is a highly mobile tissue. Label 
retaining methods with vital dyes and radioactive tracers are utilized in the early years of  
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Fig 1.5 Cre recombinase structure and sequence. (a) Ribbon diagram depicting the 3D 
structure of Cre recombinase. Crystal structure is obtained for Cre 20-341. (b) Primary 
sequence of Cre recombinase and secondary structure alignment.  Cylinders represent 
alpha helices while black arrows represent beta sheets.  Active sites are boxed. Starred 
amino acid residues make contact with DNA. (c) Schematic representation of Cre/loxP 
recombination mechanism. Two Cre proteins occupy one loxP site. The floxed sequence 
is subsequently excised in this case where the two loxP sites are oriented in the same 
direction. When two loxP sites are oriented in the opposite direction, the floxed 
sequence is inverted. trans recombination (e.g., interchromosome exchange) may also 
occur when two loxP sites are located in two DNA molecules but the rate and efficiency 
is low. loxP sequence is also presented here. loxP sequence consists of two palindromic 
13mers connected by a 8mer spacer (in red). Adapted from Guo et al., 1997. 
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developmental biology but are compromised by their drawbacks such as inaccuracy, 
disruption to normal development, and signal dilution, etc. DNA analog (e.g., BrdU, EdU) 
incorporation indicates DNA replication; it is not an accurate readout for cell 
differentiation but is still used for short term lineage tracing under certain circumstances. 
Transfection and viral transduction of genetic markers such as GFP and lacZ gene are 
superior to label-retaining methods because of marker inheritability across many cell 
generations. However, transfection and viral transduction lack precision and cellular 
resolution and thus are not versatile tools to label a specific cell type. Intra- and 
interspecies tissue transplantation is used to study organ origin during gastrulation but 
the lack of single cell resolution and the need of surgery and sometimes irradiation 
render this method unpopular.  
Modern developmental biologists now use genetic methods to trace cell lineages. 
The two most commonly used genetic cell lineage tracing systems are the Cre/loxP 
system and the FLP/FRT system (Branda and Dymecki, 2004; Lewandoski, 2001). Both 
systems consist of two components: the Cre or FLP recombinase and the loxP or FRT 
recognition sequence. Both systems function in very similar mechanisms. The FLP/FRT 
system is inferior to and less commonly used than the Cre/loxP system in the 
mammalian models because of its lower recombination efficiency (Anastassiadis et al., 
2009). Most mouse models use the Cre/loxP system and I will focus on the Cre/loxP 
system in the following. 
The Cre recombinase is a 38 kilo-Dalton protein (343 amino acid residues) that 
belongs to the integrase family. It is first found in the P1 bacteriophage (Sternberg and 
Hamilton, 1981). Unlike other bacteriophage such as lamda phage, P1 bacteriophage 
does not integrate its DNA into the host genome. Rather, its DNA is circulized and 
maintained like a plasmid. The function of Cre recombinase is to promote P1 DNA 
cyclization after infection and resolve plasmid multimer to stabilize plasmid copy number 
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(Lobocka et al., 2004). Crystal structure has been solved for Cre recombinase (Fig 1.5 a, 
b) (Guo et al., 1997). It has two distinct N-terminal and C-terminal domains connected by 
a short peptide. Both domains contribute to DNA binding and contain active amino acid 
residues that coordinate nucleotides at the site of attack and concertedly nick DNA (Gibb 
et al., 2010; Van Duyne, 2001).  
The binding sequence of Cre recombinase is the 34bp loxP site. loxP sequence 
is composed of two 13bp palindromic elements connected by an 8bp spacer. In a floxed 
sequence (sequence flanked by two loxP sites), each Cre protein occupies a 13mer half-
site, thus forming a Cre4loxP2 complex. Because the 8bp spacer is asymmetrical and 
thus directional, the flanked sequence can be either excised or inverted depending on 
the relative orientation of the two loxP sites (Fig 1.5 c).   
A cell lineage tracing reporter is usually a transgene with a fluorescent protein or 
lacZ gene following a floxed stop cassette. When used with a reporter, the Cre 
recombinase recognizes the loxP sites and excises the stop cassette, activating the 
reporter. Most but not all reporters are inserted into the Rosa26 locus. Rosa26 locus 
provides a constitutively active gene expression environment which allows the inserted 
transgene to be expressed in all types of tissues and at all life stages. Rosa26 does not 
encode a functional protein and the insertion of exogenous DNA does not cause 
developmental or functional abnormality (Friedrich and Soriano, 1991; Zambrowicz et al., 
1997). Once Cre recombinase excises the stop cassette from a reporter inserted into the 
Rosa26 locus, the reporter is activated and expressed thereafter, regardless of the 
expression pattern of the Cre recombinase afterwards. In this way, cells will be 
permanently marked and their origins can be traced back.  
Due to the success when this method was initially introduced, many 
modifications and improvements of the Cre/loxP system have been done over the years 
(Hayashi and McMahon, 2002; Lewandoski, 2001). First, to study the cell lineages from 
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a specific group of progenitor cells, various tissue-specific Cre-drivers are created, such 
as Ngn3Cre (endocrine pancreas), RIPCre (β cell), Lgr5CreERT2 (intestinal stem cell), and 
AlbuminCre (hepatocyte), etc. (Barker et al., 2007; Gu et al., 2003; Lewandoski, 2001; 
Postic et al., 1999). A list of common Cre drivers used in pancreas research can be 
found in the review by Dr. Magnuson and Dr. Osipovich (Magnuson and Osipovich, 
2013).   
Second, to control the timing of Cre-mediated recombination, a Cre-estrogen 
receptor (ER) fusion protein and its various derivatives (CreER, CreERT2) are designed 
and applied in mammalian models (Feil et al., 1997; Indra et al., 1999; Metzger et al., 
1995). CreER is retained in the cytoplasm by heat shock protein (HSP) 70 and 90. Upon 
the administration of tamoxifen (TM) or its active metabolite 4-hydroxyltamoxifen (4OH-
TM), 4OH-TM binds with the estrogen receptor and dissociates the CreER-HSP complex, 
enables CreER to translocate to the nucleus (Metzger et al., 1995). A fusion protein of 
Cre and progesterone receptor is also created but not widely used (Kellendonk et al., 
1996). Similar to CreER, doxycycline controlled tetON/OFF systems also serve as 
temporal control switches in cell lineage analysis (Belteki et al., 2005; Lewandoski, 2001; 
Urlinger et al., 2000).  
Third, researchers have developed a palette of reporters. These include lacZ 
reporters (Soriano, 1999) and reporters with fluorescent proteins of various colors 
(Madisen et al., 2010; Mao et al., 2001; Srinivas et al., 2001). Dual color reporters, which 
show different colors before and after recombination, not only track cell lineages but also 
allow the visualization of the transition state (Muzumdar et al., 2007; Novak et al., 2000). 
An MADM (mosaic analysis with double markers) reporter is designed to allow 
interchromosomal recombination and mosaic analysis (Tasic et al., 2012; Zong et al., 
2005). The confetti mouse model advances reporters to a new level and is powerful in 
clonal analysis (Livet et al., 2007). Recently, other permissive gene loci, such as Hprt 
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and Cd6, are also reported to be good sites for reporter insertion (Ichise et al., 2014; 
Tasic et al., 2011). The combinatorial utilization of multiple reporters knocked into these 
loci may be useful in certain situations. 
The application of Cre/loxP-based methods provides a powerful tool for 
developmental biologists to track cell lineages. All these toolkits enable researchers to 
analyze cell lineages in great spatial and temporal resolution. In addition to its power in 
cell lineage tracing, Cre/loxP-mediated recombination is also widely used in conditional 
gene activation, inactivation, and cell ablation, etc. (Ivanova et al., 2005; Lewandoski, 
2001; Zhang and Lutz, 2002). Cre-mediated conditional gene manipulation allows 
versatile control of gene expression.  
Despite its power as a cell lineage tracing tool, the Cre/loxP system should be 
used with caution.  In Chapter II, I will discuss the limitations of Cre/loxP-mediated cell 
lineage tracing and gene manipulation. Specifically, I will report the observation of non-
parallel recombination of multiple floxed alleles in the same cell and caution that non-
parallel recombination should be kept in mind when interpreting the results from 
Cre/loxP-mediated DNA recombination experiments. Furthermore, in addition to the 
floxed alleles/reporters, I will review issues around Cre drivers and what we should 
consider in selecting or designing Cre drivers in the discussion section of Chapter II.  
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CHAPTER II 
 
NON-PARALLEL RECOMBINATION LIMITS CRE/LOXP-BASED REPORTERS AS 
PRECISE INDICATORS OF CONDITIONAL GENETIC MANIPULATION 
This chapter is adapted from a publication under the same title (Liu et al., 2013). 
 
2.1 Abstract 
 
Cre/loxP-mediated recombination allows for conditional gene activation or 
inactivation. When combined with an independent lineage-tracing reporter allele, this 
technique traces the lineage of presumptive genetically modified Cre-expressing cells. 
Several studies have suggested that floxed alleles have differential sensitivities to Cre-
mediated recombination, which raises concerns regarding utilization of Cre reporters to 
monitor recombination of other floxed loci of interest. Here, we directly investigate the 
recombination correlation, at cellular resolution, between several floxed alleles induced 
by Cre-expressing mouse lines. The recombination correlation between different reporter 
alleles varied greatly in otherwise genetically identical cell types. The chromosomal 
location of floxed alleles, distance between loxP sites, sequences flanking the loxP sites, 
and the level of Cre activity per cell all likely contribute to observed variations in 
recombination correlation. These findings directly demonstrate that, due to non-parallel 
recombination events, commonly available Cre reporter mice cannot be reliably utilized, 
in all cases, to trace cells that have DNA recombination in independent-target floxed 
alleles, and that careful validation of recombination correlations are required for proper 
interpretation of studies designed to trace the lineage of genetically modified populations, 
especially in mosaic situations.    
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2.2 Introduction 
 
The introduction of Cre/loxP-mediated DNA recombination technique has 
facilitated the investigation of cell origins and the manipulation of gene expression. With 
the advent of a vast array of tissue and cell-specific Cre drivers, fluorescent reporters, 
and high resolution microscopy, this technique has been wildly used in developmental 
biology, immunology, cancer research, and countless other fields. Compared to other 
cell lineage tracing methods, such as dye/radioactive labelling, BrdU incorporation etc., 
genetically-based Cre/loxP method permits a more accurate means of cell lineage 
analysis (Kretzschmar and Watt, 2012).  In addition to its power in cell lineage tracing, 
Cre/loxP-mediated recombination is also widely used in conditional gene activation, 
inactivation, and cell ablation, etc. (Ivanova et al., 2005; Lewandoski, 2001; Zhang and 
Lutz, 2002).  
Nonetheless, the efficiency of Cre does not guarantee 100% recombination. 
Incomplete recombination results in the missing of certain cells in lineage tracing and 
mosaic pattern in the case of ectopic gene expression or gene inactivation. Incomplete 
recombination does not exhibit prohibiting issues as long as proper quantification and 
interpretation are applied, but it is problematic when there are two floxed alleles in one 
cell and their recombination doesn’t occur simultaneously. For instance, Cre/loxP-based 
lineage tracing reporters are often utilized to determine the consequence of genetic 
manipulation at another floxed locus within individual cells or populations of cells. 
However, this assumes that the activation of a reporter allele indicates the recombination 
of the other floxed locus (Dzierzak and Speck, 2008; Gu et al., 2003; Herrera et al., 1998; 
Kawaguchi et al., 2002; Kretzschmar and Watt, 2012; Lao et al., 2012; Spence et al., 
2009). Nonetheless, because the chromosomal location of loxP sites (Vooijs et al., 2001), 
distances between loxP sites (Collins et al., 2000; Koike et al., 2002; Zong et al., 2005), 
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and cell-type-specific epigenetic context of floxed loci (Hameyer et al., 2007; Long and 
Rossi, 2009) all affect recombination efficacy, the occurrence of recombination in one 
allele may not predict recombination in the other within the same cell. Here, we directly 
demonstrate such non-parallel recombination with commonly utilized Cre reporter alleles 
and several Cre/CreERT mouse lines (Table 1). We report that simultaneous 
recombination is not always guaranteed, which complicates results and makes data 
interpretation difficult. We conclude that non-parallel recombination exists and should be 
taken into consideration when examining and interpreting experimental results involving 
Cre/loxP. 
 
2.3 Results  
 
In order to examine the factors that affect Cre-mediated recombination, we 
utilized several pancreatic gene-based Cre driver and several commonly used reporter 
mouse lines to investigate reporter activation. The Cre lines include Pdx1Cre, Pdx1CreERT, 
Ngn3B-Cre, and Sox9CreERT2, which induce recombination in pancreatic or endocrine 
progenitors. The reporters include R26RAi9, R26ReYFP, R26ReGFP, and R26RmTmG, and a 
transgenic Z/EG reporter. Besides the transgenic Z/EG reporter, the other Cre reporters 
are all knocked into the Rosa26 locus but they differ in their floxed sequences and 
ancillary CAG promoter usage. A Pdx1FLOX allele is also used in line with the reporters.  
 
Floxed alleles in the same cell are not always recombined simultaneously  
First, we derived Ngn3B-Cre; R26RAi9/eYFP neonatal mice, wherein the reporter 
alleles at the Rosa26 locus are R26RAi9 and R26ReYFP, and examined the extent of 
parallel reporter activation in endocrine and exocrine pancreatic lineages. Progenitor 
cells that express high levels of Ngn3 become endocrine islet cells, whereas cells that  
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Fig 2.1 Recombination in multiple floxed alleles are independent events. (a–c) Reporter 
activation in neonatal Ngn3B-Cre; R26ReYFP/Ai9 pancreas. RFP (tdTomato), eYFP, and a 
merged channel are presented. Islet cells, broken-lined circle (panel a). Green arrows 
indicate eYFP only cells; red arrows indicate RFP only cells; and yellow arrows indicate 
cells expressing both fluorescent proteins. (d–g) E15.5 pancreatic sections from 
Pdx1FLOX/-; Sox9CreERT2; R26ReYFP embryos (0.3 mg TM injected at E12.5) with 
immunodetection for Pdx1, Sox9, and eYFP. Two merged images [d (Pdx1, Sox9, and 
eYFP) and e (Pdx1 and eYFP)] and two individual channels [f (Pdx1) and g (eYFP)] are 
shown. Yellow arrows, Pdx1+eYFP+ cells. Green arrows, Pdx1-eYFP+ cells. Bars=20 μm. 
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express low levels of Ngn3 become exocrine cells (Schonhoff et al., 2004; Wang et al., 
2010). These properties allowed us to assess the influence of differential Ngn3B-Cre-
driven promoter activity on the recombination correlation between R26RAi9 and R26ReYFP 
(express RFP (tdTomato) or eYFP, respectively). Most, if not all, endocrine islet cells 
(recognizable as tightly packed cell clusters) in Ngn3B-Cre; R26RAi9/eYFP neonatal pancreas 
produced both reporters. In contrast, many acinar and duct cells only produced a single 
reporter, indicating non-parallel recombination (Fig 2.1 a–c). These above findings 
suggest that “high Ngn3-expressing cells” produced high Cre levels sufficient to 
recombine both alleles within individual cells, whereas low-Ngn3- expressing cells 
recombine one allele but not the other.  
To assess the incidence of non-parallel recombination under mosaic 
experimental conditions, we used a Sox9CreERT2 transgene to drive CreERT2 (a 
tamoxifen (TM)- inducible Cre), to recombine a Cre reporter (R26ReYFP) and a floxed 
Pdx1 allele (Pdx1FLOX) whose recombination results in a null mutation. Most, if not all, 
pancreatic progenitor cells express Sox9 and a low level of Pdx1 (Pdx1Lo). When 
pancreatic progenitor cells differentiate into β cells, Pdx1 expression is upregulated 
(Pdx1Hi), while Sox9 becomes inactivated (Fujitani et al., 2006; Kopp et al., 2011). 
Therefore, any Sox9+ pancreatic progenitor cell that has inactivated Pdx1 will be 
incapable of becoming a Pdx1HiSox9- cell. We administered 0.3 mg/mouse TM to 
plugged females at E12.5 to activate CreERT2 in Pdx1FLOX/+; Sox9CreERT2; R26ReYFP 
mouse pancreas in a mosaic fashion, and scored eYFP+ cells for Sox9 and Pdx1 
expression statuses. Three days after TM administration, about half of the eYFP+ cells 
retained Pdx1 production, with a portion of these cells displaying a high Pdx1 signal (Fig 
2.1 d–g), demonstrating that the Pdx1FLOX allele is not inactivated even though 
recombination in the R26ReYFP allele had occurred in some cells. Together, the above  
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Table 1. Reporter alleles, Cre drivers, and conditional alleles used for non-parallel 
recombination study 
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Fig 2.2 Cre-reporter alleles have different sensitivity to Cre-induced recombination. (a) 
Diagrammatic representations of the reporter alleles utilized in this study. (b–g) 
Representative neonatal pancreatic sections of Pdx1CreERT transgene in combination with 
reporter lines: Z/EG, R26ReYFP, R26ReGFP, R26RmTmG, and R26RAi9 without TM 
administration. Natural fluorescence of the expressed FPs is shown. White arrows in 
panel c point to two eGFP+ cells. An image of R26RAi9 pancreatic section (without 
Pdx1CreERT) is also included, to show that its reporter activation depends on the presence 
of CreERT (g). DAPI marks all nuclei, including non-pancreatic mesenchymal cells that 
do not express Cre. (h and i) PCR-based detection of DNA products after expected 
recombination in Pdx1CreERT; R26RAi9; R26RmTmG (h) and Pdx1Cre; R26RAi9; R26RmTmG (i) 
pancreas, respectively. The locations of utilized oligos, P1, P2, and P3 are noted in 
panel (a). A wild control band (WT, a fragment in the Myt1 locus) was utilized as PCR 
control (450bp). The Lox out bands were only detectable after Cre-mediated 
recombination (250bp). Bar=20 μm. 
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findings demonstrate that different levels of Cre influence the efficiency with which one 
can recombine two independent floxed alleles in an individual cell.  
 
Cre reporters have different sensitivity to Cre recombinase activity  
Several available reporters including R26ReGFP, R26RAi9, R26RmTmG, and 
R26ReYFP are derived by Rosa26-based targeting, and contain different stop signals and 
reporter genes (Table 1). Conversely, Z/EG reporter is an insertion-based transgene 
(Lobe et al., 1999; Novak et al., 2000). Recombination events in R26Ai9, R26RmTmG, 
R26ReYFP, and Z/EG lines activate a downstream fluorescence reporter only, whereas 
recombination in R26ReGFP results in an iRES-based bi-cistronic mRNA that produces 
both rtTA and eGFP (Fig 2.2 a). Thus, R26ReGFP produces lower levels of eGFP 
compared with other reporters after recombination. Yet, the eGFP expression pattern in 
R26ReGFP faithfully identifies cells that have undergone recombination (Belteki et al., 
2005). To evaluate, within a linear range, the level of Cre required to activate each 
reporter gene, we took advantage of a Pdx1CreERT line that maintains a low level of Cre 
activity in pancreatic progenitor cells (Gu et al., 2002) in the absence of TM (see below). 
No TM-independent recombination was observed in Pdx1CreERT; Z/EG pancreatic cells 
(Fig 2.2 b). Similarly, less than 0.1% of all pancreatic cells of Pdx1CreERT; R26ReGFP 
underwent recombination (n=6; Fig 2.2 c). Both Pdx1CreERT; R26ReYFP and Pdx1CreERT; 
R26RmTmG mice displayed between 0.4 and 2.7% pancreatic cells with recombination 
(n=6–8; Fig 2.2 d-e). Surprisingly, over one-third of all pancreatic cells in Pdx1CreERT; 
R26RAi9 mice recombined to express RFP (Fig 2.2 f; n=5). None of the reporter mice 
express detectable FPs in the absence of the Cre-expressing transgene (Fig 2.2 g and 
data not shown). To confirm that the lack of reporter gene expression was not a result of 
gene silencing after recombination, we examined DNA recombination in Pdx1CreERT; 
R26RAi9/mTmG (with two reporter alleles at the Rosa26 locus) pancreas by PCR analysis.  
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Fig 2.3 Cre-reporter allele sensitivity can lead to different lineage tracing outcomes. 
Ngn3B-Cre-mediated recombination of the Z/EG (a–c) and R26ReYFP (d–f) reporter alleles. 
Sections from 2-month-old pancreata were utilized [counter-stained with DAPI (blue)]. 
Islets are marked with arrows. In sections of Ngn3B-Cre; Z/EG pancreata, GFP+ cells did 
not react with DBA lectin, which specifically marks pancreatic ducts (c). Note that eGFP+ 
cells observed in duct (green arrows) expressed endocrine hormones (insets in b). Inset 
in c, a higher magnification image to show lack of green cells in a duct section. In Ngn3B-
Cre; R26ReYFP mice, significant numbers of duct (e, green arrows) and acinar cells (f, 
white arrowhead) expressed eYFP reporter. In e, the inset shows hormone staining 
within the boxed area. Also note that the acinar labeling in pancreatic tissues is not 
randomly distributed, so that some microscopic fields do not have eYFP+ exocrine cells 
(d and e). Bar=50 μm. 
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Recombinant DNA product was detected from the R26RAi9 allele but not from R26RmTmG 
(Fig 2.2 h). As a positive control for PCR detection, recombinant products were detected 
at R26RAi9 and R26RmTmG loci in Pdx1Cre; R26RAi9/ mTmG pancreas (Fig 2.2 i). Taken 
together, these data demonstrate differential recombination efficiencies between select 
reporter alleles in a model for low-level Cre activity.  
The above findings strongly suggest that experimental lineage tracing results 
may vary in a reporter line–dependent fashion. We tested this possibility by following the 
lineage of Ngn3-expressing cells using different reporter alleles, to reconcile 
observations suggesting in one case that Ngn3+ cells only give rise to endocrine islet 
cells (Gu et al., 2002), and in another case that Ngn3+ cells also give rise to exocrine 
pancreatic cells (Schonhoff et al., 2004; Wang et al., 2010). We derived Ngn3B-Cre; Z/EG 
and Ngn3B-Cre; R26ReYFP adult pancreata to examine eGFP or eYFP expression. Most of 
the identifiable eGFP+ cells in Ngn3B-Cre; Z/EG pancreata were localized in cell clusters 
producing endocrine hormones (Fig 2.3 a–c). Several single eGFP-producing cells were 
found and within the duct of Ngn3B-Cre; Z/EG pancreas; yet, these lineage-traced cells 
also expressed endocrine hormones (inset in Fig 2.3 b). In contrast, a large number of 
eYFP+ cells were found in pancreatic duct and acinar tissue of Ngn3B-Cre; R26ReYFP mice 
(Fig 2.3 d–f). These findings suggest that reporter selection in Cre-reporter-based 
lineage tracing influence experimental outcomes.  
 
High level of Cre activity cannot fully normalize non-parallel recombination 
Finally, we investigated whether high levels of Cre activity can normalize the 
observed differential sensitivities of R26ReGFP and R26ReYFP reporters. Both Pdx1Cre and 
Pdx1CreERT under high-TM dose conditions were used to produce high Cre activities. One 
milligram of TM was administered to E14.5 pregnant female mice to activate CreERT in 
Pdx1CreERT; R26ReYFP or Pdx1CreERT; R26ReGFP embryos, respectively. Reporter  
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Fig 2.4 Increased Cre activity cannot normalize the variable sensitivity of different floxed 
alleles. Neonatal pancreatic sections of different reporter mice when activated by 
increased levels of Cre with Pdx1CreERT plus TM administration or Pdx1Cre. In the 
presence of TM, Pdx1CreERT induced over a third of pancreatic cells to activate reporter 
expression in R26ReYFP (a). Less than 8% pancreatic cells activated eGFP in R26ReGFP 
mice with TM+Pdx1CreERT (b). Similarly, R26ReYFP also showed higher recombination than 
R26ReGFP when a Pdx1Cre line was analyzed at E11.5 and E14.5 (c–f). Note the red only 
cells (Pdx1 staining to visualize the pancreatic cells) in panels c–f, which indicate the 
cells that failed to undergo recombination. DAPI, blue. Bar=50 μm. 
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expression was characterized in newly born neonates (n=3). Over one-third of 
pancreatic cells in Pdx1CreERT; R26ReYFP mice expressed eYFP (Fig 2.4 a), whereas less 
than 8% of pancreatic cells in Pdx1CreERT; R26ReGFP mice expressed eGFP (Fig 2.4 b). 
Similarly, Pdx1Cre induced eYFP expression in more than 85% of Pdx1Cre; R26ReYFP 
pancreatic cells at E11.5 (Fig 2.4 c), but only 35% of pancreatic cells activated eGFP 
expression in Pdx1Cre; R26ReGFP pancreata at the same stage (Fig 2.4 d). By E14.5, over 
93% of pancreatic cells in Pdx1Cre; R26ReYFP mice activated eYFP expression (Fig 2.4 e), 
whereas only 72% of pancreatic cells activated eGFP expression in Pdx1Cre; R26ReGFP 
mice (Fig 2.4 f; n=3). These data suggest that increased Cre activity is not sufficient to 
normalize the differential sensitivity detected for these two floxed reporter alleles.  
 
2.4 Discussion  
 
Our studies demonstrate that R26RAi9 is the most sensitive reporter of Cre-
mediated recombination, whereas Z/EG is the least sensitive reporter. Our studies also 
directly demonstrate that Cre-mediated recombination in one floxed allele does not 
necessarily report recombination at another allele within the same cell. While this 
phenomenon has been implicated in other experimental settings, it has not been 
demonstrated directly (Hameyer et al., 2007; Long and Rossi, 2009; Schmidt-Supprian 
and Rajewsky, 2007; Vooijs et al., 2001). Importantly, observed non-parallel 
recombination is particularly severe in cells with low levels of Cre activity, which can 
occur in many experimental settings, such as weak promoter-driven Cre or TM-inducible 
CreER activation for mosaic analysis. Our data further implies that reporter sensitivity 
inversely correlates with the distance between loxP sites in the R26-reporter transgenes 
(Table 1). This implication also seemed to be applicable to the Z/EG line, which has the 
greatest inter-loxP distance and lowest sensitivity to recombination, albeit with the 
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additional variable that the Z/EG cassette is located on a different chromosome from the 
R26-based reporters. Furthermore, one unexpected finding from our analysis is that 
R26ReYFP and R26ReGFP have vastly different recombination sensitivities despite identical 
floxed stop signals. This observation suggests that sequences outside the loxP sites 
may influence Cre-based recombination efficiencies. At least two mechanisms could 
contribute to this difference. It is likely that the different sequences downstream the loxP 
sites of R26ReYFP and R26ReGFP result in different methylation status, which has been 
suggested to affect recombination efficiency (Long and Rossi, 2009). Alternatively, the 
different sequences surrounding loxP sites could form different nucleasomal structures 
that affect the accessibility of loxP sites to Cre enzyme. Our current data do not allow us 
to differentiate these two possibilities. Future efforts to unravel these possibilities will 
likely facilitate engineering floxed alleles with specific recombination efficiencies.   
In the above, we primarily focused on the Cre reporters or floxed conditional 
alleles. Nonparallel recombination within a cell results in discrepancies in cell lineage 
tracing results and compromises the use of fluorescent reporters as an accurate 
surrogate marker for gene activation/inactivation. We tapped on the recombinase activity 
level from different Cre drivers and found that high Cre activity level do not fully 
normalize the sensitivity variation from different Cre reporters. In the following discussion, 
I will discuss more about the issues in the design of a new Cre driver or the selection of 
an existing Cre driver in research.  
First of all, Cre protein, especially when excessively expressed as is often the 
case with strong promoter-driven Cre transgenes, exerts toxicity to mammalian cells 
(Schmidt-Supprian and Rajewsky, 2007). The mammalian genome contains pseudo-
loxP sites where Cre recombinase might bind and disrupt the genome (Thyagarajan et 
al., 2000). Although the binding affinity and recombination efficiency is remarkably lower 
on the pseudo-loxP site than on the wild type loxP site, Cre-mediated recombination 
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occurs or leads to DNA damage that is not faithfully repaired. For instance, Cre 
expression under the mouse Protamine 1 (Prm1) promoter causes male sterility due to 
unfaithful Cre activity (Schmidt et al., 2000). It is, therefore, good practice to include 
proper controls, including wild-type, Cre-driver-only, and reporter-only groups, in 
experimental designs.  
Second, the expression pattern of Cre driver one chooses should be carefully 
examined when tissue-specific gene manipulation is desired. Cre driver should faithfully 
recapitulate the expression pattern of the gene of interest. Take RIPCre for example, 
RIPCre is widely used in β-cell and diabetes research as a β-cell-“specific” Cre driver. 
However, RIPCre mice show glucose intolerance and impaired glucose-stimulated insulin 
secretion in both males and females, although severity of the phenotype depends on 
mouse genetic background (Lee et al., 2006). In fact, the RIP promoter is active not only 
in pancreatic β cells but also in the brain, especially the hypothalamus (Lee et al., 2006; 
Wicksteed et al., 2010). Undesirable gene editing in the brain might confound β-cell-
related phenotype and cause ambiguity in interpreting results, providing that the 
hypothalamus is pivotal in regulating food intake and energy metabolism (Koch and 
Horvath, 2014; Mighiu et al., 2013; Sousa-Ferreira et al., 2014). Therefore, extensive 
characterization should be performed the first time a new Cre driver mouse strain is 
generated. In general, knock-in Cre alleles are preferred than transgenes. Transgenes 
are randomly inserted into the genome and they may not fully recapitulate the 
expression pattern of the gene of interest. In addition, random insertion may lead to 
undesirable activation/inactivation of endogenous genes. The Jackson Laboratory has 
comprehensively characterized commonly used Cre drivers and the information is 
publically accessible (Heffner et al., 2012). Cre drivers commonly used in pancreas 
research are also reviewed (Magnuson and Osipovich, 2013).  
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Third, germ line recombination might occur. It has been reported in several cases 
that recombination of floxed alleles occurs in all mouse embryos even when not all of 
them inherit the Cre driver (Hafner et al., 2004; Ramirez et al., 2004; Schmidt-Supprian 
and Rajewsky, 2007). This is probably because Cre recombinase remains active in the 
oocytes until fertilization. To avoid germ line recombination, it is better to maintain Cre 
driver and floxed allele in different parents.  
Fourth, recombination efficiency should be examined. Cre recombinase may not 
be expressed at a substantial amount, especially when it is expressed from a tissue/cell 
type-specific promoter (Long and Rossi, 2009; Postic and Magnuson, 2000). Suboptimal 
Cre expression causes incomplete recombination, leading to mosaic gene 
activation/inactivation and loss of track of progenitors etc., which confounds the 
quantification and interpretation of results. The efficiency of a new Cre driver could be 
tested in vitro and benchmarked against well characterized Cre drivers. In some cases, 
an indicator protein (EGFP) is expressed along with a Cre driver in a bicistronic fashion 
or as fusion proteins, allowing researchers to visualize the Cre+ domain and estimate the 
recombination efficiency (Arnes et al., 2012; Choi et al., 2012; Hudson et al., 2011; 
Magnuson and Osipovich, 2013; Passegue et al., 2004; Woodhead et al., 2006). 
Implementation and development of vast site-specific DNA recombination toolkits, 
including Cre/loxP and FLP/FRT, etc. permits us to interrogate the origins of cell 
lineages in an unprecedented level of versatility and resolution, as well as manipulate 
gene activation or inactivation in a spatiotemporally controlled manner at our will. 
Despite its invaluable power as an indispensable research tool, the interpretation of 
Cre/loxP-mediated DNA recombination and cell lineage tracing should always be treated 
with care.   
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2.5 Materials and methods 
 
Mouse Strains and Care  
Mouse lines R26ReYFP, R26RAi9, Z/EG, and R26ReGFP (see Table 1 for details) 
were from Jackson Laboratory (Bar Harbor, ME). Ngn3B-Cre was a gift from A. Leiter 
(Schonhoff et al., 2004). Sox9CreERT2 was a gift from M. Sander (Kopp et al., 2011). 
Pdx1CreERT, Pdx1Cre, and Pdx1FLOX were previously reported (Gannon et al., 2008; Gu et 
al., 2002; Wang et al., 2007). Tissue collection and section preparation followed 
published methods (Wang et al., 2008).  
Conventional PCR (31 cycles) was utilized to detect the genomic sequences 
derived from recombination of R26RAi9 and R26RmTmG alleles. Control oligos to amplify 
genomic DNA: 5’-CCATGCATATGCCTGGTGCTTGT-3’ and 5’-
GGGTTAGGATTAAGAGTTTTAGT-3’. Oligos for detecting the recombination product 
P1: 5’-GGTTCGGCTTCTGGCGTGTGAC-3’, P2: 5’-GCACCTTGAAGCGCATGAACTC-
3’ and P3: 5’-ACGCTGAACTTGTGGCCGTTTAC-3’ (see Fig 2.2 a). 
All mice were housed and cared in the Vanderbilt Division of Animal Care and in 
compliance to IACUC regulations.  
 
Immunostaining and Confocal Imaging  
Antibodies utilized were as follows: chicken anti-GFP (Aves Labs, Inc., Tigard, 
OR), 1:500; rabbit anti-Sox9 (Millipore, Billerica, MA); guinea pig anti-insulin, guinea pig 
anti-glucagon, rabbit anti-SS, goat anti-PP, FITC-conjugated donkey anti-rabbit, FITC-
conjugated donkey anti-guinea pig, Cy3- conjugated donkey anti-rabbit, Cy3-conjugated 
donkey anti-guinea pig, Cy3-conjugated donkey anti-goat, Cy5- conjugated donkey anti-
rabbit, Cy5-conjugated donkey anti-goat, and FITC-conjugated streptavadin were all 
from Jackson Immunoresearch. Biotin-DBA was from Sigma Aldrich. Antibody detection 
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followed standard protocols (Wang et al., 2007). All antibodies were utilized at a 1:1000 
dilution ratio, or as noted.  
Both confocal imaging and epifluorescence microscopy were used. For semi-
quantification, a quarter (embryonic pancreata) to one-tenth (postnatal pancreata) of the 
pancreas, in 10–20μm sections, was analyzed. Images (usually low magnification to 
image a large area, but high enough to discern single cells properly) were captured 
at >20 microscopic views/slide. Cell numbers were quantified with ImageJ.  
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CHAPTER III 
 
ACTIVATION OF MYT1 IN A SUBSET OF NGN3+ PROGENITORS FACILITATES 
ΒETA-CELL FATE CHOICE 
 
3.1 Abstract    
 
In the developing pancreas, the basic helix-loop-helix (bHLH) transcription factor 
Neurogenin3 (Ngn3) specifies endocrine cells, including insulin-expressing β cells, 
glucagon-expressing α cells, δ, PP, and  cells. How Ngn3+ progenitors differentiate into 
various endocrine cell types is not clearly understood. Interestingly, we found that Ngn3+ 
progenitors are heterogeneous in terms of their co-expression pattern with other 
transcription factors, such as Myt1. This heterogeneous co-expression pattern divides 
Ngn3+ progenitors into subsets (i.e., Ngn3+Myt1+ and Ngn3+Myt1- subsets). By using a 
novel bipartite Cre lineage tracing method, we were able to perform lineage tracing of 
the Ngn3+Myt1+ progenitor subpopulation and found that Ngn3+Myt1+ progenitors 
favored β cells over α cells. Preliminary epigenetic studies showed that DNA methylation 
of a regulatory element, Myt1 region 2, decreased from E10.5 to E15.5, which may 
facilitate enhanced Myt1 expression and β cell differentiation. Perturbing methylation by 
chemical inhibition and Dnmt3b (DNA methyltransferase 3b) overexpression both altered 
β-to-α ratio, although detailed mechanism awaits further investigation. The bipartite Cre 
cell lineage tracing technique will enable us to delineate the differentiation program of 
pancreatic endocrine progenitors and holds great potential in mapping stem cell fate in 
other systems. 
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3.2 Introduction 
 
The pancreas is a pivotal organ of the human body. It is composed of both 
exocrine and endocrine cells. The exocrine cells, including duct cell and acinar cells, are 
responsible for secreting and delivering digestive enzymes to the duodenum. The 
endocrine pancreas is scattered among the acinar cells as islets and comprises α, β, δ, 
PP, and ε cells. Endocrine pancreas development is regulated by a cascade of 
transcription factors. During embryogenesis, a domain within the foregut epithelium 
expressing Pdx1 is reserved for pancreas (Jonsson et al., 1994; Offield et al., 1996). 
Ngn3 is then activated in the Pdx1+ primordia, which marks the endocrine progenitors 
(Gradwohl et al., 2000; Gu et al., 2002). Ngn3+ pro-endocrine progenitors then 
differentiate into all types of endocrine cells, as a result of the interplay of various 
transcription factors, including Pax4, Arx, Myt1, Nkx2.2, Insm1, and Nkx6.1, etc. 
(Collombat et al., 2006; Jensen, 2004; Pan and Wright, 2011).  
Although Ngn3+ progenitors as a population produce all types of endocrine cells, 
it is unclear how individual Ngn3+ progenitor makes its decision to become one 
endocrine cell type. Johansson et al. proposed a competence window model that the 
specification of endocrine cells occurs in sequential time windows but not in random 
(Johansson et al., 2007). α cells are produced first, starting from as early as E9.5. Next, 
during E12.5–E16.5, there is a major wave of β-cell generation, with many α cells also 
being differentiated during this time period. δ and PP cells do not appear until late 
gestational stages. The phenomenon of successive (but partially overlapping) 
differentiation of endocrine cells suggests that Ngn3+ endocrine progenitors pass 
through consecutive temporal windows during which their differentiation competence 
changes. Johansson et al. also found that the competence of Ngn3+ progenitors is 
intrinsic to the epithelium but not influenced by signaling from the surrounding 
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mesenchyme. When they recombined embryonic pancreatic epithelium and 
mesenchyme in a stage-matched or heterochronic manner, they discovered that the 
distribution of endocrine cells is similar between groups if the pancreatic epithelia are of 
the same stage, regardless of the stage of the mesenchyme used (Johansson et al., 
2007). It appears endocrine differentiation in the pancreatic epithelium is autonomously 
regulated. I therefore focused on the many transcription factors pertaining to the 
endocrine progenitors but not external signaling and investigated the roles of 
transcription factors in determining endocrine cell fate.  
A cascade of transcription factors regulates the endocrine differentiation process 
(Jensen, 2004; Wilson et al., 2003) and many of them are Ngn3 downstream targets. 
These include Arx (Collombat et al., 2003), Pax4 (Smith et al., 2003), NeuroD (Huang et 
al., 2000), Nkx2.2 (Watada et al., 2003), and Insm1 (Mellitzer et al., 2006; Osipovich et 
al., 2014) etc. In the early pancreatic endocrine progenitors, Arx and Pax4 are co-
expressed (Collombat et al., 2005). Then, Pax4 is gradually restricted to β and δ 
lineages and is switched off after birth; Arx expression, on the other hand, is restricted to 
α cells and its expression persists in adult α cells. Experimental evidences suggest that 
Arx and Pax4 specify α cell and β/δ cell lineages, respectively. Deletion of Pax4 results 
in the loss of β and δ endocrine lineages (Sosa-Pineda, 2004). In contrast, loss of Arx 
leads to increased β and δ cell number at the expense of α cells (Collombat et al., 2003). 
Expectedly, Pax4 ectopic expression in α cells converts them into β cells in vivo 
(Collombat et al., 2009) while misexpression of Arx in β cells leads to their conversion to 
glucagon+ and PP+ cells (Collombat et al., 2007). NeuroD, a basic helix-loop-helix 
transcription factor and an Ngn3 downstream target (Huang et al., 2000), is required for 
endocrine differentiation. Loss of NeuroD results in the reduction of all endocrine cells 
and a reduced β-to-α and β-to-δ cell ratio, suggesting the significance of NeuroD in 
regulating endocrine differentiation, especially β-cell lineage specification (Naya et al., 
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1997). The homeodomain transcription factor Nkx2.2 functions in both β-cell 
specification during embryogenesis and β-cell function maintenance in the adulthood 
(Doyle and Sussel, 2007; Sussel et al., 1998). Nkx2.2-deficient mice develop 
hyperglycemia due to the lack of β cells and die shortly after birth (Sussel et al., 1998). 
In β cells, Nkx2.2 can recruit a repressor complex composed of Groucho 3 (Grg3), DNA 
methyltransferase 3a (Dnmt3a) and histone deacetylase 1 (Hdac1) to enhance the 
methylation of Arx upstream regulatory elements and thus prohibit the acquisition of α 
cell fate (Mastracci et al., 2011; Papizan et al., 2011). The zinc finger transcription factor 
Myt1 is expressed in endocrine progenitor cells as well as most mature endocrine cells 
(Wang et al., 2007). Loss of Myt1 in the developing pancreas results in abnormal multi-
hormone positive cells, suggesting that endocrine differentiation or maturation is 
disrupted (Wang et al., 2007). Insm1, another Ngn3 downstream gene (Mellitzer et al., 
2006), regulates pancreatic endocrine differentiation through a gene network that 
involves cell adhesion, cell migration, extracellular matrix remodeling, cell proliferation, 
and mRNA alternative splicing etc. Loss of Insm1 decreases the delamination of pro-
endocrine progenitors, leads to alternative splicing of Ngn3 mRNA, and decreases β-cell 
production (Osipovich et al., 2014). In addition to transcription factors, connective tissue 
growth factor (CTGF), an extracellular protein, also influences endocrine lineage 
allocation. Deletion of CTGF results in a reduced β-to-α cell ratio and altered islet 
morphology in the adult mice, although it is not clear how CTGF affects endocrine 
lineage allocation (Crawford et al., 2009). Since CTGF contains multiple domains that 
modulate TGF-β, BMP, and Wnt signaling, it could transduce extracellular signal into the 
nucleus and regulate the expression of endocrine lineage determination effectors.  
Although much effort has been devoted to investigating the role of individual 
transcription factors in endocrine lineage determination, little information is known 
concerning how transcription factors concertedly specify endocrine lineages. To this end, 
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simultaneous loss of transcription factors is achieved in mouse models and endocrine 
lineage allocation is altered as a result. Such double knockout experiments unveil the 
interactions between transcription factors. For instance, simultaneously loss of Arx and 
Pax4 promotes δ cell fate at the expense of α and β cell fate (Collombat et al., 2005). 
Compound loss of Arx and Nkx2.2 results in somatostain+ghrelin+ cells at the expense of 
α and β cells (Kordowich et al., 2011; Mastracci et al., 2011). Co-loss of Nkx2.2 and 
Pax4 results in the loss of β cells (Wang et al., 2004). In addition to global gene 
knockout, conditional deleting or overexpressing key endocrine transcription factors 
specifically in the Ngn3+ domain also causes the reallocation of endocrine lineages. For 
instance, loss of Nkx6.1 in Ngn3+ progenitors results in the loss of β cells and increases 
non-β endocrine cells. The remaining insulin+ cells lack MafA and Pdx1 expression and 
are probably dysfunctional, suggesting that Nkx6.1 is necessary for both β-cell 
differentiation and maturation (Schaffer et al., 2013). On the contrary, Ngn3Cre-mediated 
Nkx6.1 overexpression favors β-cell allocation (Schaffer et al., 2013). In another report, 
ectopic Pdx1 overexpression in the Ngn3+ domain promotes β-cell differentiation at the 
expense of α cells (Yang et al., 2011). A “combinatorial transcription factor code” is 
proposed that co-expression of transcription factors designates certain endocrine cell 
lineage(s) (Jorgensen et al., 2007). Indeed, we observed that the Ngn3+ progenitors are 
a heterogeneous population with a mosaic expression pattern with Myt1, Nkx2.2, Pax4, 
among many others (Fig 3.1 and references: Collombat et al., 2003; Soyer et al., 2010). 
Thus, we hypothesize that different Ngn3+ subpopulations (e.g., Ngn3+Myt1+ and 
Ngn3+Myt1-) possess different differentiation potential.  
However, the above data are obtained through loss-of-function or ectopic 
expression experiments. No definitive cell lineage tracing experiments have been done 
to directly test the possibility of transcription factor combination-mediated endocrine 
lineage determination. The currently available recombinase-based cell lineage tracing 
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techniques, including Cre/loxP and FLP/FRT systems, can hardly answer the above 
question because they can only capture progenitor cells marked by one molecular 
marker.  
In order to analyze the differentiation potential of Ngn3+ progenitor subsets, e.g., 
Ngn3+Myt1+ progenitor subpopulation, we utilized a novel bipartite Cre cell lineage 
tracing system. This bipartite Cre system allowed us to track cell lineages of double 
marked progenitors. With this tool, we found that Ngn3+Myt1+ progenitors favored β cells 
over α cells. It should be noted that pancreatic endocrine cells are differentiated 
successively according to a competence window model (Johansson et al., 2007). α cells 
are produced starting from E9.5, while β cells are produced mainly from E12.5 to E16.5.  
Our preliminary epigenetic studies showed that methylation of a Myt1 regulatory region 
in the Ngn3+ progenitors decreased from E10.5 to E15.5, which was correlated with 
elevated Myt1 expression and β cell production. It is possible that enhanced Myt1 
expression in the Ngn3+ progenitors initiated the β-cell differentiation program, although 
the involvement of other transcription factors or signaling pathways could not be 
excluded. 
 
3.3 Results 
 
Ngn3+ progenitors are heterogeneous  
In order to dissect the heterogeneity of endocrine progenitors, I first examined 
the co-expression pattern between Ngn3 and several other endocrine transcription 
factors, including Myt1, Nkx2.2, Pdx1, and Pax4 (Fig 3.1). In the E14.5 pancreas, 
34.0±2.1% (n=6) of the Ngn3+ progenitors were Ngn3+Myt1+ and 67.0±1.7% (n=8) of the 
Ngn3+ progenitors were Ngn3+Nkx2.2+. This heterogeneity was not observed for every 
transcription factor though. For instance, Pdx1 expression was detected in all Ngn3+  
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Fig 3.1 Ngn3+ progenitors are heterogeneous. Co-staining of Ngn3 and other 
transcription factors (TFs) Myt1, Nkx2.2 or Pax4HA showed a mosaic co-expression 
pattern. Both Ngn3 single (green arrow) and Ngn3/TF double positive cells could be 
found. Pax4 expression was visualized by staining against HA tag in the Pax4HA/+ mouse 
pancreas. Pdx1 was expressed in all Ngn3+ progenitors. Stage: E14.5. Scale bar: 50μm. 
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Fig 3.2 Myt1 etc. expression is Ngn3-dependent. (a) Embryonic pancreas sections were 
stained with Myt1, Nkx2.2, HA (for Pax4), in together with Pdx1. Left panel: wild-type 
pancreas. Right panel: Ngn3EGFP/EGFP (Ngn3-null) pancreas. The expression of Myt1, 
Nkx2.2 and Pax4 was almost absent in the Ngn3EGFP/EGFP pancreas whereas Pdx1 
expression was largely unaffected. Stage: E14.5. Scale bar: 50μm. (b, c) Gene 
transcription data from RNA-Seq. y axis: normalized transcript abundance RPKM 
(readings per kilobase per million reads); x axis: three embryonic stages. Solid lines 
represent data from the Ngn3EGFP/+ sample while dashed lines represent data from the 
Ngn3EGFP/EGFP sample. Lines of the same color in each graph represent the same gene.  
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cells, although Pdx1 is a key transcription factor in establishing and maintaining β-cell 
fate (Gao et al., 2014; Yang et al., 2011). I also examined the co-expression pattern at 
E16.5 and the percentages were not significantly different: 32.7±1.3% (n=8) of Ngn3+ 
progenitors were Ngn3+Myt1+ and 63.6±2.8% were Ngn3+Nkx2.2+ (n=8), implying that 
the heterogeneous pattern did not shift along development. Though without 
quantification, I also found that Pax4 was expressed only in a subset of Ngn3+ 
progenitors (Fig 3.1).  
Interested in whether this heterogeneous co-expression pattern was Ngn3-
dependent, I performed co-staining in both wild-type and Ngn3EGFP/EGFP pancreas. 
Ngn3EGFP allele is an Ngn3-knockout allele in which the EGFP cassette is knocked into 
the endogenous Ngn3 locus to replace the entire coding region of Ngn3 (Lee et al., 
2002). I did not detect Myt1 or Nkx2.2 expression in the pancreatic epithelium of the 
Ngn3EGFP/EGFP pancreas, indicating that the expression of Myt1, Nkx2.2 and Pax4 
depended on Ngn3 (Fig 3.2 a).  
Ngn3-dependent expression pattern was corroborated by RNA-Seq data. 
Previously, the Gu lab obtained RNA-Seq data for Ngn3+ progenitors (using EGFP as a 
surrogate marker for Ngn3 expression; data unpublished) at E10.5, E15.5 and E18.5. At 
all stages, Myt1, Nkx2.2, Pax4, and Arx showed negligible expression in the 
Ngn3EGFP/EGFP pancreas in contrast to the Ngn3EGFP/+ pancreas (Fig 3.2 b, c), suggesting 
that these transcription factors were Ngn3-dependent. The RNA-Seq data were 
consistent with immunostaining results (Fig 3.2 a) and previous reports that these 
transcription factors were Ngn3 downstream targets (Collombat et al., 2003; Smith et al., 
2003; Wang et al., 2008; Watada et al., 2003).  
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Design of a novel bipartite Cre cell lineage tracing system  
In order to understand the endocrine lineage allocation process in pancreas 
development, I wanted to follow the cell fate of Ngn3+ progenitor subsets, for example, 
Ngn3+Myt1+ cells. However, the conventional recombinase-based cell lineage tracing 
system (Cre/loxP or FLP/FRT) is not sufficient to track the cell fate of double-marked 
cells. Dual-reporters, which take advantage of both the Cre/loxP and FLP/FRT 
recombination system, are created (Imayoshi et al., 2012; Yamamoto et al., 2009). Such 
dual-reporters usually have two tandem cassettes each flanked by loxP or FRT sites. 
The activation pattern of the dual-reporters varies depending on how the dual-reporters 
are designed and should be examined case-by-case. The principle underlying the dual-
reporters is the same; that is, reporter activation pattern reflects whether one or two 
genes of interest are active. However, these dual-reporters cannot address our research 
question either because the recombination events mediated by Cre and FLP are 
independent. Dual-reporters cannot distinguish between successive recombination and 
simultaneous recombination events. The expression time frames of the two genes used 
to drive the expression of Cre and FLP do not necessarily have to overlap for reporter 
activation. In the pancreas, Ngn3 and Myt1 are both expressed in progenitor cells. The 
expression window of Ngn3 in an individual progenitor cell is less than 48 hours (Gu et 
al., 2002; Schwitzgebel et al., 2000). Then Ngn3 expression diminishes in the mature 
endocrine cells whereas Myt1 expression persists in most endocrine cells (Wang et al., 
2007). Therefore, these dual-reporters would not allow us to capture and only capture 
the real Ngn3+Myt1+ progenitors as long as two recombination events are involved. 
To circumvent this obstacle, the Gu lab designed a bipartite Cre cell lineage 
tracing system (Fig 3.3).  In this system, the Cre protein is split into two halves, the N-
terminal half (nCre) and the C-terminal half (cCre). Neither of the two halves is functional 
unless they reassemble into a full Cre. We also added nuclear localization signal (NLS)  
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Fig 3.3 Design of the bipartite Cre. (a) Conception of the bipartite Cre. In conventional 
Cre-mediated DNA recombination, one promoter (e.g., Ngn3) drives the expression of 
full length Cre, which subsequently excises a stop cassette and activates reporter 
expression (e.g., red fluorescent protein (RFP) reporter). However, this strategy only 
allows tracking progenitor cells with one marker (e.g., Ngn3). In the bipartite Cre design, 
full length Cre recombinase is split into two halves and driven by distinct promoters (e.g., 
Ngn3 and Myt1). Neither Cre half is functional unless they are expressed in the same 
cell and reconstitute into a full Cre, which in turn activates the reporter. (b) Schematic 
design of bipartite Cre. Wild type Cre is split between S279 and G280. Leucine zipper 
(N- and C- peptide) and nuclear localization signal (NLS) sequences are fused to nCre 
and cCre to facilitate reconstitution and nuclear localization, respectively.  
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Fig 3.4 Generation of mouse lines and gene targeting scheme. (a) Gene targeting 
scheme of Ngn3nCre allele. A targeting vector containing nCre-T2A-Ngn3 is inserted into 
the endogenous locus of Ngn3 through RMCE. An existing Ngn3HA.LCA allele serves as 
the loxed cassette acceptor. The nCre-T2A-Ngn3 coding sequence follows the ATG 
starting codon of endogenous Ngn3. The FRT-flanking hygromycin selection marker is 
removed via crossing with a transgenic FLPe mouse. (b) Generation of the transgenic 
Myt1cCre mouse. Myt1cCre mouse is generated through BAC recombineering. A targeting 
vector containing cCre is first inserted into the Myt1 BAC to harness Myt1 regulatory 
sequence. Recombined BAC is then introduced into the mouse genome by pronuclear 
injection. (c) Genotyping bands. 
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and leucine zipper sequences to both the nCre and cCre to facilitate their nuclear 
localization and reconstitution. The initial work was published in Nucleic Acids Research 
in 2007 (Xu et al., 2007). Since then, the Gu lab has optimized this bipartite Cre system, 
including optimizing codon usage for the expression in mammals, and selecting a new 
split site to improve the reassembly and the reconstituted recombinase activity. In the 
current version of bipartite Cre, the split site is between Ser299 and Gly280. This 
position resides in a flexible region between α-helix J and K, minimizing the disruption of 
Cre three-dimensional structure (Guo et al., 1997). A similar split Cre system has been 
used to map the fate of neural stem cells (Beckervordersandforth et al., 2010; Hirrlinger 
et al., 2009b), but ours is the first one to be used in pancreas development research. 
Besides, the split site choice and the peptide used for facilitating reconstitution are 
different in the two designs.  
I wanted to use Ngn3 and Myt1 promoters to drive the expression of nCre and 
cCre respectively so that I could perform lineage tracing for the Ngn3+Myt1+ progenitors. 
Because Ngn3 expressing level affects cell lineage allocation during pancreas 
development (Wang et al., 2010), I decided to make an Ngn3-T2A-nCre knock-in mouse 
by utilizing the T2A peptide to avoid potential haploinsufficiency effect. T2A peptide is an 
18-amino acid (AA) peptide that allows bicistronic expression from a single mRNA 
through a ribosome skip mechanism (Donnelly et al., 2001). After its cleavage, the T2A 
peptide leaves a 17-AA tail in the leading protein and a proline in the N-terminus of the 
following protein. Concerned about the effect of the 17-AA tail and the leading proline on 
the stability and function of Ngn3 and nCre (Varshavsky, 1996), I first compared Ngn3-
T2A-nCre and nCre-T2A-Ngn3 in a cell transfection-based reporter assay. I found that 
nCre-T2A-Ngn3 gave higher recombinase activity than Ngn3-T2A-nCre when other 
conditions were the same. 62.7±1.8% (n=3) of transfected cells underwent 
recombination by the nCre-T2A-Ngn3 (in together with a cCre) while only 49.4±2.7% 
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(n=3) of transfected cells were recombined by the Ngn3-T2A-nCre (p value = 0.01). 
Therefore, I decided to create an Ngn3nCre-T2A-Ngn3 knock-in allele (Ngn3nCre thereafter). In 
collaboration with the Transgenic Mouse/ES Share Resource at Vanderbilt, we used the 
recombination-mediated cassette exchange (RMCE) strategy to generate the Ngn3nCre 
knock-in mouse. The nCre-T2A-Ngn3 target vector was electroporated into embryonic 
stem (ES) cells derived from the Ngn3HA.LCA mouse (mouse generated by the Gu lab; 
data unpublished yet) and knocked into the endogenous Ngn3 locus (Fig 3.4 a).   
Instead of making a knock-in Myt1cCre mouse, we created a transgenic Myt1cCre 
allele because a previously made knock-in Myt1cCre failed to achieve robust 
recombination activity. In making the Myt1cCre mouse, we utilized a bacteria artificial 
chromosome (BAC) recombineering strategy such that as many regulatory sequences 
as possible were preserved in the transgenic mice (Fig 3.4 b).  
Because reconstituted bipartite Cre had lower activity than full length Cre (Xu et 
al., 2007), we decided to use the Rosa26tdTomato (Ai9 for short) reporter for lineage tracing 
analysis (Madisen et al., 2010). Ai9 is a very sensitive reporter possibly due to its 
relatively shorter stop cassette than most other reporters (Liu et al., 2013). tdTomato 
displays bright signal under the microscope and its signal is preserved even after 
paraformaldehyde fixation, making it an ideal fluorescent protein reporter for cell lineage 
tracing. 
 
Characterization of mouse models  
I first characterized the mouse models before proceeding to perform lineage 
tracing experiments. 
First of all, the transgenes did not affect the overall mouse physiology. Mouse 
litters were born in a Mendelian ratio. Their body weight and blood glucose level were 
measured and no significant differences were observed between the  
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Fig 3.5 Characterization of the bipartite Cre cell lineage tracing mouse model. (a, b) 
Quantification of β-cell amount in P0 pancreas. (a): Insulin staining. P0 pancreas sample 
is stained with insulin antibody and signal is amplified with DBA staining. Sample is 
counter-stained with eosin. (b): quantification of β-cell amount. β-cell amount is 
measured as the percentage of total pancreas area. There is no significant difference 
between the wild-type pancreas and the Ngn3nCre/+;Myt1cCre;Ai9/+ (NMA) pancreas. (c) 
Measurement of newborn blood glucose level. No significant difference in blood glucose 
concentration is detected between the wild-type and the Ngn3nCre/+;Myt1cCre;Ai9/+ 
neonates . (d) Intraperitoneal glucose tolerance test (IPGTT) of the wild-type and the 
Ngn3nCre/+;Myt1cCre;Ai9/+ adult mice (6 weeks). Glucose clearance capacity is not 
impaired in the Ngn3nCre/+;Myt1cCre;Ai9/+ mice. 
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Ngn3nCre/+;Myt1cCre;Ai9/+ trigenic mice and their wild-type littermates. Resting blood 
glucose of the trigenic neonates was 67.2±2.0mg/dL (n=6), which was indistinguishable 
from the wild-type newborns (72.2±2.5mg/dL, n=6; p value=0.171) (Fig 3.5 c).  
Second, β-cell mass (measured by the percentage of insulin+ cells out of total 
pancreas area) was not significantly different between the trigenic mice and the wild-type 
mice. At P0, 3.39±1.02% (n=5) of the total pancreas area of the trigenic mice was 
insulin+ and the percentage for the wild-type mice was 3.38±1.16% (Fig 3.5 a-b) (n=3, p 
value=0.996).  
Mouse physiology was also normal in the adulthood (Fig 3.5 d). At 6 weeks, the 
blood glucose level of the Ngn3nCre/+;Myt1cCre;Ai9/+ mice after overnight fasting was 
107.9±8.0mg/dL (n=7) and was not statistically different from that of the wild-type mice 
(102.8±9.6mg/dL, n=6; p value=0.695). I also performed intraperitoneal glucose 
tolerance test (IPGTT) assay on these mice and did not observe any significant 
differences either. Although the Ngn3nCre/+;Myt1cCre;Ai9/+ mice showed higher blood 
glucose level (361.0±16.3mg/dL) than their wild-type littermates (327.3±47.6mg/dL) 15 
minutes after IP glucose challenge, the difference was not statistically significant (p 
value=0.528) and the trigenic mice could quickly clear excessive blood glucose. By 2 
hours, the blood glucose level returned to normal (133.6±10.0mg/dL for trigenic versus 
136.8±10.5mg/dL for wild type). There appeared no significant differences between 
female and male trigenic mice.  
Last but not least, this bipartite Cre system was stringently regulated. As 
expected, tdTomato was only expressed in the islets when the Ai9 reporter was 
activated (Fig 3.6). In addition, of all the genotypes I examined, only the 
Ngn3nCre/+;Myt1cCre;Ai9/+ pancreas expressed tdTomato. This suggested that the bipartite 
Cre system is a very robust system and only labels double-marked cells.  
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Fig 3.6 Overall labelling of pancreas of the bipartite Cre mouse model. low magnification 
confocal images showing the overall expression pattern of tdTomato. Upper panel: 
Ngn3nCre/+;Myt1cCre;Ai9/+mouse pancreas section. Lower panel: representative images 
from all other non-trigenic mice. tdTomato (Ai9 reporter) is only activated in the 
Ngn3nCre/+;Myt1cCre;Ai9/+ mouse islets. Stage: P0. Scale bar: 100μm. 
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Lineage tracing shows β-cell biased cell fate of Ngn3+Myt1+ progenitors  
I and Dr. Gu then examined the cell lineages derived from Ngn3+Myt1+ 
progenitors with the Ngn3nCre/+;Myt1cCre;Ai9/+ mouse model. P0 pancreas was dissected 
and the labeling of each endocrine cell type by the Ai9 reporter was examined by 
immunostaining, imaging and quantification.  
Cell lineage tracing quantification showed β-cell biased choice made by the 
Ngn3+Myt1+ progenitors (Fig 3.7). At P0, we found that 52.6±2.9% of the insulin+ cells 
were labelled by the Ai9 reporter while this number was only 12.7±1.9% for the 
glucagon+ cells, 35.5±2.4% for the SS+ cells, and 55.9±4.0% for the PP+ cells (n=8-13). 
Since dramatically more insulin+ cells than glucagon+ cells were labelled by the Ai9 
reporter (p<0.0001), this suggested a β-cell biased choice made by the Ngn3+Myt1+ 
progenitors. This cell fate bias appeared as early as E16.5 when the Ngn3+Myt1+ 
progenitors contributed to 57.1±4.9% of the β cells but only 12.9±1.5% of the α cells 
(p<0.0001, n=7-8). Moreover, we obtained consistent results when using the Rosa26EYFP 
reporter (Srinivas et al., 2001) that the Ngn3+Myt1+ progenitors favored β cells over α 
cells. These results suggested that earlier Ngn3+Myt1+ progenitors preferentially gave 
rise to β cells, but not α cells. At late gestational stages, the Ngn3+Myt1+ progenitors also 
preferentially gave rise to δ and PP cells. 
 
DNA methylation of a Myt1 regulatory element in the Ngn3+ progenitors decreases 
over development  
The Gu lab previously obtained RNA-Seq data for Ngn3+ progenitors at E10.5, 
E15.5 and E18.5 and the data allowed us to assess the temporal expression pattern of 
major endocrine transcription factors. For instance, Myt1 and its homologous gene Myt3 
all showed low expression at E10.5 but dramatic increase at E15.5 and continued high 
expression at E18.5. Another Myt gene member, Myt1L, was minimally expressed  
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Fig 3.7 Bipartite Cre cell lineage tracing result and quantification. (A) Pancreas sections 
were stained with anti-endocrine hormone antibodies (green). Red: tdTomato. Stage: P0. 
Genotype: Ngn3nCre/+;Myt1cCre;Ai9/+. Scale bar: 50μm. (B) Quantification of cell lineage 
tracing results at two time points, P0 and E16.5. 
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across all stages, probably due to genetic redundancy and expression repression (Wang 
et al., 2007) (Fig 3.2 b). Pax4 expression was negligible at E10.5 while Arx displayed 
robust expression. At 15.5, although both Pax4 and Arx showed relatively high mRNA 
amount, Arx was outcompeted by Pax4 (Fig 3.2 c). The balance between Pax4 and Arx 
is important in specifying β- versus α-cell lineages because of their antagonizing 
relationship (Collombat et al., 2003). Our RNA-Seq data of Pax4 and Arx fitted well in 
the competence window model (Johansson et al., 2007): Arx was initially expressed and 
α cells were mainly produced; later on, Pax4 dominated Arx and β cells were generated 
during the secondary transition.  
To examine what caused the change in gene transcription, Dr. Gu and I 
investigated the epigenetic status of Ngn3+ progenitors. We focused on DNA methylation 
of key transcription factors using a bisulfite sequencing assay. The bisulfite sequencing 
data will provide us with information of gene regulation and endocrine lineage 
specification.  
In choosing candidate loci for DNA methylation analysis, I consulted both the 
literature and bioinformatics prediction. To this end, I focused on a regulatory element 
we coined as Myt1 region 2. Myt1 region 2 lies in the first intron of Myt1 gene and is a 
predicted CpG island by the MethPrimer algorithm (Li and Dahiya, 2002). In addition, 
this Myt1 region 2 overlaps with a reported conserved promoter region across species, 
which is supposedly bound by Ngn3 (Wang et al., 2008).  
We made several interesting discoveries about the DNA methylation status of 
Myt1 region 2 (Fig 3.8). First, it seemed that DNA methylation of Myt1 region 2 was 
Ngn3-independent because the average DNA methylation rate of the region was not 
significantly different between the Ngn3EGFP/+ and the Ngn3EGFP/EGFP pancreas and this 
was true for both E10.5 and E15.5 stages. This implied that Ngn3 was not involved in 
the deposition, maintenance, or removal of DNA methylation marker in Myt1 region 2.  
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Fig 3.8 Temporal change of DNA methylation status of Myt1 region 2. (A) Bisulfite 
sequencing results of Myt1 region 2 (+3684bp to +3865bp). Two types of samples were 
used: Het (Ngn3EGFP/+) and Null (Ngn3EGFP/EGFP). EGFP+ cells were sorted by FACS and 
subject to bisulfite conversion, amplification and sequencing. Black dots represent 
methylated CpG dinucleotides. Open circles represent unmethylated CpG dinucleotides. 
(B) Box-whisker graph of the quantification of CpG methylation. EGFP+ progenitors of 
E10.5 had higher DNA methylation at Myt1 region 2 than that of E15.5. 
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Secondly, DNA methylation of Myt1 region 2 was statistically higher in the EGFP+ 
progenitors isolated from E10.5 Ngn3EGFP/+ pancreas (71.4±9.4%, n=7) than the E15.5 
counterpart (47.5±5.2%, n=23). DNA methylation data was consistent with our RNA-Seq 
data. It is possible that DNA methylation-mediated Myt1 transcription repression 
restricted Myt1 expression at a low level at E10.5, when α cells were primarily generated. 
As development progresses, hypomethylation of Myt1 region 2 led to elevated Myt1 
expression, which facilitated β-cell generation. Whether this was passive loss of DNA 
methylation or active demethylation was not clear though. 
 
Interfering with DNA methylation alters β-to-α cell ratio 
Because the methylation status of Myt1 region 2 decreased from E10.5 to E15.5, 
Dr. Gu and I wanted to know whether the disruption of DNA methylation would change 
endocrine cell lineage allocation. To this end, we attempted two methods to manipulate 
DNA methylation.  
In the first method, we cultured embryonic pancreas in vitro in the presence of a 
small chemical inhibitor, adenosine periodate oxidized (Adox) to inhibit overall 
methylation. In this in vitro culture assay, E11.5 pancreas was dissected out and 
cultured on Matrigel or porous membrane filter for three days before fixation and 
examination by either whole mount staining or section staining. Though preliminary, our 
data showed that 10μM Adox treatment increased the insulin+ to glucagon+ cell ratio (Fig 
3.9). In order to validate this result and examine the changes of gene expression that 
caused this elevated β-to-α cell ratio, I performed quantitative real-time PCR (qRT-PCR) 
to detect the expression level of hormone and endocrine transcription factor genes. 
However, due to the fact that the enveloping mesenchyme cannot be fully dissected 
away from the pancreatic epithelium, qRT-PCR data fluctuated depending on how much 
the epithelium was contaminated by the mesenchyme (data not shown). An epithelium- 
70 
 
 
 
 
 
 
 
Fig 3.9 Adox treatment increases β-to-α cell ratio in in vitro cultured pancreatic buds. 
Either 10μM Adox or DMSO was added into the culture medium for in vitro pancreatic 
buds culturing. Pancreatic buds were dissected out from E11.5 wild-type embryos and 
cultured for 3 days. Sections were prepared on the 3rd day and stained with anti-insulin 
and anti-glucagon antibodies. 
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Fig 3.10 Dnmt3b overexpression results in an increased β-to-α cell ratio. Timed pregnant 
female mice were administered with doxycycline intraperitoneally from E8.5 to E15.5 to 
induce Dnmt3b overexpression in the Rosa26M2-rtTA/+;ColA1tetOP-Dnmt3b/+ fetus. Pancreas 
was dissected at E15.5 and analyzed with standard IHC by staining sections with anti-
insulin and anti-glucagon antibodies. Scale bar: 20μm.  
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specific normalization control, in contrast to the commonly used house-keeping genes 
GAPDH or PPIA, will possibly solve this problem. Nonetheless, whether the expression 
of such an epithelium-specific gene is influenced by Adox treatment remains unclear. It 
will be helpful to include several epithelium-specific genes to determine whether anyone 
of them can serve as a proper normalization control.  
In a second strategy, we attempted to increase DNA methylation with an 
inducible Dnmt3b (DNA methyltransferase 3b) overexpression model (Linhart et al., 
2007). In this Rosa26M2-rtTA/+;ColA1tetOP-Dnmt3b/+ model, Dnmt3b overexpression was 
induced by doxycycline administration. We treated timed pregnant female mice with daily 
intraperitoneal injection of 150μl 5mg/ml doxycycline from E8.5 to E15.5. At the end of 
E15.5, we examined the endocrine lineage allocation of the Rosa26M2-rtTA/+;ColA1tetOP-
Dnmt3b/+ embryos with immunostaining. We observed that Dnmt3b overexpression 
increased β-to-α cell ratio (Fig 3.10 and preliminary quantification data not shown). 
 
3.4 Discussion 
 
How seemingly equivalent progenitor cells give rise to different cell types remains 
an outstanding question. We utilize endocrine islet cell differentiation in the mouse 
pancreas to dissect this process.  In this case, pancreatic progenitor cells that transiently 
produce a bHLH transcription factor Ngn3 differentiate into all endocrine cell types (α, β, 
δ, PP and ε). Because each Ngn3-expressing cell only gives rise to one endocrine cell, 
we postulate that the Ngn3-expressing cells can be divided into subpopulations, each of 
which has a preference for specific endocrine lineage(s). Indeed, we found that Ngn3+ 
progenitors can be classified into two cell populations based on their co-expression with 
Myt1 (i.e., Ngn3+Myt1+ and Ngn3+Myt1- cells). We developed an effective bipartite Cre-
based technique to reconstitute Cre activity in cells that co-expressed the two proteins. 
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This method allowed us to examine whether the subset of Ngn3+ cells that co-expressed 
Myt1 represented specialized progenitor cells. Genetic lineage tracing showed that the 
Ngn3 and Myt1 proteins preferably marked progenitors for β cells, but not that for α cells. 
Interestingly, we further showed that the activation of Myt1 in subsets of Ngn3+ cells 
depended on the activity of Ngn3. Because Myt1 is a downstream target of Ngn3, the 
phenomenon of Myt1 expression in selective Ngn3+ progenitors implies that activation of 
Myt1 in the Ngn3+ progenitors probably arises from unidentified stochastic events. 
Preliminary DNA methylation analysis demonstrated the temporal change of a regulatory 
element of Myt1 gene, Myt1 region 2. This element was hypermethylated in E10.5 Ngn3+ 
progenitors, which was correlated with low Myt1 expression as revealed by RNA-Seq 
and more α-cell production at this stage.  At E15.5, loss of DNA methylation derepressed 
Myt1 expression, leading to substantial Ngn3 and Myt1 co-expression in the progenitors, 
which were funneled into a β-cell differentiation program.  
Allocation of endocrine lineages from pro-endocrine progenitors is a cryptic 
process and deciphering this process requires investigation at multiple levels that 
regulate gene expression and ultimately affect cell fate choice, including cell signaling, 
epigenetic regulation, transcriptional and translational regulation, as well as post-
transcriptional and post-translational regulation, etc. Here, I focused on transcriptional 
analysis with RNA-Seq and DNA methylation with bisulfite sequencing. It is desirable to 
extract the most information from our multi-stage RNA-Seq data by means of 
bioinformatics tools such as gene clustering and gene ontology annotation, which will 
provide invaluable information of the changes that Ngn3+ pro-endocrine progenitors 
undergo during endocrine differentiation. In addition, a systematic profiling of the DNA 
methylome and histone modification will reveal important clues for decoding the enigma 
of endocrine differentiation. Another intriguing and important question regards the 
differences between Ngn3+Myt1+ cells and Ngn3+Myt1- cells. It is an appealing idea to 
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harvest these two cell populations and scrutinize their similarities and differences with 
regard to their transcription profile and epigenetic landscape. Here, I will mainly discuss 
the roles DNA methylation and histone modification play during endocrine differentiation, 
as well as immediate experiments that can be executed based on the methodologies we 
have developed so far. More discussions about epigenetic regulation and potential 
approaches to tackle its engagement and function in pancreatic endocrine differentiation, 
along with sorting Ngn3+Myt1+ cells and Ngn3+Myt1- cells, will be continued in the future 
directions section in Chapter VI.  
 
DNA methylation of transcription factor genes other than Myt1 
There are three DNA methyltransferase genes in mammals, Dnmt1, Dnmt3a, and 
Dnmt3b (Moore et al., 2013). Dnmt1 maintains DNA methylation propagation during cell 
division by methylating the newly synthesized DNA strand based on the DNA 
methylation pattern of the mother strand. In contrast, Dnmt3a and Dnmt3b are de novo 
DNA methyltransferases that deposit new DNA methylation markers but not simply 
copying existing DNA methylation markers.  
DNA methylation-mediated gene expression control is not an uncommon 
mechanism in regulating endocrine transcription factor genes. For example, DNA 
methylation of the upstream regulatory (UR) elements UR1, UR2 and UR3 of Arx 
mediates Arx repression and is required to maintain β-cell identity (Dhawan et al., 2011). 
Dnmt1 deletion in β cells leads to reduced DNA methylation of these Arx upstream 
regulatory elements and the conversion of β cells to α cells (Dhawan et al., 2011).  
In Fig 3.10, Dnmt3b overexpression resulted in increased β-to-α cell ratio, but 
how that was achieved remained unclear. Specifically, what gene regions besides Myt1 
region 2 were methylated to cause β-cell lineage expansion at the expense of α-cell 
lineage?  In the Rosa26M2-rtTA/+;ColA1tetOP-Dnmt3b/+ mice, induced Dnmt3b overexpression 
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does not cause overwhelming DNA methylation. Although the researchers lacked whole 
genome sequencing evidence, they found that the amount of 5’methylcytosine is not 
increased in the Dnmt3b overexpression mice. Rather, DNA methylation is increased at 
selective loci (Linhart et al., 2007). Thus, instead of being limited to Myt1 region 2, we 
need to assess more genomic loci or even global methylome to unveil the underlying 
mechanism. Next, I will discuss some candidate loci that are worth investigation.  
DNA elements of some key endocrine transcription factors are reported to be 
binding sites of regulatory proteins and are predicted to be CpG islands (CpG islands 
are predicted by MethPrimer), but no explicit DNA methylation analysis has been done 
for these DNA elements. For instance, the AEG element of the Pax4 promoter (Brink et 
al., 2001; Brink and Gruss, 2003), which is a binding site for transcription activators 
Ngn3, Pdx1, and NeuroD, is located close to a predicted CpG island. Whether DNA 
methylation of AEG regulates Pax4 expression could be tested with bisulfite sequencing. 
An Hnf3β/Ngn3 binding site of the Nkx2.2 promoter (Watada et al., 2003), the B1 and 
the PBE site of the Nkx6.1 gene (Iype et al., 2004; Watada et al., 2000) are all such 
examples and good candidate loci. 
I have encountered many problems with bisulfite sequencing, primarily because 
of the difficulties of obtaining high quality PCR fragments. After bisulfite conversion, the 
complexity of the genomic DNA is reduced and thus non-specific primer binding occurs 
more frequently. Besides, DNA secondary structures frequently form after bisulfite 
conversion, especially when there are long AT-rich stretches. DNA instability after 
bisulfite conversion is also a potential reason prohibiting successful PCR. I have thus far 
optimized the bisulfite PCR protocol to balance the trade-off between efficiency and 
specificity. I have designed nested primers (Table 3) and used a touchdown and nested 
PCR strategy to amplify regions of interest. In the future, we should obtain more colonies 
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for Myt1 region 2 in order to reach a more robust conclusion. Meanwhile, I am also 
testing many other regions, including those regulating Pax4, Arx, Nkx2.2, and Nkx6.1 etc.  
 
Histone modification and pancreatic endocrine lineage allocation 
Histone modification has been shown to be important in specifying endocrine 
lineages during pancreas development in many studies. For instance, human α cells 
exhibited distinct histone modification patterns from exocrine cells and β cells, with many 
more genes at a poised status marked by both the activating H3K4me3 marker and the 
repressing H3K27me3 marker (Bramswig et al., 2013). β-cell-specific deletion of Ezh2, 
the histone methyltransferase subunit of the Polycomb Repressive Complex 2 (PRC2), 
derepresses the Ink4a/Arf locus and reduces β-cell proliferation (Chen et al., 2009). 
Class IIa histone deacetylase (Hdac) Hdac4, 5, and 9 inhibit the β/δ cell lineages. Loss 
of Hdac4 or Hdac5 results in more δ cells, while loss of Hdac5 or Hdac9 increases the β-
cell pool (Lenoir et al., 2011). 
Our in vitro culture assay showed that Adox increased β-to-α cell ratio. A similar 
result is reported by Bramswig et al., in which they described murine α-to-β cell 
conversion upon Adox treatment (Bramswig et al., 2013). However, it should be noted 
that Adox targets the S-adenosyl-homocysteine (SAH) hydrolase and decreases the 
production of the methyl-group donor S-adenosyl-methionine (SAM) (Vaes et al., 2010). 
Thus, Adox inhibits global methylation events, including DNA methylation and histone 
methylation. Adox-induced β-to-α cell ratio increase suggests the involvement of 
epigenetic regulation in pancreatic endocrine lineage allocation, but it is not clear which 
epigenetic modification is accounted for the altered endocrine lineage allocation. Thus, 
other more specific inhibitors, such as 5-Aza-2’-deoxycytidine (AZA, an DNA 
methyltransferase inhibitor) (Christman, 2002), BIX 01294 or UNC 0638 (inhibitors of 
G9a, a histone methyltransferase for depositing H3K9me2 marker), 3-deazaneplanocin 
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(DZNep) or EPZ-6438 (inhibitors of the H3K27me3 methyltransferase Ezh2) among 
many others (Helin and Dhanak, 2013; Kubicek et al., 2007; Vedadi et al., 2011) could 
be tested in the future. The in vitro pancreas culture experiment was hindered mostly by 
technical issues. Due to their small size, cultured pancreatic buds were frequently lost 
during section preparation. We obtained a very small sample size and the robustness of 
these results will be characterized with further experimentation. Complementary to 
immunostaining on sections, we could perform qRT-PCR with these samples to examine 
gene expression alteration and endocrine cell allocation change. I believe that the Ngn3+ 
progenitor subsets differ not only in their transcription profile and DNA methylation as 
discussed above, but also in their histone modification landscape, which could be 
investigated in the future by chromosome immunoprecipitation (ChIP) assay, small 
molecule interference, and genetic mouse models.  
 
Diabetes is a major healthcare issue threatening the world. Type I diabetes is 
caused by the loss of β cells, presumably because of the immune attack on β cells due 
to defects in the immune system (Knip et al., 2005). Type II diabetes, on the other hand, 
is characterized by insulin resistance in the periphery organs or tissues, although β-cell 
loss is also observed as the disease deteriorates (Ashcroft and Rorsman, 2012). Islet or 
β-cell transplantation is a promising therapy for diabetes and several successful cases of 
islet transplantation in type I diabetic patients have been reported (Shapiro et al., 2000; 
Shapiro et al., 2006). The remaining problems are the lack of sufficient islet donor 
sources and the immune rejections that impair successful engraftment (Rother and 
Harlan, 2004). Generating β cells from hESCs or iPSCs or even terminally differentiated 
cells is a promising alternative to cadaveric islets. Many research teams have claimed 
the generation of β cells but these β cells have intrinsic drawbacks to be used as a 
therapy. For example, they do not show robust insulin secretion in response to glucose 
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stimulation and lack β-cell maturation markers (Basford et al., 2012; Bruin et al., 2013; 
D'Amour et al., 2006; Efrat, 2013; Kroon et al., 2008; Pagliuca et al., 2014). Therefore, it 
is necessary to have a better understanding of the pancreas development process, 
especially β-cell generation, in order to come up with a refined in vitro β-cell 
differentiation protocol. Our bipartite Cre cell lineage tracing experiment as well as the 
ongoing epigenetic analysis will contribute to the understanding of transcription factor 
interactions and the endocrine lineage commitment mechanism, which will provide 
educated suggestions to the design of β-cell regeneration protocol. 
 
3.5 Materials and Methods  
 
Mouse strains and care 
The Ngn3nCre knock-in mouse was generated by RMCE (recombination-mediated 
cassette exchange). A targeting vector was constructed through conventional molecular 
cloning and it contained a lox71 site, FRT flanked hygromycin selection cassette, 3.5kb 
Ngn3 5’ region, nCre-T2A-Ngn3, polyA signal and a lox2272 site. The loxed cassette 
acceptor (LCA) allele is Ngn3HA.LCA (unpublished), which contained a lox66 site inserted 
3.5kb upstream of the transcription initiation site of Ngn3 and a lox2272 site 1kb 
downstream of the Ngn3 polyA signal. Targeting vector was prepared through E.coli 
amplification followed by QIAGEN Maxiprep (#12162) and was electroporated into ES 
cells possessing the Ngn3HA.LCA allele. ES cell clones were screened through PCR and 
Southern blot for correct recombination. Selected ES cell clones were injected into 
mouse blastocoel and implanted into the uterus of pseudo-pregnant female mice. Pups 
were genotyped and germ line transmissible strains were kept. The FRT-site flanked 
hygromycin expression cassette was used for positive selection of targeted ES cells and 
was later removed by crossing with a transgenic FLPe mice. 
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The Myt1cCre allele was generated through BAC recombineering. A targeting 
vector containing ~250bp 5’ arm, cCre coding sequence, FRT-flanked Neo/Kan selection 
cassette, and ~350bp 3’ arm was constructed. The 5’ and 3’ homologous arm were 
designed around exon2 of Myt1 such that cCre was inserted there. The BAC that 
comprises Myt1 gene was electroporated into EL250 cells. Subsequently, the targeting 
vector was electroporated into the EL250 cells and allowed for recombineering. Colonies 
were screened with PCR for correct recombineering. Neo/Kan selection cassette was 
removed with L-arabinose induction. BAC was proliferated, purified and used for 
pronuclear injection.  Pups were genotyped by tail biopsy and correct ones were 
retained.  
Rosa26tdTomato/+ (Ai9) (Madisen et al., 2010) and Ngn3EGFP/+ (Lee et al., 2002) 
mice were purchased from the Jackson Laboratory. Genotyping primers used for all 
mouse lines in this study were listed in Table 2. 
Mice were generated in collaboration with the ES/Transgenic Shared Resource 
at Vanderbilt University. All mice were housed and cared in the Vanderbilt Division of 
Animal Care and in compliance to IACUC regulations.  
 
Immunostaining 
Immunostaining methods followed protocols described before (Wang et al., 2008; 
Wang et al., 2010; Xu et al., 2007). Either paraffin or cryo-preserved sections were used. 
In general, dissected pancreata were fixed in 4% paraformaldehyde overnight. They 
were then embedded in OCT cryo-preservant (Sakura 4583) and stored in -80°C freezer. 
Pancreas tissue was cut at 10μm. Sections were washed with 1X PBS three times, 5min 
each. They were then permeablized with permeablization solution (0.2% Trition-X 100 in 
1XPBS) for 10min. After washing again, sections were blocked with blocking solution 
(0.1% Tween-20 in 1X PBS, 5% donkey serum, 1% BSA). Then primary antibodies were 
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added and incubated at 4°C overnight. The second day, slides were washed. Secondary 
antibodies were added and incubated at room temperature for 30-60min. After washing, 
slides were ready for examination and imaging. For long time preservation, slides can be 
sealed in mount medium. Staining protocol was similar for paraffin sections, except that 
tissues had to go through dehydration and rehydration processes. Depending on the 
antibody used, it was sometimes necessary to perform antigen retrieval between the 
permeablization and blocking steps. Slides were boiled in 10mM Tris-HCl, 0.5mM EGTA 
pH 9.0 (cytoplasmic antigen) or 10mM Sodium Citrate pH 6.0 (nuclear antigen) antigen 
retrieval buffer in water bath for 10min.  
Primary antibodies used: guinea pig anti-Ngn3, goat anti-Ngn3, rabbit anti-Myt1, 
guinea pig anti-Pdx1, mouse anti-Nkx2.2 (74.5A5-c, DSHB), guinea pig anti-insulin 
(DAKO), rabbit anti-glucagon (DAKO), rabbit anti-somatostain (Invitrogen), guinea pig 
anti-pancreatic polypeptide (Invitrogen), etc. Secondary antibodies used: FITC-
conjugated donkey anti-guinea pig, Cy3-conjugated donkey anti-rabbit, etc. (Jackson 
Immunoresearch).  
 
Confocal microscopy  
All confocal images were taken with Leica TCS-SP5 scanning confocal 
microscopy or Olympus FV-1000 confocal microscopy.  
 
Quantification of β cell mass 
P0 pancreas was prepared into paraffin sections and stained with guinea pig-
anti-insulin, followed by DAB (3, 3’-diaminobenzidine)-Peroxidase signal amplification 
(Vector, SK-4100). Sections were counter stained with eosin and then scanned by Leica 
Aperio ScanScope. Image processing and quantification was done with ImageScope 
Viewer from Leica. Total insulin+ area from one animal was normalized to its eosin+ 
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pancreas area. Blood vessels and non-pancreatic tissue were excluded manually. At 
least three animals for each genotype were quantified.    
 
Blood glucose measurement and IPGTT test 
Random blood glucose level was measured with blood glucose monitor (Nova 
Max). Blood samples were obtained with tail bleeding. For IPGTT test, 6 week old mice 
were fasted overnight. In the next morning, glucose was given through IP injection at 
2mg glucose (concentration: 10% (w/v) ) per gram body weight. Blood glucose level was 
monitored before giving IP glucose administration (0min), and 15min, 30min, 60min, 
90min, 120min after IP glucose injection with blood glucose monitor (Nova Max). Blood 
samples were obtained with tail bleeding.  
 
Bisulfite sequencing 
Ngn3EGFP/+ male and female mice were crossed to obtain E10.5 and E14.5/E15.5 
embryos. Both Ngn3EGFP/+ and Ngn3EGFP/EGFP embryos were collected and pancreata 
dissected. After dissociation, pancreatic cells were subject to fluorescence-activated cell 
sorting (FACS) to collect EGFP+ cells. After FACS, cells were subject to bisulfite 
conversion with EZ DNA Methylation-Direct Kit (Zymo Research, D5020). Bisulfite 
conversion was done according to the manufacturer’s protocol. Then, DNA region of 
interest was amplified with nested PCR (primer sequence: Table 3). PCR product from 
the first round of PCR with outer primer pair was used as template for the second round 
PCR with inner primer pair. A touchdown PCR method was used to ensure specificity. 
PCR program: 1st PCR: 94°C5:00 [94°C0:30;60-54/0.5°C0:30;72°C1:00]12 
[94°C0:30;54°C0:30;72°C1:00]25 72°C
5:0012°C5:00; 2nd PCR: 94°C5:00 
[94°C0:30;54°C0:30;72°C1:00]35 72°C
5:0012°C5:00. The PCR fragment was ligated into the 
pBluescript KS II SmaI site using Takara ligation kit. Ligation product was transformed 
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into DH5α cells followed by blue/white screening. White colonies were picked and 
checked with PCR (with T3 and T7 primers). Colonies with inserts were propagated and 
plasmids were prepared for sequencing. Sequence alignment and visualization was 
done with CLC Sequence Viewer 7 and R programming, respectively. 
 
 In vitro pancreas bud culture assay 
E11.5 pancreas buds were dissected and placed on the Matrigel or porous 
membrane filters. Pancreas buds were cultured in RPMI 1640 medium (Gibco, 
11875093) supplemented with 10% FBS (Gibco, 26140079) and 100 unit/ml penicillin-
streptomycin (Gibco, 15140-122). Adox was added into the culture medium at a final 
concentration of 10μM. Culture medium was changed daily. After 3 days of culturing, 
pancreas buds were retrieved and prepared into sections for staining. Alternatively, 
whole pancreas buds were stained in test tubes without sectioning. 
 
Quantitative real time-PCR (qRT-PCR) 
qRT-PCR experiments was done to quantify the mRNA level of cells of interest. 
First, RNA was extracted from dispersed cultured pancreatic buds with TRIzol (Life 
Technologies, Cat#: 15596026). Then, cDNA was prepared with the High Capacity 
cDNA Reverse Transcription Kit (Cat #: 4368814) or Bio-Rad iScript cDNA Synthesis Kit 
(Cat #: 170-8890). Next, real-time PCR was done with the Bio-Rad SsoAdvanced 
Universal SYBR Green Supermix (Bio-Rad, Cat #: 172-5271) following manufacturer’s 
instructions. PCR reaction was performed with Bio-Rad CFX96 Real Time System. qRT-
PCR primer sequences are listed in Table 4. qRT-PCR experiments was also done for 
the FACS-sorted cells (see Fig 6.3).   
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Statistical analysis 
Data in the figures were all represented as mean ± s.e.m. Student’s t-test was 
used for statistical comparison. P-values less than 0.05 were considered significant.  
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Table 2. Genotyping primers 
Allele Primer name Primer sequence (5’-3’) 
Ai9 oIMR9020  AAGGGAGCTGCAGTGGAGTA 
 oIMR9021  CCGAAAATCTGTGGGAAGTC 
 Ai9-1  GCGGCCACTACCTGGTGGAGT 
 Ai9-2 CCACGCCACGTTGCCTGACAA 
Ngn3nCre ngn3ncreO1 GACTTGAGCAGGGACCGTCTCT 
 ngn3ncreO2 CTCAGAGAGGGAAACGGCTTGT 
or ngn3ncre5a CCAAAGGGTGGATGAGGGGCG 
 ngn3ncre5s ATGTGGCGTCCACGGGGAGT 
Myt1cCre myt1cCreOs GGCAAACTTCTGACCCAGAGGT 
 myt1cCreOas GTTGGTCCATCCGCCAGCCTGCA 
or myt1cCreOs GGCAAACTTCTGACCCAGAGGT 
 myt1cCre_geno ACGTTGGTCCATCCGCCAGC 
Nkx2.2cCre nkxcCreout2 CTGGAAGGGCGTGCTCCAGGCT 
 nkxcz-300 GCTCGCTCCAACCTGGGCCATT 
or NkxcCreOS GTCCAGGCCCAGCAGTGGACTT 
 myt1cCre_geno ACGTTGGTCCATCCGCCAGC 
Ngn3EGFP Ngn3_A_KK ATACTCTGGTCCCCCGTG 
 Ngn3_B_KK TGTTTGCTGAGTGCCAACTC 
 Ngn3_C_KK GAACTTGTGGCCGTTTACGT 
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Table 3. PCR primers for bisulfite sequencing 
Locus                   Primer sequence (5’ to 3’) 
Arx UR2 Outer primers: 
ATAGAGAGTTTGAAAGTTTTTTGGG; 
TCTCATCTAACTTTAACCCAATATT 
 Inner primers: 
TGGATTTATTTTTATTTTATTTTTTGC;  
AACTCTTAAATTTCCCTCAAACTTC 
Pax4 -2.1K Outer primers: 
AGGAGAATGATTTTGGATTTGTGG; 
AACCATTCCAACTCCTTCCTCACCT 
 Inner primers: 
AAAGGGTAGATGAGGATTAGGATTT; 
ATTAAAATTCCTCCCTACTTCCTTC 
Pax4 AEG Outer primers: 
GGAGTTTTTTAAAGGTAGGAGTTAA; 
CTTCACTATCTAACTCTCCTAACTAC 
 Inner primers: 
TTATATTTAGGTGAGGAAGGAGTTG; 
CTATACCCAACCCCCAAACTACTA 
Myt1 region 2 Outer primers: 
GATTTATTTTTTTGATGTTATATTGTAAATTTATTT; 
AACAACTACCTCCCTCACCACAATCACATATA 
 Inner primers: 
AGAGAGTAAATAGATATATTGGAGTTTTAAGGG; 
TAAATTTCAATTAAATATCTTCTCCCCTC 
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Table 4. qRT-PCR Primers used for gene transcription quantification 
  
Gene target Primer name Primer sequence (5’-3’) 
Ngn3 qmNgn3F GAGGCTCAGCTATCCACTGC 
 qmNgn3R TGTGTCTCTGGGGACACTTG 
Myt1 qmMyt1F TGTGCTGGAGAATGATGAGG 
 qmMyt1R TCTCCATGGACGAGATCTGA 
Nkx2.2 qmNkx2.2-F1 CTTTCTACGACAGCAGCGAC 
 qmNkx2.2-R1 CCCTGGGTCTCCTTGTCATT 
Pdx1 mPdx1-F GAAATCCACCAAAGCTCACG 
 mPdx1-R CGGGTTCCGCTGTGTAAG 
Pax4 mPax4-F TCCCAGGCCTATCTCCAAC 
 mPax4-R TATGAGGAGGAAGCCACAGG 
Arx mArx-F TTCCAGAAGACGCACTACCC 
 mArx-R TCTGTCAGGTCCAGCCTCAT 
Nkx6.1 mNkx6.1-F ACTTGGCAGGACCAGAGAG 
 mNkx6.1-R GCGTGCTTCTTTCTCCACTT 
Sox9 Sox9 RT2 3646F TTGTGACACGGGACAACACA 
 Sox9 RT2 3762R CCAGCCACAGCAGTGAGTAA 
MafA qmMafAF ACCACGTGCGCTTGGAGGAG 
 qmMafAR ATGACCTCCTCCTTGCTGAA 
MafB qmMafB-F1 TGGGATTATCTCTTCGCCCC 
 qmMafB-R1 TCGTGGGTGTGTGTATGTCA 
Pax6 qmPax6-F1 TCACCATGGCAAACAACCTG 
 qmPax6-R1 CCATGGGCTGACTGTTCATG 
Ins1 ins1a GGGACCACAAAGATGCTGTT 
 ins1s CAGCAAGCAGGTCATTGTTT 
Ins2 qmIns2-F1 TGAAGTGGAGGACCCACAAG 
 qmIns2-R1 GTAGTGGTGGGTCTAGTTGC 
Gcg glc2a TGGTGGCAAGATTATCCAGA 
 glc2s GCGAGACTTCCCAGAAGAAG 
PPY pp1a AGAGAGGCTGCAAGTCCATT 
 pp1s GGAGGAGAACACAGGTGGAC 
SST ss1a ACTTGGCCAGTTCCTGTTTC 
 ss1s CCCAGACTCCGTCAGTTTCT 
Ptf1a/p48 p482a TAATTCTTCAGGCACCATGC 
 p482s TGCTCCTGCTACTACTGCCA 
GAPDH mGAPDH-F AACTTTGGCATTGTGGAAGG 
 mGAPDH-R GGATGCAGGGATGATGTTCT 
PPIA qmPPIA-F1 AAGCATACAGGTCCTGGCATC 
 qmPPIA-R1 ATGCCTTCTTTCACCTTCCCAAA 
Glut2 glut21a AAGAACACGTAAGGCCCAAG 
 glut21s AGCAACTGGGTCTGCAATTT 
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CHAPTER IV 
 
DESIGN AND CHARACTERIZATION OF AN INDUCIBLE BIPARTITE CRE 
 
4.1 Abstract 
 
Our bipartite Cre-based lineage tracing allows us to examine the lineages of 
double-marked progenitor cells (Ngn3+Myt1+). Yet it does not allow us to examine the 
stage-specific fate of progenitor cells. It should be noted that the pancreatic endocrine 
cells are produced in a sequential yet partially overlapping manner. Glucagon-secreting 
α cells emerge at ~E9.5 and are the first endocrine cell type generated during pancreas 
development. Insulin-secreting β cells appear later, reach the peak of production in the 
secondary transition and decline gradually after perinatal period. δ and PP cells are 
produced in late gestational stages. In Chapter III, we found that Ngn3+Myt1+ progenitors 
favor β-cell fate over α-cell fate by utilizing a novel bipartite Cre lineage tracing method. 
However, this cell lineage tracing result represents the overall differentiation potential of 
Ngn3+Myt1+ progenitors across embryonic stages; it does not reflect the differentiation 
potential of Ngn3+Myt1+ progenitors at specific embryonic stages. It is possible that 
Ngn3+Myt1+ progenitors have different endocrine cell fate preferences as they pass 
through competence windows. As an initial step to address this hypothesis, I created a 
tamoxifen-inducible bipartite Cre system and characterized its recombination activity 
here. I found one inducible bipartite Cre construct that showed negligible background 
recombinase activity but substantial recombinase activity after 4-hydroxyltamoxifen 
(4OH-TM) induction in a dosage-dependent manner. This construct could be used to 
generate transgenic mouse and perform stage-specific cell lineage tracing experiments 
in the future. 
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4.2 Introduction 
 
The pancreas is composed of endocrine islets of Langerhans and exocrine cells 
(duct and acinar cells) (Edlund, 2002; Gittes, 2009; Pan and Wright, 2011). The islets of 
Langerhans are mainly composed of insulin-secreting β cells and glucagon-secreting α 
cells, with a small percentage of δ, PP and ε cells, all of which are critical hormones to 
maintain blood glucose homeostasis (Edlund, 2002; Gittes, 2009; Pan and Wright, 2011). 
The bHLH transcription factor Neurogenin3 (Ngn3) specifies pancreatic endocrine cells 
(Gradwohl et al., 2000; Gu et al., 2002). Notably, endocrine cells are generated in 
ordered temporal windows, during which Ngn3+ progenitors are competent to generate 
each endocrine subtype (Johansson et al., 2007).  α cells are detected as early as E9.5; 
β cells are generated in concurrence with the secondary transition while δ and PP cells 
do not emerge until E15.5.  
The temporally controlled differentiation of Ngn3+ progenitors is a manifestation 
of regulated and hierarchical expression of various transcription factors. For example, 
the expression of Pax4, Pdx1, Nkx2.2 and Nkx6.1 in Ngn3+ progenitors facilitates β-cell 
production, while the expression of Arx, Brn4 and MafB marks α cells (Collombat et al., 
2006; Murtaugh, 2007; Pan and Wright, 2011). As discussed in Chapter III, it is possible 
that combinations of different transcription factors specify endocrine subtypes. However, 
most of the published data are obtained through loss-of-function and ectopic expression 
experiments. No definitive cell lineage tracing experiments have been done to test this 
possibility. In Chapter III, I described an innovative bipartite Cre cell lineage tracing 
system, which allowed me to investigate the differentiation potential of the Ngn3+Myt1+ 
progenitors, and found that the Ngn3+Myt1+ progenitors favored β cells over α cells.  
Because pancreatic endocrine cells are differentiated in sequential competence 
windows, I wonder whether the differentiation potential of Ngn3+Myt1+ progenitors 
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changes over developmental stages. The cell lineage tracing result from Chapter III only 
represents the overall differentiation potential of Ngn3+Myt1+ progenitors, but does not 
reveal the dynamic properties of progenitors over time. To unveil the cell lineage 
preference of Ngn3+Myt1+ progenitors at different embryonic stages, it is preferable to 
perform a “pulse-chase” experiment and only label the Ngn3+Myt1+ progenitors for a 
short time period and then track their descendent cells. To this end, I designed bipartite 
Cre and estrogen receptor (ERT2) fusion proteins and tested their recombinase activity 
in vitro. I compared different fusion proteins and found one nCreERT2/cCreERT2 pair 
that possessed optimal induced recombinase activity and minimal leaky activity. This 
inducible bipartite CreERT2 could be used to generate transgenic mouse models in the 
future and investigate the dynamics of Ngn3+Myt1+ progenitors’ differentiation potential.  
 
4.3 Results 
 
Bipartite CreERT2 construction and comparison 
I decided to create fusion proteins between bipartite Cre halves and estrogen 
receptor (ER) to achieve temporal regulation. CreER has been widely used and 
mutagenesis studies have created ER variants with improved characteristics, one of 
which is ERT2 (Feil et al., 1996; Feil et al., 1997; Indra et al., 1999). ERT2 has a low 
affinity for natural ER ligands and is highly sensitive to 4-hydroxytamoxifen (4OH-TM, 
the metabolized and active form of tamoxifen). This minimizes the confounding effects 
from endogenous estrogen and the toxicity of high tamoxifen dosage, making it a perfect 
choice for temporal gene regulation. Although the doxycycline-regulated tetON/OFF 
system can also regulate gene expression temporally (Lewandoski, 2001), it is less 
convenient than the ER system when it comes to mouse crossing. Therefore, I decided 
to create a bipartite CreERT2 cell lineage tracing system.  
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Fig 4.1 Design of the inducible bipartite CreERT2. (A) Graph representation of the 
inducible bipartite CreERT2 design. ERT2 module is fused to the N-terminus of nCre 
and C-terminus of cCre. (B) Different inducible bipartite CreERT2 constructs. YW737 
and YW819 are non-inducible bipartite Cre constructs, based on which the inducible 
bipartite CreERT2 constructs were made. YW926, YW941, YW942 and YW951 are 
constructs with NLS while YW927, YW936, YW937 are ones without NLS sequences. 
YW951 contains an HA and an Myc tag and is derived from YW942. YW943 has a full 
length CreERT2. mCherry is used a transfection indicator. iRES sequences are used for 
multi-cistronic expression. 
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I strived to find a construct that had: (1) limited background activity prior to 4OH-
TM induction; (2) high activity upon induction. All constructs were based on the 
previously used non-inducible bipartite Cre system in Chapter III. Basically, ERT2 was 
fused with nCre or cCre and then replaced the non-ERT2 counterparts in the original 
pmCherry-C1 expression vector through conventional restriction digestion and ligation 
(Fig 4.1). These constructs were then tested in a cell transfection assay followed by flow 
cytometry analysis.   
There were several considerations when I constructed bipartite CreERT2 fusion 
proteins: (1) Do not mask the leucine zipper sequences. The leucine zipper sequences 
facilitate bipartite Cre reconstitution and shall not be blocked from accessing each other. 
Thus, I fused ERT2 with Cre halves in the opposite ends of the leucine zipper 
sequences. In other words, I fused ERT2 to the N terminus of nCre and the C terminus 
of cCre (Fig 4.1 a). (2) Inclusion of nuclear localization signal (NLS) peptide or not. The 
presence of NLS facilitates the nuclear localization of Cre halves but it also poses the 
potential problem of high background Cre activity prior to induction. Thus, I made and 
tested constructs with or without NLS sequences (Fig 4.1 a). (3) Copy number of ERT2. 
It is not clear whether and how the additional ERT2 will interfere with the expression and 
reconstitution of Cre halves, so I tested different combinations in which only nCre or only 
cCre or both were fused with ERT2 (Fig 4.1 b). (4) Since almost all inducible CreERT2 
constructs have the ERT2 domain fused to the C terminus of Cre protein (Magnuson and 
Osipovich, 2013), I was concerned whether fusing the ERT2 domain to the N terminus of 
nCre protein might interrupt the folding and activity of ERT2 and nCre. Thus, I added a 
short linker sequence (Glycine-Glycine-Serine) to join ERT2 and nCre.  
The construct YW942 stood out in the flow cytometry result. This construct had 
ERT2 fused to both nCre and cCre. It also had NLS sequences in both Cre halves. This 
construct showed negligible background Cre activity (7.0±1.3%, n=3) but substantial  
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Fig 4.2 Comparison of different inducible bipartite CreERT2 constructs. (a) 
Representative images of transfected cells (upper panel) and flow cytometry analysis 
plots (lower panel). Shown here is construct YW942 treated with methanol or 10μg/ml 
4OH-TM. Image: red channel: mCherry; green channel: GFP. Scale bar: 20μm. Flow 
cytometry plot: y-axis: GFP; x-axis: mCherry. (b) Quantification of the reconstituted 
recombinase activity, with or without induction. Data are represented as mean±s.e.m. p-
value: ***<0.001<**<0.01<*<0.05<n.s. (c) Fold increase of recombinase activity upon 
4OH-TM induction. YW942 has a remarkably higher induction ratio, suggesting its robust 
induced recombinase activity as well as low background activity.  
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Fig 4.3 Immunotagged inducible bipartite CreERT2. (a) Graph representation of the 
immunotagged bipartite CreERT2 to show the position of HA/Myc tags. (b) HA and Myc 
tags are readily detectable by standard IHC. Scale bar: 50μm. (c) Flow cytometry 
analysis demonstrates that adding immunotags does not impair the reconstituted 
recombinase activity. Data are represented as mean±s.e.m. p-value: 
***<0.001<**<0.01<*<0.05<n.s. 
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recombination activity upon 10μg/ml 4OH-TM treatment (50.4±2.1%, n=3) (Fig 4.2 a, b). 
An induction ratio of 7.2 was achieved, the highest of all constructs (Fig 4.2 c). 
Compared to constructs with ERT2 fused with nCre or cCre only, the background of 
YW942 was much lower. A possible reason could be that the nCre and cCre protein bind 
to each other through the interaction of leucine zipper peptides in the cytoplasm and one 
copy of ERT2 is insufficient to retain the reconstituted Cre in the cytoplasm. Omitting 
NLS impaired Cre activity and this is possibly because the nCre or cCre protein cannot 
be efficiently translocated into the nucleus. However, I observed one NLS-free construct 
that displayed appreciable recombinase activity even in the absence of 4OH-TM 
induction. This could probably happen because saturated cytoplasmic protein leaks into 
the nucleus due to the overexpression nature of cell transfection assay.  
 
Addition of immunotags simplifies bipartite CreERT2 detection  
For the convenience of future analysis, I added immunotags to both bipartite 
CreERT2 halves and derived a construct YW951 from the above YW942. Similar to the 
considerations when adding ERT2 domains, the immunotags were fused to the opposite 
ends of leucine zipper sequences to avoid disrupting Cre reconstitution. Specifically, an 
HA tag was fused to the N-terminus of ERT2-nCre, making HA-ERT2-nCre; a Myc tag 
was fused to the C-terminus of cCre-ERT2, making cCre-ERT2-Myc (Fig 4.3 a). Cell 
transfection assay and flow cytometry analysis showed that the tagged version and the 
untagged version had no significant differences in their background activity. Though the 
tagged version displayed lower response to 4OH-TM induction than the untagged 
version, it was sufficient to activate the reporter in most transfected cells (Fig 4.3 c). The 
HA and Myc tags were readily detected with standard IHC (Fig 4.3 b). 
With the same transfection protocol, full length CreERT2 fusion protein showed 
high background activity almost as comparable when it was induced with 4OH-TM (Fig 
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4.3 c). In contrast, the bipartite CreERT2 protein showed lower background activity. High 
background activity of the full length CreERT2 can be explained by the overexpression 
nature of transfection assay and the strong CMV promoter I used to drive the expression 
of Cre recombinase. Because full length CreERT2 drivers have been successfully used 
in vast amount of in vivo studies, one could be certain that the in vivo expression level of 
CreERT2 is much lower than that of the in vitro assay. Thus, it is foreseeable that our 
bipartite CreERT2 would have trivial background activity in transgenic mouse models.  
That being said, I quantified the bipartite CreERT2 recombinase activity with a 
series of DNA amounts for transfection and dissected the overexpression effect of cell 
transfection assay (Fig 4.4 a). At high DNA amount, recombination efficiency was 
actually lower, probably due to toxicity caused by Cre overexpression-induced cellular 
stress. When YW951 plasmid amount was reduced to 10ng per well of a 24-well plate, 
the recombination activity went higher, to 46.4%. Reducing DNA amount to 1ng 
decreased recombination activity by ~5%. I expected to see lower recombination activity 
when transfected DNA amount was further reduced. However, flow cytometry data 
became unreliable when a small quantity of DNA was used and the number of 
transfected cells was low. A strong linear correlation between the transfected DNA 
amount and recombinase activity was not observed in this case.  
 
Bipartite CreERT2 shows 4OH-TM dosage-dependent response 
I further characterized the immunotagged inducible bipartite CreERT2 construct 
YW951 by testing its responsiveness to a gradient of 4OH-TM. This inducible bipartite 
CreERT2 construct showed increasing activity up to 1μg/ml 4OH-TM. Beyond 1μg/ml, 
high 4OH-TM might have caused cell toxicity, resulting in reduced Cre recombination 
activity (Fig 4.4 b). This was supported by the observation of a large number of cells 
detaching from the Petri dish and undergoing cell death. It was also very obvious during  
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Fig 4.4 Detailed characterization of the inducible bipartite CreERT2. (a) Recombination 
efficiency of YW951 is tested at different DNA amount. (b) Recombination efficiency of 
YW951 is tested at 4OH-TM gradient concentrations. Data are represented as 
mean±s.e.m. p-value: ***<0.001<**<0.01<*<0.05<n.s. 
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flow cytometry analysis in which 4',6-diamidino-2-phenylindole (DAPI) signal formed a 
strong positive peak and living cell yield was reduced (data not shown).  
Although the construct showed 4OH-TM dosage-dependent responsiveness and 
1μg/ml 4OH-TM was found to be the optimal concentration in this in vitro assay, the TM 
dosage administered to mice should be titrated in the future if transgenic mice are 
generated. TM dosage varies from protocol to protocol and is determined based on the 
experimental design and purpose. Typically, 1-2mg per adult mouse is a good start and 
TM dosage is recommended to be normalized to mouse body weight. 
 
4.4 Discussion 
 
Pancreatic endocrine cells are generated in a temporally controlled manner, with 
α cells emerging first followed by β cells, δ and PP cells (Johansson et al., 2007). 
Though I found that Ngn3+Myt1+ progenitors give birth to more β cells than α cells, it is 
not clear whether the differentiation potential of Ngn3+Myt1+ progenitors is biased 
towards β cells at all embryonic stages. To address this question, I attempt to upgrade 
the bipartite Cre system into an inducible system by creating estrogen receptor fusion 
proteins.  
I found a pair of nCre- and cCre-ERT2 fusion proteins that possessed optimal 
characteristics for induced DNA recombination. The nCre was fused with ERT2 at its N-
terminal end and the cCre was fused with ERT2 at its C-terminal end. Both ERT2-nCre 
and cCre-ERT2 had NLS sequences and leucine zipper sequences for nuclear 
localization and facilitated reconstitution, respectively. Besides, HA and Myc 
immunotags were fused to the ERT2-nCre and cCre-ERT2 to assist the detection of 
nCre and cCre expression in the future. The recombination activity of this inducible 
bipartite CreERT2 was minimal without 4OH-TM induction but showed a dramatic 
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increase after 4OH-TM induction. Moreover, the responsiveness to 4OH-TM induction 
was dosage-dependent.  
Since the inducible bipartite Cre construct was well characterized in vitro, it can 
be used to generate transgenic mouse models, for example, Ngn3ERT2-nCre and Myt1cCre-
ERT2 transgenic mice. These mice can be crossed and pregnant females be administered 
with tamoxifen at specific embryonic stages. In this way, cell lineage allocation of 
Ngn3+Myt+ progenitors at different embryonic stages can be examined and quantified 
with reporter labelling. Such data will give a clearer map of pancreatic endocrine 
specification.  
The competence window model is not limited to pancreatic endocrine 
differentiation. Many other cell types are generated following a competence window 
model. In vertebrate retina, the retinal progenitors divide asymmetrically. At each stage, 
they can only produce one or a few cell types. For instance, ganglion cells and cone 
cells are the first cell types to emerge, followed by rod cells and then bipolar cells and 
Muller glia, albeit much overlap exists (Cepko et al., 1996; Livesey and Cepko, 2001). A 
similar inducible split Cre is also reported (Hirrlinger et al., 2009a). These inducible 
bipartite Cre toolkits can be used in many organs or tissues for cell lineage tracing, 
conditional gene activation and inactivation.  
 
4.5 Materials and Methods 
 
Plasmid construction 
All Cre plasmids were constructed based on the pmCherry-C1 vector (Clontech) 
though the multiple cloning site (MCS) was partly modified to accommodate our inserts 
(Xu et al., 2007). The nCre fragment series were inserted after mCherry-iRES cassette 
between the EcoRI and XhoI sites, which were followed by the iRES-cCre fragment 
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series between the XhoI and NotI sites. Thus, mCherry, nCre and cCre portions were all 
connected by iRES sequences (Fig 4.1). A full length CreERT2 fragment was inserted 
after mCherry-iRES with restriction enzymes EcoRI and NotI. Overlap extension PCR 
was used to create fusion proteins of ERT2 and Cre halves (Heckman and Pease, 2007). 
A single nucleotide change was introduced in some primers to kill an extra XhoI 
restriction site without altering the amino acid encoded. As indicated in the main text, 
additional three amino acids (GGS) were introduced to fuse ERT2 and nCre as a linker; 
its coding sequence (GGTGGAAGC) was accordingly introduced into PCR primers. HA 
or Myc tag were added to the fusion proteins by adding coding sequences to the overlap 
extension PCR primers (HA tag: TACCCATACGATGTTCCAGATTACGCT; Myc tag: 
GAACAAAAACTCATCTCAGAAGAGGATCTG). Similar to the creation of ERT2-nCre 
fusion protein, the GGS linker was used to fuse HA and Myc tag to ERT2-nCre and 
cCre-ERT2, respectively. A Cre reporter plasmid YW421was previously constructed by 
inserting loxP-STOP-loxP-EGFP after a CMV promoter (Xu et al., 2007).  
Three starting plasmids were used as template to construct ERT2 fusion proteins. 
YW737 contains nCre and cCre, both of which contain NLS sequences; YW819 contains 
nCre and cCre, but the cCre lacks NLS; and a pCreERT2 vector from which ERT2 was 
cloned. YW737 and YW819 were used in Chapter III to compare the relative 
recombination efficiency. The cloning strategy for YW737 and YW819 followed 
published methods (Xu et al., 2007) with only the codons optimized for mammalian 
expression.  
Primers used: for cCre-ERT2: JL003 (5'gtgaatatctcgagatccgc3') + JL004 
(5'agctctcatgtctccagcagatggctccagATCTCCGTCCTCCAGCAGGCGCACCATTGC3'); 
JL005(5'GCAATGGTGCGCCTGCTGGAGGACGGAGATctggagccatctgctggagacatgagag
ct3') + JL006 (5'GCGGCCGCtcagatcttcatcaagctgt3'); template: YW737 and a pCreERT2 
vector. For cCre-ERT2 (without NLS), same primers were used but with YW819 as 
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template. For ERT2-nCre (without NLS): JL007 
(5'aagaattctagatctccaccatgCTGGAGCCATCTGCTGGAGA3') + JL008 
(5'CAGATTCTGGTGGACGGTGAGCAGGTTACTagctgtggcagggaaaccctctgcctcccc3'); 
JL009(5'ggggaggcagagggtttccctgccacagctAGTAACCTGCTCACCGTCCACCAGAATCT
G3') + JL010 (5'atctcgagatattcactgtgcca3'); template: YW737 and pCreERT2. For ERT2-
nCre (with NLS), same templates were used, but two primers were replaced: JL007 + 
JL012 (5'caggttactcaccttccgctttttctttgggcttccaccagctgtggcagggaaaccctctgcctcccc3'); 
JL011(5'ggggaggcagagggtttccctgccacagctggtggaagcccaaagaaaaagcggaaggtgagtaacctg
3') + JL010. To make immunotagged construct YW951 using YW942 as template: for 
HA-ERT2-nCre portion (with NLS): JL015 (5’ 
tagaattccaccATGTACCCATACGATGTTCCAGATTACGCTggtggaagcctggagccatctgctgg
agacatgagagct3’) + JL010; for cCre-ERT2-Myc portion (with NLS): JL003 + JL016 
(5’ttgcggccgccatcaCAGATCCTCTTCTGAGATGAGTTTTTGTTCgcttccaccagctgtggcagg
gaaaccct3’) 
All constructs were sequenced for confirmation and the end sequences are 
available for reference. 
 
Cell culture and transfection 
293T cells were cultured in DMEM medium (Gibco, 11995-065) supplemented 
with 10% FBS (Gibco, 26140079) and 100 unit/ml penicillin-streptomycin (Gibco, 15140-
122).  50ng (25ng) Cre driver plasmid and 200ng (100ng) Cre reporter plasmid were 
used per well of a 12-well (24-well) cell culture for transfection into 293T cells. Cells 
were grown for 24 hours before 4OH-TM (Sigma) was added to a final concentration of 
10μg/ml and cultured for another 24 hours. 4OH-TM was dissolved in methanol as a 
high concentration stock (10mg/ml) and methanol was always used as a vehicle control. 
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DNA amount and 4OH-TM concentration varied in titration experiments and were 
indicated in the text. After that, cells were collected for flow cytometry analysis.  
 
Flow cytometry analysis 
After transfection and induction with 4OH-TM, cells were trypsinized into single 
cells. DAPI was added as a viability control. These cells were analyzed by 5-laser BD 
LSR II or BD LSR Fortessa. Flow cytometry analysis was performed with the help from 
Vanderbilt Flow Cytometry Shared Resources.  
 
Immunostaining and imaging 
For immunostaining purpose, cells were cultured on cover slips. Cover slips were 
dipped in 90% ethanol and then sterilized over flame for a few seconds. Sterilized cover 
slips were put into 6-well culture plates to allow cells growing on. Transfected 293T cells 
were grown for 24 hours and treated with 10μg/ml 4OH-TM for another 24 hours. Cells 
were fixed with 4% PFA for 15min. Cells were permeablized with 0.2% Trixon X-100 and 
stained thereafter. Primary antibody: 1:100 rabbit anti-HA (Santa Cruz, HA-probe 
Antibody (Y-11): sc-805); 1:3000 rabbit anti-Myc (Millipore, gift from Dr. Wright’s Lab, 
Vanderbilt). Secondary antibody: 1:500 Cy5-conjugated donkey anti-rabbit IgG (Jackson 
Immunoresearch). Confocal images were taken with Olympus FV-1000.  
 
Statistical analysis 
Data in the figures were all represented as mean ± s.e.m. Student’s t-test was 
used for statistical comparison. P-values less than 0.05 were considered significant.  
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CHAPTER V 
 
miRNA-MEDIATED INHIBITION OF NOTCH SIGNALING ENHANCES NGN3 
EXPRESSION 
 
5.1 Abstract 
 
The pro-endocrine gene Ngn3 marks the progenitors for all pancreatic endocrine 
cells. Loss of Ngn3 or reduced Ngn3 expression level leads to endocrine cell agenesis 
or reduction. It is, therefore, important to keep the regulation of Ngn3 expression pattern 
and level under tight control. Ngn3 expression regulation is subject to many factors and 
signaling pathways, including Sox9, Hnf6, Pdx1, and most importantly Notch signaling. 
The inhibition exerted on Ngn3 expression by Notch signaling prevents the pancreatic 
epithelium from excessive endocrine cell differentiation, which is important for keeping 
the endocrine/exocrine balance. However, I observed side-by-side or even small clusters 
of Ngn3+ progenitors, which violates the canonical lateral inhibition model of Notch 
signaling. Here I report preliminary data that certain miRNAs can inhibit Notching 
signaling pathway, potentially by targeting on its components Hes1 and Psen1, and thus 
derepress Ngn3 expression. In addition, these miRNAs could possibly translocate 
among neighboring cells and enhance Ngn3 expression in a non-cell-autonomous 
manner, unleashing lateral inhibition due to Notch signaling. The preliminary data 
support this miRNA-mediated inhibition of Notch signaling hypothesis and the possibility 
of miRNAs traveling through gap junctions. With further examination, I will be able to fill 
the gaps of the hypothesis and obtain a better understanding of Ngn3 expression 
regulation.  
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5.2 Introduction 
 
During embryogenesis, the pancreatic primordia in the foregut epithelium 
undergo primary transition and secondary transition to form a mature pancreas. The 
development of the pancreas and the allocation between endocrine and exocrine cells is 
a complicated process that involves the coordination of various transcription factors and 
signaling pathways. The transcription factor Ngn3 is best known as a pro-endocrine 
factor. Ngn3-null mice produce almost no endocrine cells (Gradwohl et al., 2000). 
Ectopic expression of Ngn3 leads to precocious differentiation of pancreatic precursors 
into endocrine cells at the expense of exocrine lineages (Apelqvist et al., 1999; 
Schwitzgebel et al., 2000). Lineage tracing demonstrates that Ngn3-expressing cells 
give rise to endocrine islet cells (Gu et al., 2002).  
However, the separation between endocrine and exocrine lineages does not 
merely depend on the presence or absence of Ngn3 but also on Ngn3 protein level. 
Although Gu et al. has reported that all Ngn3-expressing endocrine progenitors give rise 
to endocrine islet cells (Gu et al., 2002), Schonhoff and colleagues find that Ngn3-
expressing cells also give rise to a small portion of duct and acinar cells in the pancreas 
(Schonhoff et al., 2004). It appears that this above discrepancy may be due to the 
sensitivity differences of Cre reporters used in the two studies and reflects the distinct 
fate of progenitors that express different levels of Ngn3 (Liu et al., 2013; Wang et al., 
2010). In a previous paper published by the Gu lab, Wang et al. used a BAC-based 
transgenic Ngn3Cre driver and the Rosa26EYFP/+ reporter to track the fate of Ngn3-
expressing cells at different Ngn3 expression levels. In the wild-type pancreas, more 
than 85% of the Ngn3+ cells become endocrine cells. However, when the Ngn3 
expression level is decreased in the haploinsufficient Ngn3+/- mouse pancreas, about 45% 
Ngn3-expressing cells are shunted to the exocrine lineages, suggesting that Ngn3 
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expression should reach a threshold level to initiate the endocrine differentiation 
program (Wang et al., 2010). hESCs with Ngn3 being knocked-out with CRISPR/Cas9 
cannot differentiate into endocrine cells but hESCs with Ngn3 being knocked-down with 
shRNA can form endocrine cells, though fewer than unmanipulated hESCs , again 
suggesting the importance of Ngn3 level in endocrine specification (McGrath et al., 
2015). In fact, Ngn3-expression level is semi-quantified with immunostaining and two 
populations, Ngn3low and Ngn3high cells, are reported in various articles (Seymour et al., 
2008; Shih et al., 2012). These results suggest that Ngn3 dosage can affect the 
differentiation potential of Ngn3+ progenitors, underscoring the importance of 
understanding Ngn3 expression regulation.  
Many factors have so far been reported to regulate Ngn3 expression. For 
instance, Sox9, Pdx1, and Hnf6 activate Ngn3 expression (Jacquemin et al., 2000; Lynn 
et al., 2007b; Oliver-Krasinski et al., 2009), while Notch signaling inhibits Ngn3 
expression (Apelqvist et al., 1999; Lee et al., 2001). It is also reported that Ngn3 can 
repress its own expression and this self-inhibitory effect is proposed to explain the 
reduced expression of Ngn3 after lineage commitment (Smith et al., 2004). However, 
this result comes from an in vitro cell transfection and overexpression experiment and 
may not reflect the in vivo situation.  
Of all the factors that regulate Ngn3 expression, Notch signaling is the 
predominant signaling pathway. In Notch signaling, binding of the membrane-bound 
ligand (Delta, Jagged, etc.) to the Notch receptor in adjacent cells triggers two 
successive proteolysis events of the Notch receptor and results in the release of the 
Notch intracellular domain (NICD domain). One of the two successive proteolysis events 
is mediated by the γ-secreatase. The γ-secretase is a protein complex composed of four 
proteins, including Presenilin 1 (Psen1), Nicastrin, Anterior Pharynx-defective 1 (APH-1), 
and Presenilin Enhancer 2 (PEN-2). The released NICD domain will translocate into the 
105 
 
nucleus and activate Notch downstream genes such as Hes1. Hes1 in turn represses 
the expression of Ngn3. In this way, Notch signaling can repress Ngn3 expression 
(Edlund, 2001; Kim et al., 2010). Mice deficient for the NICD-binding coactivator gene 
Rbp-jκ or the Notch ligand gene Dll1 display overexpression of Ngn3 and precautious 
endocrine differentiation at the expense of exocrine lineages (Apelqvist et al., 1999). 
Repression of Notch signaling by expressing a dominant negative N3IC protein has the 
same effects (Apelqvist et al., 1999). In addition, deletion of Hes1 causes significant 
pancreatic hypoplasia (Jensen et al., 2000). It is notable that activation of Notch 
signaling usually leads to Notch inactivation in the neighboring cells, a phenomenon 
called lateral inhibition (Edlund, 2001; Kim et al., 2010). The lateral inhibition model has 
been proposed to express Ngn3 in selective cells and maintain the balance between 
endocrine and exocrine lineages. However, contrary to this model, careful 
immunostaining always shows that many Ngn3-expressing cells reside side-by-side (Fig 
5.1), suggesting that a non-classical lateral inhibition mechanism exists to regulate Ngn3 
expression.  
microRNAs (miRNAs) have also been implicated in regulating endocrine 
development. For instance, knockdown of miR375 with morpholino oligonucleotides 
causes pancreatic islet abnormalities in zebrafish (Kloosterman et al., 2007). Global 
Dicer deletion in mice is embryonically lethal (Bernstein et al., 2003) and mice deficient 
for Dicer specifically in the pancreas (Pdx1Cre-driven) only survive to P3, along with 
severe pancreas hypoplasia, reduced Ngn3+ cells and endocrine cell mass, as well as 
altered endocrine cell type allocation (Lynn et al., 2007a). Pdx1Cre-driven Dicer deletion 
does not affect Pdx1 expression but cause Hes1 overexpression, suggesting that the 
reduction of Ngn3+ cells is not due to the depletion of the Pdx1+ progenitor pool but 
because of enhanced Notch signaling.  Interestingly, Ngn3Cre-driven Dicer-knockout mice 
demonstrate normal islet development and hormone staining (Lynn et al., 2007a). This 
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suggests that the function of miRNAs is restricted within a narrow time window or that 
non-cell-autonomous effect exists. Combined, these findings lead us to explore whether 
miRNAs can regulate Ngn3 expression.  
In this chapter, we propose a modified Notch signaling model that regulates 
Ngn3 expression to reconcile the reported discrepancies and to accommodate our 
preliminary data (Fig 5.8). In this model, Ngn3 activates the expression of several 
miRNA genes. These miRNAs can then target Notch signaling components Hes1 and 
Psen1 to tune down Notch inhibition on Ngn3 expression. In this way, Ngn3 can 
enhance its own expression indirectly. Because miRNAs can translocate to the 
neighboring cells, most likely via gap junctions (Valiunas et al., 2005; Wong et al., 2008), 
it allows pancreatic progenitors to escape lateral inhibition as multi-cell clusters. Below, I 
will present the preliminary data that support this model.  
 
5.3 Results 
 
Ngn3+ cells reside side-by-side 
Since Notch signaling inhibits Ngn3 expression, the classical lateral inhibition 
model predicts that Ngn3+ endocrine progenitors are scattered in the pancreatic 
epithelium as isolated single cells. However, by immunostaining I found that E14.5 
pancreas demonstrated a side-by-side Ngn3 expression pattern (Fig 5.1), casting doubt 
on the validity of the classical lateral inhibition model in regulating Ngn3 expression. 
Observation of side-by-side Ngn3+ progenitors is reported by others as well (Jensen, 
2004). In addition, imaging Ngn3EGFP/+ pancreas sections revealed neighboring or small 
clusters of EGFP+ cells (data not shown). This side-by-side Ngn3 expression pattern 
violates the prediction by the canonical Notch lateral inhibition model and prompts us to 
investigate other mechanisms that coexist to regulate Ngn3 expression.  
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Fig 5.1 Ngn3+ progenitors reside side-by-side or in small clusters. E14.5 pancreas is 
stained with anti-Ngn3 antibody and anti-E-cadherin antibody. White arrows indicate 
Ngn3+ clusters that violate the prediction by the classical lateral inhibition model. Scale 
bar: 20μm.  
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Ngn3 activates its own expression 
We utilized a knock-in Ngn3EGFP allele (Lee et al., 2002) to study Ngn3 expression 
regulation. This knock-in allele produces EGFP instead of Ngn3 protein. Dr. Gu 
dissected the E14.5 Ngn3EGFP/+ and Ngn3EGFP/EGFP pancreas and compared their EGFP 
expression level under a fluorescent microscope. Surprisingly, Ngn3EGFP/+ pancreas had 
higher EGFP intensity than the Ngn3EGFP/EGFP pancreas did, suggesting that Ngn3 
activated its own expression (Fig 5.2 a-b). Dr. Gu quantified the EGFP intensity with flow 
cytometry after digesting the embryonic pancreas into single cells. Flow cytometry 
revealed two EGFP+ cell populations: the EGFPhi and EGFPlow population in the 
heterozygous pancreas, but only EGFPlow population in the null pancreas (Fig 5.2 e).  
The same result was observed and reported by the Sander group as well (Shih et al., 
2012). These data suggest that Ngn3 activates its own expression. The discrepancy 
between our data and the previously reported self-repressing property of Ngn3 (Smith et 
al., 2004) may lie on the fact that the latter experiment was done in a cell transfection 
assay where Ngn3 is overexpressed and did not reflect the in vivo situation.  
 
Dicer is necessary for high Ngn3 expression 
Previous reports have shown that Dicer is essential for pancreatic cell survival 
and Ngn3 expression (Bernstein et al., 2003; Lynn et al., 2007a), yet the regulation 
mechanism is not well known. To investigate how Dicer regulates Ngn3 expression at a 
cellular level, Dr. Gu crossed and obtained the DicerF/F; Pdx1Cre; Ngn3EGFP/+ compound 
mice (Pdx1Cre: Gu et al., 2002; DicerF/F: Harfe et al., 2005) and analyzed their EGFP 
expression in the developing pancreas. He found that pancreas-specific Dicer deletion 
did not eliminate Ngn3 expression. Instead, Ngn3 expression pattern in the Dicer 
conditional knockout pancreas phenocopied that of the Ngn3EGFP/EGFP mice (Fig 5.2 c-d), 
indicating that Dicer is not required to initiate Ngn3 expression but can enhance Ngn3  
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Fig 5.2 Ngn3 activates its own expression. (a-d) The left panel presents confocal images 
of E14.5 pancreas of different genotypes as labeled. Confocal images show higher 
EGFP expression in the heterozygous Ngn3EGFP/+ pancreas (a) compared to the 
Ngn3EGFP/EGFP pancreas (b), suggesting that Ngn3 activates its own expression. 
Pancreas-specific deletion of Dicer (d) phenocopies Ngn3-null pancreas (b), indicating 
that Dicer could positively regulate Ngn3 expression. (e) The right panel is the flow 
cytometry analysis result of WT, Ngn3EGFP/+ and Ngn3EGFP/EGFP pancreas. Flow cytometry 
analysis reveals EGFPhi and EGFPlow populations and a reduced EGFPhi population is 
evident in the Ngn3EGFP/EGFP pancreas. Source: Dr. Guoqiang Gu. 
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Fig 5.3 Dicer is necessary for enhancing Ngn3 expression. This figure shows flow 
cytometry analysis results of pancreas of three genotypes as labeled. Dicer-deletion 
reduces EGFPhi cells (EGFPlow to EGFPhi estimated ratio 10:1) in contrast to the control 
pancreas (EGFPlow to EGFPhi estimated ratio 3:1). Source: Dr. Guoqiang Gu. 
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expression. Flow cytometry analysis confirmed a reduced number of EGFP+ cells and 
lower EGFPhi to EGFPlow ratio in the Dicer conditional knockout pancreas as compared 
to control pancreas (Fig 5.3), again suggesting that Dicer, or in other words, miRNAs, 
can augment Ngn3 expression.  
 
RNA-Seq reveals Ngn3-dependent miRNAs 
In order to identify what miRNAs are involved in regulating Ngn3 expression, Dr. 
Gu sorted out EGFP+ cells from the E14.5 Ngn3EGFP/+ and Ngn3EGFP/EGFP pancreas and 
conducted an RNA-Seq experiment. Among the ~500 well characterized miRNAs in the 
mouse genome (Chiang et al., 2010), only 20 members whose expression differed by 2-
fold between the two groups were identified. Specifically, miR7, miR9, miR96 and 
miR182 were enriched in the Ngn3EGFP/+ pancreas compared to the Ngn3EGFP/EGFP 
pancreas. These miRNAs were of particular interest because miR7 and miR9 were 
predicted to target Notch signaling component Psen1, whereas miR96 and miR182 were 
predicted to target Hes1. I used various web-based miRNA target prediction algorithms, 
including TargetScan.org, miRBase.org and microRNA.org, for cross validation. In 
addition, I also examined mRNA expression in these two cell populations (described in 
Chapter III) and did not detect significantly elevated Sox9 or Hnf6 transcripts in the 
Ngn3EGFP/+ pancreas, ruling out the possibility of a positive feedback loop via Sox9 or 
Hnf6. These above findings suggest that Ngn3 activates the expression of the above 
several miRNA to enhance its own expression, pushing pancreatic progenitors towards 
endocrine cell fate.  
In order to validate the predicted targets of miRNAs, I performed luciferase/GFP 
reporter assays (Fig 5.4 a). miRNAs were cloned from mouse genomic DNA and 
constructed into the SIBR vector for expression (Chung et al., 2006). The 3’ untranslated 
region (UTR) sequences of predicted target genes, including Hes1 and Psen1, were 
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cloned into luciferase or mCherry reporter vectors. miRNA-expressing plasmids derived 
from the SIBR vector and the luciferase/mCherry reporter plasmids were co-transfected 
into 293T cells and analyzed with a luminometer or flow cytometry in the end. Meanwhile, 
I designed and constructed mutated miRNAs with directed mutagenesis PCR to 
introduce point mutations in the miRNAs’ seed sequences (the conserved sequence 
usually from nucleotide 2 to 7 of a mature miRNA) (Horwich and Zamore, 2008). 
Mutation in the seed sequences of miRNAs abolishes miRNAs’ capacity to knockdown 
their mRNA targets. These mutant miRNA-expressing plasmids were tested side-by-side 
with wild-type miRNA-expressing plasmids for validating sequence specificity (Table 5). I 
found that both miR96 and miR182 downregulated Hes1 level. Mutations of miR96 and 
miR182 partially rescued the phenotype but did not fully restore to the negative control 
level. miR9, however, quite unexpectedly upregulated Psen1 (Fig 5.4 b). It was not clear 
why miR9 upregulated Psen1 expression but there were technical issues and theoretical 
reasons to explain it. First of all, when I repeated the luciferase assay several times, the 
results were not always consistent. In theory, firefly luciferase and the normalization 
control Renilla luciferase are relatively stable during the time span of my assay 
(Thompson et al., 1991). It was not likely that loss of activity or degradation of 
luciferases caused the inconsistency. That being said, I constructed mCherry reporters 
and will try to use flow cytometry to analyze the inhibitory effects of miRNAs on their 
targets. Second, in the cell transfection assay, miRNAs and reporters are overexpressed 
as compared to the physiological expression level. The ratio between miRNAs and 
target mRNAs also affects the readout and thus titrating transfected plasmids to a higher 
miRNA/target ratio is necessary, otherwise the miRNA interference effect might not be 
obvious or even masked (Kuhn et al., 2008). Preparing stable cell lines harboring the 
reporters is also under consideration. Lastly, the cloned regions of 3’UTR sequences of 
Psen1 and Hes1 were chosen based on bioinformatics predictions. They were only part  
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Fig 5.4 Validating miRNA targets with luciferase reporter assay. (a) Schematic 
representation of the design of miRNA-expression plasmids and luciferase reporters. 
miRNA genes are cloned from the mouse genome and are inserted in-between the 
EcoRI and XhoI sites of the SIBR vector. 3’UTR sequences of target genes are cloned 
from the mouse genome and are inserted downstream of a luciferase expression 
cassette. (b) Quantification of luciferase reporter assay. Firefly luciferase activity is 
normalized to Renilla luciferase activity. A control SIBR plasmid, a miRNA-expressing 
plasmid, and a mutant miRNA-expression plasmid are tested side-by-side for testing 
sequence specificity. Data are represented as mean±s.e.m. p-value: 
***<0.001<**<0.01<*<0.05<n.s. 
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of the 3’UTR sequences. It is possible that miRNAs have additional target sites outside 
of the cloned region or even within the coding sequences (Forman et al., 2008).    
 
Gja1 is expressed in embryonic pancreas 
It is previously known that gap junctions exist in endodermal progenitors, which is 
necessary for their survival (Saund et al., 2012). It has come to our attention that 
miRNAs can freely transport through gap junctions and enable neighboring cells to 
communicate (Valiunas et al., 2005; Wong et al., 2008). We envision that 
communication among neighboring cells via miRNAs may explain the observation of 
side-by-side Ngn3+ cells that the classical lateral inhibition model could not.  
First of all, I detected the expression of a gap junction protein, Gja1 (connexin43), 
in embryonic pancreas (Fig 5.5). Gja1 forms relatively large gap junction channels that 
allow siRNAs to move between cells (Valiunas et al., 2005), fitting in our proposed 
models. Gja1, Gjc1 (connexin45), and Gjd2 (connexin36) are previously reported to be 
expressed in mouse pancreatic islets (Theis et al., 2004); they are also detected by our 
RNA-Seq analysis (data not shown).  
To test the functional involvement of gap junctions in regulating Ngn3 expression, 
Dr. Gu blocked gap junctions with inhibitors 18-α-glycyrrhetic acid or 18-β-glycyrrhetic 
acid in an ex vivo pancreas culture assay. The number of EGFP+ cells in Ngn3EGFP/+ 
pancreas decreased but more EGFPHi cells surged (Fig 5.6). Since 18-α-glycyrrhetic 
acid or 18-β-glycyrrhetic acid blocked the free translocation of miRNAs, miRNAs could 
not enhance Ngn3 expression by repressing Notch signaling in the neighboring cells, 
thus less EGFP+ cells formed. Meanwhile, miRNAs were concentrated in selective cells 
because of the translocation restriction, leading to more EGFPHi cells by reinforcing the 
expression from the Ngn3 promoter.  
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Fig 5.5 Gja1 is expressed in embryonic pancreas. Wild-type and Ngn3EGFP/EGFP pancreas 
are co-stained with anti-Ngn3 and anti-Gja1 antibodies. Gja1 is expressed in the 
developing pancreas and is Ngn3-independent. In fact, Gja1 expression is higher in the 
Ngn3EGFP/EGFP pancreas, both semiquantitatively by confocal imaging and by RNA-Seq 
(see main text for details). Stage: E14.5. Scale bar: 50μm. 
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Fig 5.6 Blocking gap junctions in the Ngn3EGFP/+ pancreas results in intensified EGFP 
expression per cell but loss of EGFP+ cells. In an in vitro pancreatic bud culture assay, 
dissected E8.5 Ngn3EGFP/+ embryonic pancreas is cultured in medium in the presence or 
absence of a gap junction inhibitor, 18-α-glycyrrhetic acid (or 18-β-glycyrrhetic acid). 
Gap junction inhibition results in more EGFPHi cells but less EGFP+ cells, an effect 
probably due to the restriction of miRNA translocation across gap junctions. Scale bar: 
20μm. Source: Dr. Guoqiang Gu. 
  
117 
 
5.4 Discussion  
 
The pro-endocrine transcription factor Ngn3 plays a central role in pancreatic 
endocrine specification. Ngn3 expression is initiated in the Pdx1+ pancreatic epithelium 
domain and can be detected as early as E9.5. It reaches its peak of expression at 
around E14.5-E15.5 and then gradually declines during the perinatal stage. Ngn3 
expression is maintained at a very low level in adult islets and the Ngn3 protein is hardly 
detectable with regular immunostaining (Wang et al., 2009a). Although Ngn3 expression 
almost diminishes in the adult pancreas, some researchers report that Ngn3 expression 
can be reinitiated in the adult pancreas and repopulate β cells. (Al-Hasani et al., 2013; 
Xu et al., 2008). Ngn3 is also a key transcription factor in transdifferentiating acinar cells 
into β cells (Li et al., 2014b; Zhou et al., 2008). Knocking down or completely deleting 
Ngn3 in mouse pancreatic progenitors or hESCs leads to the failure of massive 
endocrine cell differentiation (McGrath et al., 2015; Sugiyama et al., 2013). All these 
results underscore the central role of Ngn3 in pancreatic endocrine differentiation.  
Ngn3 expression is subject to Notch repression. The classical Notch lateral 
inhibition model prohibits adjacent cells to become Ngn3-positive simultaneously but this 
model could not explain our observation of side-by-side Ngn3+ cells. It is likely that 
unidentified cell-cell communication allows neighboring cells to break this lateral 
inhibition constriction. This communication could be mediated by protein-receptor 
interaction, or by direct information exchange via junctional channels. Here I focused on 
gap junction communications.  Indeed, we detected the expression of Gja1 in E14.5 
pancreas with immunostaining and other connexins with RNA-Seq. Furthermore, 
blockade of gap junctions with 18-α-glycyrrhetic acid or 18-β-glycyrrhetic acid reduced 
EGFP+ cells in the in vitro cultured Ngn3EGFP/+ pancreas. These findings allow us to 
propose that miRNAs can translocate to neighboring cells via gap junctions and execute 
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their function non-cell-autonomously, allowing the formation of Ngn3+ clusters. This type 
of coordinated Ngn3 expression in many pancreatic progenitor cells is necessary to 
warrant the production of enough β cells for normal physiology. 
 
Functional involvement of miRNAs in pancreas development 
To investigate the functional invovlement of miRNAs, it is desirable to perform 
loss-of-function or gain-of-function experiements. To this end, antagomirs can be 
administered in an in vitro assay to inhibit miRNA activity. Antagomirs are RNA analogs 
that can bind with and silence their target miRNAs (Krutzfeldt et al., 2007; Krutzfeldt et 
al., 2005). In vitro cultured pancreatic buds can be treated with antagomirs and their 
transcription profile can then be analyzed by immunostaining, qRT-PCR, and flow 
cytometry etc.  
A primary advantage of antagmirs over genetic knockout is that antagomirs can 
block miRNAs of the same family and of the same seed sequence. Both miR7 and miR9 
have multiple members in their family, and it is difficult to genetically knockout all miRNA 
genes because of this genetic redundancy, let alone the demanding time and cost. 
Moreover, the pharmaceutical potentials of antagomirs make the research promising for 
future clinical translation. There are concerns about antagomir efficiency and specificity 
though. To this end, antagomirs could be modified with a cholesterol moiety to enhance 
the delivery efficiency (Horwich and Zamore, 2008). Scrambled or mutated antogamirs 
should be utilized in parallel to serve as specificity controls.  
To achieve in vivo knockdown, complementary miRNAs could be overexpressed 
as “miRNA sponges” to block the endogenous miRNAs of interest (Ebert et al., 2007; 
Ebert and Sharp, 2010; Kluiver et al., 2012). Like antagomirs, miRNA sponges bypass 
the redundancy problem of miRNA gene families. In a similar fashion, miRNAs can be 
overexpressed, often in targeted tissue and in a temporally controlled manner (Chen et 
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al., 2011; Chung et al., 2006), to analyze their functional involvement in pancreas 
development.  
 
Does non-cell-autonomous effect exist? 
Although we found that the blockade of gap junctions by chemical inhibitors 
interfered with Ngn3 expression, it is not clear whether this is a direct result of blocked 
miRNA transportation or only a secondary effect. Although gap junctions are shown to 
be permeable to miRNAs in cell assays (Valiunas et al., 2005), a fundamental question 
of our model is whether miRNAs translocate among neighboring cells and function non-
cell-autonomously in the developing pancreas. To this end, fluorophore moiety-
conjugated or radioactive-labeled miRNAs, together with microinjection and high 
resolution microscopy, can be used to examine the movement of miRNAs within and 
among cells.  
If non-cell-autonomous effect does exist, I expect that miRNAs produced in one 
cell will likely rescue Dicer defects in neighboring cells. To test this possibility, I can 
create mosaic Dicer deletion in the pancreatic progenitor cells and examine whether 
Ngn3 expression in these cells can be rescued by neighboring Dicer+ cells (Fig 5.7). 
Mosaic Dicer deletion can be achieved by administering a low dose of tamoxifen to 
pregnant female mice and harvesting DicerF/F;Pdx1CreER;Ngn3EGFP/+ embryos. Then co-
localization of Dicer and Ngn3/EGFP can be examined by immunostaining. Alternatively 
if no good anti-Dicer antibody is available, Dicer allele copy number in the EGFP+ cells 
can be quantified and compared between the TM-treated group and the control group. In 
brief, EGFP+ cells are collected by FACS. These cells are homogenized and DNA is 
extracted. The copy number of Dicer allele is then quantified with qRT-PCR. I will then 
measure the copy number of Dicer allele on a per cell basis by normalizing it to the 
EGFP+ cell number. This result will test the existence of non-cell-autonomous effects. If  
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Fig 5.7 A proposed experiment for testing non-cell-autonomous effect. Mosaic Dicer 
deletion is achieved by administering timed pregnant female mice with a low dose of 
tamoxifen (TM). DicerF/F;Pdx1CreER;Ngn3EGFP/+ embryos will be dissected and dissociated 
into single cells, which are subject to FACS and quantitative real-time PCR for 
measuring Dicer allele copy number. Dicer allele copy number is normalized to EGFPhi 
cell (green cells) number. The normalized Dicer copy number is a measurement for 
testing the existence of non-cell-autonomous effect. TM: tamoxifen. NCA: non-cell-
autonomous. D+: there is an effective Dicer gene. D-: Dicer null. Cells of green color 
represent EGFPhi cells. 
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non-cell-autonomous effect does not exist, then the ratio of Dicer allele to EGFP+ cell 
number will be approximately the same between TM-treated and non-treated pancreas. 
In contrast, if non-cell-autonomous effect exists, then the ratio of Dicer allele to EGFP+ 
cell number will be lower in the TM-treated pancreas than the non-treated controls.  
 
Gap junction genetic models and pancreas development  
Gap junctions are passive diffusion channels between adjacent cells. A gap 
junction is composed of two connexons; each is a hexamer of connexins and is docked 
on the membrane of two adjacent cells. Gap junctions have selective permeability for 
small molecules, such as ions (Na+, K+, Cl-, Ca2+), second messengers (cAMP), amino 
acids and siRNAs (Valiunas et al., 2005; Wong et al., 2008). It is well-established that 
endodermal progenitor cells communicate through gap junctions (Saund et al., 2012).  
In order to fully dissect the functional involvement of gap junctions in pancreas 
development, genetic models are preferred, complementary to the above chemical 
inhibition assay. To this end, we can take advantage of the existing connexin alleles, for 
example, Gja1 knockout (Eloff et al., 2001), Gjc1 knockout (Kumai et al., 2000), and 
Gjd2 knockout mice (Guldenagel et al., 2001) etc., for the analysis of their role in 
pancreas development. Due to the wide expression of connexins, global knockout might 
cause growth or developmental defects in multiple organs, such as the heart and the 
eyes etc. (Guldenagel et al., 2001; Kumai et al., 2000). To circumvent this problem, 
pancreas- or β-cell-specific deletion of connexins can be achieved by using the floxed 
connexin alleles (Liao et al., 2001; Nishii et al., 2003). One disadvantage of genetic 
knockout lies on the connexin family redundancy, which should be taken into 
consideration when interpreting results. In addition, Ngn3+ progenitor-specific 
overexpression of Gja1, Gjb1, and Gjd2 could also be employed to investigate the 
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functional involvement of gap junction in pancreas development and endocrine lineage 
allocation (Klee et al., 2011).  
 
How is Ngn3 downregulated? 
Ngn3 is transiently expressed in the early pancreatic endocrine progenitor cells. 
Once the Ngn3+ progenitors differentiate into endocrine cells, Ngn3 expression declines. 
The previously reported self-repression of Ngn3 expression helps to explain the transient 
Ngn3 expression nature. However, if our model is correct and Ngn3 activates its own 
expression, how could it be down-regulated during pancreas development to prevent the 
unlimited expansion of endocrine progenitors? One possiblity is that the affinity of Ngn3 
protein for its targets differs and that Ngn3 binds to its own promoter and inhibits itself 
when Ngn3 protein level reaches a higher threshold. The other possiblity is that gap 
junctions could be shut down.  
Indeed, I found that Gja1 and Ngn3 expression were negatively correlated. Gja1 
level was higher in the Ngn3-null pancreas than in the wild-type pancreas. This 
discovery by immunohistochemsitry was consistent with our RNA-Seq data. It seems 
that there is a feedfack mechanism between Ngn3 and Gja1 to fine tune the expression 
level of Ngn3. At the early stage of development, gap junctions augment Ngn3 
expression and Ngn3+ progenitor expansion by allowing the translocation of miRNAs to 
neighboring cells. As Ngn3 expression increases, Gja1 is downregulated to restrict the 
dilution of miRNAs, allowing the formation of Ngn3Hi cells and preventing Ngn3+ 
progenitor expansion. Gradually, as Ngn3Hi cells differentiate into endocrine cells and 
Ngn3 expression diminishes, Gja1 expression is turned on again, possibly serve a 
function in endocrine maturation or functional maintenance. Indeed, gap junctions exist 
in the mature β cells and control insulin secretion synchronization, presumably through  
  
123 
 
 
 
 
 
 
Fig 5.8 A modified Notch lateral inhibition model. In the modified model, inhibition of 
Notch signaling on Ngn3 expression is relieved by miRNA-mediated repression of Hes1 
and Psen1, both of which are Notch signaling components. These miRNAs also allow 
neighboring cells to communicate with each other, explaining the observation of side-by-
side Ngn3+ cells. 
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mediating Ca2+ flux (Benninger et al., 2011; Calabrese et al., 2003; Serre-Beinier et al., 
2009).  
In this chapter, we proposed a model (Fig 5.8) which integrates Notch signaling 
and miRNA-mediated gap junction communication. This new model resolves the 
discrepencies between lateral inhibition prediction and actual observation, and is 
supported by lines of evidences. Further investigation is requried to validate the 
functional involement of miRNAs and gap junctions as well as elucidate the molecular 
mechanisms. Understanding Ngn3 expression regulation is central in pancreas 
organogenesis research and in vitro β cell differentiaiton.  
 
5.5 Materials and methods 
 
Mouse strains and care 
Mouse strains DicerF/F (Harfe et al., 2005) and Ngn3EGFP/+ (Lee et al., 2002) are 
purchased from the Jackson Laboratory. Pdx1Cre mouse was made by Dr. Gu (Gu et al., 
2002). All mice were housed and cared in the Vanderbilt Division of Animal Care and in 
compliance to IACUC regulations.  
 
FACS assay 
Ngn3EGFP/+ or Ngn3EGFP/EGFP pancreas was dissected out at E10.5, E15.5 and 
E18.5. Pancreas was then dissociated into single cells with trypsin and subject to flow 
cytometry analysis or cell sorting. Ngn3+/+ embryos were used as negative controls. 
DAPI was added as a viability marker. Flow cytometry analysis and cell sorting 
experiments were performed by the Vanderbilt Flow Cytometry Shared Resources. 
RNA-Seq data was previously obtained (data unpublished). In general, EGFP+ cells 
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collected by FACS were homogenized and total RNA was extracted. RNA samples were 
sent to the Vanderbilt Vantage Sequencing Core for sequencing and analysis. 
 
Immunohistology 
Primary antibody: guinea pig anti Ngn3 (1:100), mouse anti-E-cadherin (1:200), 
goat anti-Ngn3 (1:1000), rabbit anti-Gja1 (Abcam Ab11370, 1:1000). Secondary 
antibody: 1:500 FITC-conjugated donkey anti-guinea pig (1:500), Cy3-conjugated 
donkey anti-mouse (1:500), FITC-conjugated donkey anti-rabbit (1:500, all secondary 
antibodies are from Jackson Immunoresearch). Staining procedures followed previously 
published methods (Wang et al., 2008; Wang et al., 2010).  
 
Plasmid construction 
Plasmids were constructed with conventional molecular cloning methods. miRNA 
genes and 3’UTR of Hes1 and Psen1 sequences were cloned from mouse genomic 
DNA and inserted into pBluescript KS II vectors followed by sequencing. Correct 
sequences were then subcloned into SIBR plasmids (for miRNA expression; EcoRI and 
XhoI), or a pCS2-based luciferase reporter plasmid (a gift from Dr. Ethan Lee, 
Vanderbilt), or a pmCherry-C1 (Clontech) based fluorescent reporter plasmid.  
Primers for cloning miR7, miR9, miR96 and miR182:  
miR9-1s: 5’agaattcgagactacggaggtccag3’, miR9-1a: 
5’actcgagcgcgaggtggctcgggctg3’; miR7-2s: 5’agaattctagggaactgtatgagcag3’, miR7-2a: 
5’actcgagccttctgaggtttcctcaactg3’; miR96s: 5’agaattcataaacagagcagagacagatc3’, 
miR96a: 5’actcgagccagctcggattgcccagctc3’; miR182s: 
5’agaattcactggaacaggaccatacagg3’, miR182a: 5’actcgagccttttcaccgagaagaggtc3’. 
Primers for cloning 3’UTR sequences of Hes1 or Psen1: 
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Hes1s: 5’agaattctgactgagagcctcaggccactgc3’, Hes1a: 
5’aggatccttcactcttttattatattttctca3’; Psenmir7-s: 5’gtgtcacaagacatggaccatcgt3’, Psenmir7-
a: 5’gcaagtgagcctccttcatcga3’; Psen1mir9-s: 5’ctgacagcagacaaggcagctct3’, Psen1mir9-a: 
5’cccagcattggacattactcgga3’; Psen1st pa-s: 5’aaccatagcctgctttgtagccat3’, Psen1st pa-a1: 
5’ggcttgctctctgtttttgtgttt3’. 
Primers used for introducing mutations in miRNA plasmids:  
miR7_mu_1: 5’ttcaaacggggctggccc3’, miR7_mu_2: 5’cgtctagtgattttgttgttgt3’; 
miR7_mu_3: 5’aatcactagacgttcaaacgg3’, miR7_mu_4: 5’ttgttgttgtgtctctgtatcc3’; 
miR9_mu_1: 5’cacgataacaaccaaccccg3’, miR9_mu_2: 5’gattatctagctgtatgagtgg3’; 
miR96_mu_1: 5’caaaatcggccaagcagatg3’, miR96_mu_2: 5’aagctagcacatttttgcttgt3’; 
miR182_mu_1: 5’cgaaaatggtgggaggcct3’, miR182_mu_2: 5’acgatggtagaactcacacc3’. 
All constructs were sequenced for confirmation. 
 
Luciferase assay  
293T cells were co-transfected with SIBR-miRNA plasmid, pCS2-luciferase-
3’UTR reporter plasmid, and a Renilla luciferase reporter. 24 hours after cell culture, 
cells were washed with PBS and ready to be processed. The Dual-Luciferase Reporter 
Assay System from Promega (Cat # E1960) was used for luciferase assay. Luciferase 
activity was measured with an illuminator. 3 samples were prepared for each condition 
and each sample was measured twice. Firefly luciferase activity was normalized to a 
Renilla luciferase control.  
 
Pancreatic bud culture and gap junction inhibition 
E8.5 Ngn3EGFP/+ pancreas was dissected and cultured in RPMI 1640 medium 
(Gibco, 11875093) with the addition of 18-α/β-glycyrrhetic acid (75μM) for 48hrs. 
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Medium and drug was changed every day. DMSO was used as a vehicle control. At the 
end of 48hrs, pancreas buds were retrieved for confocal imaging.  
 
Confocal microscopy  
All confocal images were taken with Leica TCS-SP5 scanning confocal 
microscopy or Olympus FV-1000 confocal microscopy 
  
128 
 
CHAPTER VI 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Summary 
 
Diabetes is a worldwide health issue. In both type I and late stage type II 
diabetes, significant β-cell loss causes insulin deficiency and hyperglycemia. 
Replenishing β cells is a promising therapy and that requires either activating in vivo β-
cell replication, reinitiating a β-cell neogenesis program or transplanting exogenous β 
cells. This thesis investigates mouse pancreatic endocrine cell differentiation during 
embryogenesis. With a better understanding of bona fide β-cell differentiation, my 
research will provide useful information for the development of gene and cell therapies 
for diabetes mellitus. 
The transcription factor Ngn3 specifies endocrine pancreas (Gu et al., 2002). 
However, how Ngn3+ pro-endocrine progenitors are specified to each endocrine cell type 
is not well understood, and this issue is the main focus of this thesis. In this thesis, I 
propose a model that combinatorial transcription factor expression specifies Ngn3+ 
progenitors to specific endocrine cell fate(s). By using a novel bipartite Cre cell lineage 
tracing system, we were able to show that Ngn3+Myt1+ cells preferred β cells over α cells. 
Transcriptional and epigenetic analysis of Ngn3+ progenitors from different embryonic 
stages revealed that gene expression and DNA methylation of endocrine genes, 
including Myt1, underwent dynamic changes along the developmental timeline, which 
may explain why endocrine cells are generated in a competence window-dependent 
manner. To dissect the differentiation potential of Ngn3+Myt1+ progenitors at different 
embryonic stages, I designed a tamoxifen-inducible bipartite CreERT2 construct and 
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characterized it in cell lines. It could be used to generate mouse models in the future to 
label Ngn3+Myt1+ progenitors at specific embryonic stages and trace their differentiation 
preference. As part of the Cre technique, variability of Cre reporter sensitivity was 
observed and non-parallel recombination of floxed alleles in the same cell is reported 
here. In addition, we investigated the regulation of Ngn3 expression by Notch signaling 
and miRNAs. We found that Ngn3 augmented its own expression by a mechanism of 
miRNA-mediated inhibition of Notch signaling and explored the possibility of miRNA 
translocation through gap junctions to attenuate Notch signaling in a non-cell-
autonomous manner. Yet, with new discoveries arise more questions. In the following, I 
will discuss some future directions we may pursue.  
 
Future Directions 
 
Ngn3+ progenitor heterogeneity revisited  
With the bipartite Cre cell lineage tracing method, we found that the Ngn3+Myt1+ 
progenitors favorably differentiated into β cells rather than α cells. It should be noted, 
however, that not all Ngn3+Myt1+ cells became β cells. The Ngn3+Myt1+ progenitors 
could differentiate into all four types of endocrine cells only with a preference for β cells. 
On the other hand, the lineage tracing reporter Ai9 did not label all β cells, suggesting 
either incomplete labeling or that other Ngn3+ progenitor subtypes contribute to β-cell 
lineage in addition to the Ngn3+Myt1+ progenitors. As a matter of fact, we also generated 
an Nkx2.2cCre allele and found that the Ngn3+Nkx2.2+ progenitors also favored β-cell fate. 
This leads me to think whether the Ngn3+Myt1+ progenitors and the Ngn3+Nkx2.2+ 
progenitors are the same population or how much these two populations overlap. When I 
did co-immunostaining of Ngn3, Myt1 and Nkx2.2 on E14.5 pancreas sections, I 
observed Ngn3+Myt1+Nkx2.2+, Ngn3+Myt1+Nkx2.2-, Ngn3+Myt1-Nkx2.2+, and Ngn3+Myt1- 
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Fig 6.1 Ngn3, Myt1 and Nkx2.2 co-staining reveals a highly heterogeneous progenitor 
pool. Co-immunostaining of Ngn3, Myt1 and Nkx2.2 on E14.5 wild-type pancreas. White 
arrows indicate Ngn3+Myt1+Nkx2.2+ cells. Scale bar: 20μm.  
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Nkx2.2- cells (Fig 6.1), suggesting that the Ngn3+Myt1+ progenitors can be further 
divided into subpopulations based on the expression of other endocrine transcription 
factors, e.g., Nkx2.2. How such mosaic expression pattern is formed, whether it is a pre-
determined or stochastic event, is beyond our understanding at this moment, but this 
highly heterogeneous pattern may partially explain the mixed lineages differentiated from 
the Ngn3+Myt1+ progenitors on an intuitive level. That is, the Ngn3+Myt1+Nkx2.2+ 
progenitors and the Ngn3+Myt1+Nkx2.2- progenitors have their preferences for certain 
endocrine lineage(s). Therefore, the Ngn3+Myt1+ progenitors can still give rise to all 
endocrine cell types only with an overall preference for β cells. 
Ngn3+ progenitors are more heterogeneous than we can image. As is shown in 
Fig 3.1, Pax4 is also nonuniformly expressed in the Ngn3+ progenitor pool. Due to the 
lack of proper antibody, I was unable to examine the expression of Arx in embryonic 
pancreas but published reports demonstrate its heterogeneous co-expression pattern 
with Ngn3 (Collombat et al., 2003). Similarly, Rfx6 (Soyer et al., 2010) and Insm1 
(Mellitzer et al., 2006; Osipovich et al., 2014) also shows heterogeneous co-expression 
pattern with Ngn3 and is Ngn3-dependent (Soyer et al., 2010). Although no co-staining 
of all these transcription factors has been done yet, one can imagine the complexity and 
dynamics of Ngn3+ progenitors during pancreas development. The recently developed 
MultiOmyx technique could be employed to analyze the heterogeneity of Ngn3+ 
progenitors (Gerdes et al., 2013).  
Then there comes a question: can we experimentally dissect the fate of 
Ngn3+Myt1+Nkx2.2+ progenitors with cell lineage tracing tools similar to the bipartite Cre?  
The answer may lie in the mechanism of Cre/loxP-mediated DNA recombination. 
During Cre/loxP-mediated recombination, a Holliday junction consisting of four Cre 
proteins and two loxP sites forms. A loxP site 
(ATAACTTCGTATAGCATACATTATACGAAGTTAT) contains two 13mer palindromic 
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sequences connected by an 8mer spacer (underlined). Each 13mer is occupied by one 
Cre recombinase, thus each loxP site is occupied by two Cre molecules. A functional 
homotetramer of Cre is formed on two loxP sites. 
Researchers have developed engineered Cre proteins that recognize mutated 
loxP sequences (Gelato et al., 2008; Santoro and Schultz, 2002; Saraf-Levy et al., 2006). 
One loxP mutant, termed loxM7 (ATAACTCTATATAGCATACATTATATAGAGTTAT), is 
not recognizable by wild-type Cre but is readily recognized by a Cre mutant named 
C2(+/-)#4 (Santoro and Schultz, 2002). Furthermore, a hybrid of loxP and loxM7 by 
swapping a 13mer, termed loxP-M7 (or loxM7-P depending on which 13mer is 
exchanged), is bound by a heterodimer of wild-type Cre and C2(+/-)#4 mutant. The loxP-
M7 is more efficiently recombined in the presence of both wild-type Cre and C2(+/-)#4 
mutant than either one alone (Saraf-Levy et al., 2006). In a similar fashion, another 
group has developed Cre-FLP hybrid proteins, which were coined “Fre” and “Clp”, that 
can recognize loxP-FRT hybrid sequences and execute DNA recombination (Shaikh and 
Sadowski, 2000). 
Theoretically, if the wild-type Cre and the C2(+/-)#4 mutant are expressed from 
two promoters respectively (e.g., Ngn3 and Myt1) and a reporter is constructed with the 
loxP-M7 instead of the wild-type loxP sites, this strategy could serve the same purpose 
of double-marker cell lineage tracing as our bipartite Cre system does. Hypothetically 
then, if we blend the heterotetramer with the bipartite Cre idea, i.e., splitting both the 
wild-type Cre and the C2(+/-)#4 mutant, we could possibly create a vast array of 
combinations, which could allow us to explore the heterogeneity of Ngn3+ progenitors 
and increase the cellular resolution of lineage tracing from double-marked to triple- and 
quadruple-marked progenitors.  
However, the biggest hurdle preventing us from applying this idea to cell lineage 
tracing is the specificity issue. The research of Cre mutation is initiated by the Schultz 
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group in an effort that will ultimately allow them to design customized Cre and edit 
mammalian genome (Santoro and Schultz, 2002), but this attempt is quickly 
overshadowed by the ZFN (zinc finger nuclease), TALEN (transcription activator-like 
effector nuclease) techniques and the emerging CRISPR/Cas9 technique due to the lack 
of specificity and versatility. Further mutation and screening in search of more specific 
Cre/loxP pair is necessary if we want to advance to a multipartite cell lineage tracing 
system but it could be difficult.  
 
Attempt to sort Ngn3+Myt1+ progenitors 
To unveil the mechanisms of the biased cell fate determination, it is desirable to 
separate Ngn3+Myt1+ cells from Ngn3+Myt1- cells and compare the differences between 
them. For this purpose, I have been trying to isolate the Ngn3+Myt1+ and Ngn3+Myt1- 
subpopulations with two FACS strategies. My plan was to isolate these two cell 
populations and examine their transcription and epigenetic differences and correlate the 
differences with their endocrine fate. Yet overall, these methods did not work out for 
technical reasons. 
The first method was to immunostain pancreatic cells directly with anti-Ngn3 and 
anti-Myt1 antibodies. However, this method was not successful mainly because the 
crude antibody serum I used was not suitable for FACS purpose. The Gu lab is now 
trying to purify the anti-Ngn3 and anti-Myt1 antibodies from the crude serum with 
antibody-antigen affinity-based purification method. Hopefully, the purified antibodies will 
give less background and allow me to sort out target cells with FACS. I followed a first-
primary-antibody-then-secondary-antibody protocol, which complicated the process of 
antibody concentration titration for FACS. To solve this problem, I can chemically 
conjugate primary antibodies with fluorophores and then use these antibodies to stain 
cells in one step. It is doubtful whether this strategy will eventually help to overcome the 
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staining problem because cell surface marker is preferred in FACS assay. 
Immunostaining for nuclear transcription factors for FACS purpose is intrinsically difficult. 
Although different fixation regimes (4% paraformaldehyde or 1% formaldehyde, various 
length of time) were tested and various detergents (Triton X-100, Tween-20, Saponin) 
were tried, FACS results were not significantly improved. 
The second method was to use endogenously produced fluorescent proteins as 
surrogate markers for Ngn3 and Myt1 (Fig 6.2 a). I crossed mice to get the Ngn3nCre/EGFP; 
Myt1cCre; Ai9/+ embryos. After dissociation, pancreatic cells were stained with an anti-
CD133 antibody and subjected to FACS. CD133 (prominin-1) is a cell surface maker for 
many types of stem cells and it is expressed on the apical surface of ductal epithelial 
cells in the pancreas (Sugiyama et al., 2007). CD133+EGFP+ cells are Ngn3+ progenitor 
cells. CD133 staining is necessary in selecting Ngn3+ progenitors because EGFP does 
not only mark Ngn3+ progenitors due to its longevity. Out of the CD133+EGFP+ cells, I 
reasoned that CD133+EGFP+tdTomato+ cells were expected to be Ngn3+Myt1+ cells 
while CD133+EGFP+tdTomato- cells represented Ngn3+Myt1- cells (Fig 6.2 b).  
Based on my pilot study, CD133 staining gave a clean background and showed 
distinct negative and positive populations in FACS. I also obtained some target cell 
populations and executed qRT-PCR to validate the identity of these cell populations (Fig 
6.3). Both CD133+EGFP+tdTomato+ and CD133+EGFP+tdTomato- cells displayed higher 
Ngn3 expression than the CD133-EGFP-tdTomato+ control cells, which were 
differentiated endocrine cells that lacked both CD133 and Ngn3EGFP expression. 
CD133+EGFP+tdTomato+ cells also had higher Myt1 expression than the 
CD133+EGFP+tdTomato- counterpart. In addition, both CD133+EGFP+tdTomato+ and 
CD133+EGFP+tdTomato- cells lacked substantial Ins1, Ins2, or Gcg expression as 
compared to the CD133-EGFP-tdTomato+ control cells. In summary, qRT-PCR data 
implied that CD133+EGFP+tdTomato+ and CD133+EGFP+tdTomato- cells were  
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Fig 6.2 Experimental design for sorting Ngn3+Myt1+ and Ngn3+Myt1- progenitors. (a) 
Mouse cross scheme was designed to maximize the chance of obtaining 
Ngn3nCre/EGFP;Myt1cCre;Ai9/+ embryos. E15.5 pancreata were dissected and dissociated 
into single cells. After staining with anti-CD133 antibody, cells are subject to FACS. 
CD133+EGFP+tdTomato- and CD133+EGFP+tdTomato+ cells were collected. These two 
cell populations presumably represent Ngn3+Myt1- and Ngn3+Myt1+ progenitors and their 
identity will be confirmed with qRT-PCR. CD133-EGFP-tdTomato+ cells were also 
collected as a differentiated endocrine cell control. Sorted cells were subject to 
downstream analysis, including qRT-PCR, bisulfite sequencing, and chromatin 
immunoprecipitation (ChIP) to interrogate the differences between Ngn3+Myt1- and 
Ngn3+Myt1+ progenitors in their transcription profile, DNA methylation and histone 
modification. (b) One FACS result example showing the relative abundance of each cell 
population. There were very few CD133+EGFP+tdTomato+ cells harvested. (anti-CD133 
antibody is APC-conjugated. CD133 and APC are used interchangeably in the 
description.)  
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Fig 6.3 qRT-PCR analysis result of FACS-sorted progenitor subpopulation. Three cell 
populations were collected, the tdTomato single positive population, which are 
supposedly differentiated cells and serve as our normalization control, the 
CD133+EGFP+tdTomato- cells, and the CD133+EGFP+tdTomato+  cells. The collected 
cell populations were each homogenized and their mRNA transcripts were quantified 
with qRT-PCR. 
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Ngn3+Myt1+ and Ngn3+Myt1- progenitors, as I expected. Why CD133+EGFP+tdTomato- 
cells would possess higher expression of Pax4, Nkx2.2, and Nkx6.1 is difficult to 
interpret as CD133+EGFP+tdTomato+ cells are β-cell-prone progenitors based on our 
bipartite Cre cell lineage tracing (Fig 3.7).  
The robustness of this qRT-PCR assay was dampened by the low quantity of 
cells I obtained from FACS. It was difficult to harvest enough CD133+EGFP+tdTomato+ 
cells for downstream assays and there were several possible explanations for this. 
First, I examined the presence of CD133+EGFP+tdTomato+ cells. I examined the 
E14.5 pancreas tissue by immunostaining. Despite low image quality, I believed the 
existence of CD133+EGFP+tdTomato+ or Muc1+EGFP+tdTomato+ (Muc1 is another duct 
epithelium apical maker) cells in the tissue (data not shown). However, the number of 
CD133+EGFP+tdTomato+ cells is low, probably because CD133+EGFP+tdTomato+ is a 
very transient state. Once cells turn on tdTomato, they quickly delaminate from the duct 
epithelium and become CD133 negative.    
Another explanation is that the Ngn3nCre allele is hypomorphic. From the data in 
Chapter V, we knew that the Ngn3EGFP/+ pancreas had higher EGFP signal than the 
Ngn3EGFP/EGFP pancreas, suggesting that Ngn3 activates its own expression. This was 
bolstered by flow cytometry analysis, which showed both EGFPhi and EGFPlow cell 
populations in the Ngn3EGFP/+ pancreas but mainly EGFPlow cell population in the 
Ngn3EGFP/EGFP pancreas. Because of the feed-forward activation of Ngn3, I suspected 
that the Ngn3nCre allele might be hypomorphic and thus decreased Ngn3 and EGFP 
expression from the Ngn3 promoter. When I genotyped embryos and examined their 
fluorescence intensity under the microscope, I found that almost all Ngn3EGFP/nCre 
pancreata showed lower EGFP intensity than the Ngn3EGFP/+ pancreata, suggesting that 
the Ngn3nCre allele was indeed hypomorphic. That could be another reason why I was 
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not able to obtain enough CD133+EGFP+tdTomato+ cells because EGFPlow cells were 
not picked up by the FACS cell sorter. 
 
Why are Ngn3+Myt1+ progenitors biased to β cells? 
There are two possible mechanisms to explain the biased β-cell fate chosen by 
Ngn3+Myt1+ progenitors. One mechanism is that Ngn3 and Myt1 cooperatively activate 
or enhance the expression level of a cascade of transcription factors that favor β-cell fate. 
To validate this hypothesis, we need to identify Ngn3 and Myt1 downstream targets, 
especially whether they share any common downstream targets. Some Ngn3 
downstream targets are reported, such as Myt1, Nkx2.2, Nkx6.1, Pax4, Arx, Insm1, and 
Rfx6, etc. (Collombat et al., 2003; Mellitzer et al., 2006; Smith et al., 2003; Smith et al., 
2010; Soyer et al., 2010; Wang et al., 2008; Watada et al., 2003). Information regarding 
Myt1 downstream targets is more limited though. To systematically discover Ngn3 and 
Myt1 downstream targets, ChIP-Seq assay will be invaluable. Meanwhile, it is useful to 
test whether Ngn3 and Myt1 proteins can physically interact and activate gene 
expression as a complex. 
Because I showed that manipulating DNA methylation changed β-to-α cell ratio, 
a second and more plausible mechanism is that Ngn3 and Myt1 recruit epigenetic 
modifiers to specific genomic loci and alter the epigenetic landscape. It is reported that in 
β cells, Nkx2.2 forms a repressor complex on methylated Arx promoter by recruiting 
Hdac1, Grg3, and Dnmt3a and reinforces the repression of Arx by DNA methylation, 
preventing the acquisition of α-cell fate (Papizan et al., 2011). I speculate whether a 
similar mechanism exists for Ngn3 and Myt1. To this end, I learned that both Myt1 and 
Myt1L can bind to Sin3B, which in turn recruits Hdac1 and Hdac2 and represses a 
heterologous promoter (Romm et al., 2005). It is also reported that Myt1 physically 
interacts with lysine-specific demethylase 1(Lsd1) and represses the expression of Pten 
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(phosphatase and tensin homolog) gene (Yokoyama et al., 2014). Xenopus Neurogenin 
1 (xNgn1), a member of the bHLH neurogenin family, is shown to recruit 
CREB/p300/PACF complex, all of which possess histone actyltransferase activity, and 
activate its downstream targets xMyt1 and xNeuroD (Koyano-Nakagawa et al., 1999). 
Although these studies were done in systems other than mouse pancreas, they provide 
insightful information of how Ngn3 and Myt1 could potentially utilize the epigenetic 
machinery to distinguish Ngn3+Myt+ progenitors from the Ngn3+Myt1- progenitors. Co-
immunoprecipitation and mass spectrometry assays will aid the discovery of Ngn3/Myt1 
binding partners, at least testing whether similar results can be reproduced in the 
embryonic pancreas.  
 
What are the downstream targets of Ngn3 and Myt1? 
As discussed above, another interesting question is identifying the direct 
downstream targets of Myt1 and Ngn3. There are many occasional reports about the 
identification of Myt1/Ngn3 downstream targets. For example, Ngn3 controls the 
expression of Arx (Collombat et al., 2003), Pax4 (Smith et al., 2003), NeuroD (Huang et 
al., 2000), Myt1 (Wang et al., 2008), Nkx2.2 (Watada et al., 2003), Insm1 (Mellitzer et al., 
2006; Osipovich et al., 2014), Rfx6 (Smith et al., 2010; Soyer et al., 2010) etc. There are 
relatively less known targets of Myt1. One example is Pten (Yokoyama et al., 2014).  
Despite that, there are caveats in the interpretation of these results. First, many 
results come from in vitro assays, such as gel shift or reporter assays. Whether these 
results truly recapitulate the in vivo situation is doubtful. Second, some reports use 
Ngn3-dependent expression as the evidence for being an Ngn3 downstream target, but 
the criterion of Ngn3-dependent expression is insufficient to distinguish whether a gene 
is a direct or indirect target of Ngn3. In order to systematically discover Ngn3 targets, 
one experiment used microarray-based method and compared the differential 
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expression between Ngn3+/+ and Ngn3-/- developing pancreas (Petri et al., 2006). A 
similar but superior microarray was done by the Kaestner group by using an Ngn3EGFP 
allele which allowed them to isolate EGFP+ progenitors instead of homogenized whole 
pancreas (White et al., 2008). Microarray facilitates the systematic and fast discovery of 
potential downstream targets but still it fails to discern the direct-target versus 
secondary-effect scenarios. Thus, it is desirable to design a ChIP-Seq assay to 
systematically discover the direct targets of Myt1 and Ngn3. To this end, the Gu lab has 
been optimizing the ChIP assay protocol as well as comparing the efficiency and 
specificity of different antibodies. We are looking forward to the identification of direct 
downstream targets of Myt1 and Ngn3 in the future.  
 
How are the heterogeneous co-expression pattern established? 
Another interesting question is how the Ngn3+ progenitor heterogeneity is 
established. I have shown that Myt1, Nkx2.2 and Pax4 expression is diminished in the 
E14.5 Ngn3EGFP/EGFP pancreas, suggesting that these key endocrine transcription factors 
are controlled by Ngn3, which is consistent with previous reports (Smith et al., 2003; 
Wang et al., 2008; Watada et al., 2003). Given also that Myt1 and Ngn3 form a positive 
feed-back loop (Wang et al., 2008), it is difficult to understand how Myt1 is only 
expressed in a portion of the Ngn3+ progenitors. So are Nkx2.2 and Pax4, as they are 
also Ngn3-dependent.  
Because Ngn3 expression is transient while Myt1 expression persists after it is 
turned on, we conjecture that Myt1 is rapidly activated in some Ngn3+ progenitors but is 
delayed in other Ngn3+ progenitors, resulting in the heterogeneous co-expression pattern. 
But why does such a responsiveness difference exist? Why is Myt1 (and Nkx2.2, Pax4, 
etc.) activated quicker in some Ngn3+ progenitors but slower in others? Is there an Ngn3 
protein threshold to activate its downstream genes? Are all Ngn3 downstream genes 
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equivalently sensitive to Ngn3 binding? Is the heterogeneity determined well before 
Ngn3 expression initiates? These are all stimulating questions. Sampling developing 
pancreas at different time points and taking successive snapshots of the endocrine 
progenitors’ transcriptional profile and epigenetic landscape will provide insightful 
information. In addition, single-cell mRNA sequencing and DNA methylation sequencing 
techniques are powerful tools to dissect cellular heterogeneity and they are also options 
worth considering (Shapiro et al., 2013; Smallwood et al., 2014).  
 
Do Ngn3+Myt+ progenitors have the same differentiation potential across all 
embryonic stages? 
Our bipartite Cre cell lineage tracing results show that Ngn3+Myt1+ progenitors 
preferentially give rise to β cells. We then asked whether ectopic overexpression of Myt1 
in the Ngn3+ domain will promote the acquisition of β-cell fate. To address this question, 
Dr. Gu utilized an Ngn3Myt1 transgenic mouse model (data unpublished) to ectopically 
overexpress Myt1 in the Ngn3+ progenitors and analyzed the effect on endocrine lineage 
allocation. As expected, Ngn3+ progenitors all turned into Ngn3+Myt1+ in the transgenic 
mouse pancreas and an increased β-to-α cell ratio was observed (data not shown), 
which is consistent with the bipartite Cre lineage tracing result that Ngn3+Myt1+ 
progenitors favor β cells over α cells.  
The observed result that Ngn3+Myt+ progenitors favorably produced β cells only 
reflects the lineage tracing result of aggregated Ngn3+Myt+ progenitors across all 
embryonic stages but does not distinguish Ngn3+Myt+ progenitors from different stages. 
Because pancreatic endocrine cells are produced according to a competence window 
model (Johansson et al., 2007), whether Ngn3+Myt+ progenitors have the same 
differentiation potential at different embryonic stages is an intriguing question. On the 
other hand, since Myt1 expression is not constant during the course of pancreatic 
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endocrine differentiation but increases from E10.5 to E18.5 (Fig 3.2), forced Myt1 
expression at a precocious stage might influence the differentiation potential of Ngn3+ 
progenitors. Therefore, instead of constitutively overexpressing Myt1 in Ngn3+ 
progenitors, I would like to overexpress Myt1 in specific time windows and examine how 
it could change the competence of Ngn3+ progenitors. To this purpose, I can employ the 
TetON/OFF system to induce Myt1 expression with doxycycline administration. The 
existing Ngn3tTA/+ (Wang et al., 2009a), Myt1btet (Wang et al., 2008), or 
Ngn3Cre;Rosa26rtTA/+ (Belteki et al., 2005; Gu et al., 2002) mice could be crossed to 
obtain Ngn3tTA/+;Myt1btet or Ngn3Cre;Rosa26rtTA/+;Myt1btet mice and achieve temporally 
induced Myt1 ectopic expression.  
In addition, I would like to do a “pulse-chase” experiment in which only 
Ngn3+Myt1+ progenitors within a short time window are labeled and tracked. This “pulse-
chase” experiment is feasible with a temporally inducible bipartite Cre technique. I have 
designed and created fusion proteins between bipartite Cre and an estrogen receptor, 
ERT2. I compared different constructs and identified one bipartite CreERT2 design that 
demonstrated desired characteristics for lineage tracing, including low background 
activity prior to induction, high recombination efficiency upon induction, tamoxifen 
dosage-dependent response, as well as easy immunostaining detection. The well-
characterized inducible bipartite CreERT2 in Chapter IV is readily available to generate 
transgenic mouse models in the future and is able to answer the question of stage-
specific differentiation capacity. 
 
How are Dnmts recruited to specific loci?  
In Chapter III, I examined the endocrine lineage allocation using a Dnmt3b 
overexpression model first created by Linhart et al. (Linhart et al., 2007). In the 
Rosa26M2-rtTA/+;ColA1tetOP-Dnmt3b/+ mouse model, Linhart et al. found that Dnmt3b 
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overexpression does not cause global DNA methylation increase because no significant 
increase of 5’methylcytosine amount is observed. Instead, only selective loci show 
hypermethylation than the control group. Then how is Dnmt3b recruited to specific 
genomic loci? I speculate there are two possible mechanisms.  
First, Dnmts could be recruited to specific loci through a large complex whose 
component recognizes the loci. To this end, I learned that Nkx2.2 forms a repressor 
complex on methylated Arx promoter by recruiting Hdac1, Grg3, and Dnmt3a, thus 
reinforcing the repression of Arx by DNA methylation and promoting β-cell fate (Papizan 
et al., 2011). It is reported that Myt1 and Myt1L could form a repressor complex with 
Sin3B, Hdac1 and Hdac2 (Romm et al., 2005), or with Lsd1 (Yokoyama et al., 2014), 
and that a close family member of Ngn3, Ngn1, interacts with histone actyltransferase 
CREB/p300/PACF (Koyano-Nakagawa et al., 1999). Thus, Dnmts could potentially be 
recruited by Ngn3 and Myt1 to specific targets through similar mechanisms to the above 
or even shared adaptor proteins. If such a physical interaction is proved and target loci 
are identified, it will explain why Ngn3+Myt1+ progenitors have β-cell biased 
differentiation preference and why Dnmt3b overexpression increases β-to-α ratio 
(Chapter III).  
A second mechanism of Dnmt recruitment is through the recognition of histone 
markers or interaction with histone modification enzymes. Dnmt3L, a Dnmt-like protein 
without methyltransferase activity, recruits Dnmt3a and Dnmt3b to vacant H3 histone tail 
whereas H3K4 methylation inhibits the recruitment (Ooi et al., 2007). In addition, Dnmt3a 
can bind to protein arginine methyltransferase 5 (Prmt5)-mediated H4R3me2 site and 
subsequently methylates DNA in the nearby region (Zhao et al., 2009). Dnmt3a/b also 
physically interacts with various histone modifiers, including the PRC2 complex 
component histone methyltransferase Ezh2 (Vire et al., 2006), H3K9 methyltransferase 
G9a and Suv39h1(Epsztejn-Litman et al., 2008; Fuks et al., 2003) etc. All these results 
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suggest that histone methylation affects DNA methylation and could serve as “landing 
sites” for Dnmts. DNA methylation and histone modification are often co-dependent and 
the influence can be bi-directional (Cedar and Bergman, 2009; Rose and Klose, 2014). 
Specifically in the pancreas, Dnmt1-mediated methylation of Arx UR2 region leads to the 
binding of MeCP2, a methyl-DNA binding protein, to the Arx UR2 region, which in turn 
recruits Prmt6 to catalyze H3R2 methylation. H3R2me serves as a repressive marker 
and reinforces repression exerted by DNA methylation (Dhawan et al., 2011).  
Can we deliberately recruit Dnmts to specific loci and thus manipulate DNA 
methylation and gene expression? For this purpose, the ZFN, TALEN and 
CRISPR/Cas9 techniques could be powerful tools. Besides genome editing, 
endonuclease activity-disabled ZFN/TALEN/Cas9 have been used to make synthesized 
transcription activator or repressor for directed gene expression regulation (Beerli et al., 
2000; Cheng et al., 2013; Cong et al., 2012; Farzadfard et al., 2013; Gilbert et al., 2013; 
Kabadi et al., 2014; Konermann et al., 2013; Maeder et al., 2013; Mali et al., 2013; Miller 
et al., 2011; Perez-Pinera et al., 2013; Polstein and Gersbach, 2015; Qi et al., 2013; 
Zhang et al., 2011). In these synthesized transactivators or repressors, endonuclease-
dead ZFN/TALEN/Cas9 are fused with effector proteins, such as VP16, VP64 
(transactivator) or KRAB, ERD, SID (transrepressor) etc. But their DNA sequence-
specific binding capacity is preserved, which allows them for targeted gene activation or 
repression. We could create fusion proteins between ZFN/TALEN/Cas9 and the 
epigenetic enzymes such as Dnmts, or bona fide transcription factors, such as 
Ngn3/Myt1, instead of generic effector proteins, and bring these effector proteins to 
specific loci. The simplicity of CRISPR/Cas9 system even allows us to recruit synthetic 
factors to multiple loci if two or more gRNAs are expressed simultaneously, making it a 
versatile platform for directed gene expression regulation. 
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What are the roles of miRNAs and gap junctions in pancreas development? 
While our preliminary results support a non-canonical Notch lateral inhibition 
model in which neighboring cells communicate through the translocation of miRNAs 
across gap junctions and these miRNAs can enhance Ngn3 expression by inhibiting 
Notch signaling, many informational gaps need to be filled to validate this model. For 
example, direct evidence showing miRNA translocation through gap junctions in 
developing pancreas is unavailable. If miRNAs do transverse plasma membrane, what 
type of connexins are involved? Is it an active transportation process or passive diffusion? 
What are the targets of these miRNAs? These questions are intriguing and could be 
addressed as outlined in Chapter V. 
 
Conclusion remarks 
 
This work investigates the pancreatic endocrine differentiation process. Through 
lineage tracing with an innovative bipartite Cre system, I found that combinatorial Ngn3 
and Myt1 expression encourages the endocrine progenitors to adopt the β-cell 
differentiation pathway. It appears that epigenetics, especially DNA methylation, plays 
an important role in endocrine lineage allocation because the methylation of a Myt1 
regulatory element decreased from E10.5 to E15.5 and interfering with methylation with 
chemical inhibitors and Dnmt3b overexpression altered β-to-α cell ratio. Cellular 
variation of DNA methylation could be the reason behind the Ngn3/Myt1 heterogeneous 
co-expression pattern. Alternatively, Ngn3/Myt1 co-expression heterogeneity can cause 
the differential epigenetic marker deposition, leading to the divergence of endocrine cell 
specification. The involvement of other transcription factors, epigenetic modification 
enzymes, miRNAs, and lncRNAs in the process of endocrine lineage specification 
should also be examined. Sampling Ngn3+ progenitors and Ngn3+ progenitor subtypes 
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from successive embryonic stages and assessing their transcriptome and epigenome 
profile will elucidate many mysteries.   
Understanding the pancreas development process not only is important from a 
basic research perspective but also has clinical relevance. In vitro β-cell reprogramming 
and transplantation is a promising therapy for diabetes. Delineating pancreatic 
organogenesis, especially the β-cell differentiation process, is central in designing 
optimal in vitro β-cell reprogramming protocol. I expect this work will provide useful 
information for the pancreas research community, as well as hope for diabetic patients.  
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